Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives

ABSTRACT

The invention relates to fused bicycloheterocycle substituted azabicyclic alkane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

RELATED APPLICATION INFORMATION

This application is a divisional of U.S. patent application Ser. No.11/748,527, filed on May 15, 2007, which claims the benefit of U.S.Provisional Patent Application No. 60/802,195 filed on May 19, 2006,each of which are herein incorporated by reference in its entirely.

BACKGROUND OF THE INVENTION

1. Technical Field

The invention relates to fused bicycloheterocycle substitutedazabicyclic alkane derivatives, compositions comprising such compounds,and methods of treating conditions and disorders using such compoundsand compositions.

2. Description of Related Technology

Nicotinic acetylcholine receptors (nAChRs) are widely distributedthroughout the central (CNS) and peripheral (PNS) nervous systems. Suchreceptors play an important role in regulating CNS function,particularly by modulating release of a wide range of neurotransmitters,including, but not necessarily limited to acetylcholine, norepinephrine,dopamine, serotonin and GABA. Consequently, nicotinic receptors mediatea very wide range of physiological effects, and have been targeted fortherapeutic treatment of disorders relating to cognitive function,learning and memory, neurodegeneration, pain and inflammation, psychosisand sensory gating, mood and emotion, among others.

Many subtypes of the nAChR exist in the CNS and periphery. Each subtypehas a different effect on regulating the overall physiological function.Typically, nAChRs are ion channels that are constructed from apentameric assembly of subunit proteins. At least 12 subunit proteins,α2-α10 and β2-β4, have been identified in neuronal tissue. Thesesubunits provide for a great variety of homomeric and heteromericcombinations that account for the diverse receptor subtypes. Forexample, the predominant receptor that is responsible for high affinitybinding of nicotine in brain tissue has composition (α4)₂(β2)₃ (the α4β2subtype), while another major population of receptors is comprised ofhomomeric (α7)₅ (the α7 subtype) receptors.

Certain compounds, like the plant alkaloid nicotine, interact with allsubtypes of the nAChRs, accounting for the physiological effects of thiscompound. While nicotine has been demonstrated to have many biologicalactivities, not all of the effects mediated by nicotine are desirable.For example, nicotine exerts gastrointestinal and cardiovascular sideeffects that interfere at therapeutic doses, and its addictive natureand acute toxicity are well-known. Ligands that are selective forinteraction with only certain subtypes of the nAChR offer potential forachieving beneficial therapeutic effects with an improved margin forsafety.

The α7 and α4β2 nAChRs have been shown to play a significant role inenhancing cognitive function, including aspects of learning, memory andattention (Levin, E. D., J. Neurobiol. 53: 633-640, 2002). For example,α7 nAChRs have been linked to conditions and disorders related toattention deficit disorder, attention deficit hyperactivity disorder(ADHD), Alzheimer's disease (AD), mild cognitive impairment, seniledementia, dementia associated with Lewy bodies, dementia associated withDown's syndrome, AIDS dementia, Pick's Disease, as well as cognitivedeficits associated with schizophrenia, among other systemic activities.The α4β2 receptor subtype is implicated in attention, cognition,schizophrenia, epilepsy, and pain control (Paterson and Norberg,Progress in Neurobiology 61 75-111, 2000).

The activity at both α7 and α4β2 nAChRs can be modified or regulated bythe administration of subtype selective nAChR ligands. The ligands canexhibit antagonist, agonist, or partial agonist properties. Compoundsthat function as positive allosteric modulators are also known.

Although compounds that nonselectively demonstrate activity at a rangeof nicotinic receptor subtypes including the α4β2 and α7 nAChRs areknown, it would be beneficial to provide compounds that interactselectively with α7-containing neuronal nAChRs, α4β2 nAChRs, or both α7and α4β2 nAChRs compared to other subtypes.

SUMMARY OF THE INVENTION

The invention is directed to fused bicycloheterocycle substitutedazabicyclic compounds as well as compositions comprising such compounds,and method of using the same.

One aspect of the present invention is directed toward a compound offormula (I)

or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof,wherein

n is 1, 2 or 3;

A is N or N⁺-0⁻;

R is hydrogen, alkyl, cycloalkylalkyl and arylalkyl;

L is selected from the group consisting of O, S, and —N(R_(a))—;

Ar¹ is a 6-membered aryl or 6-membered heteroaryl ring;

Ar² is a bicyclic heteroaryl; and

R_(a) is selected from the group consisting of hydrogen, alkyl andalkylcarbonyl;

provided that if Ar¹ is

then L is O or S.

Another aspect of the invention relates to pharmaceutical compositionscomprising compounds of the invention. Such compositions can beadministered in accordance with a method of the invention, typically aspart of a therapeutic regimen for treatment or prevention of conditionsand disorders related to nAChR activity, and more particularly α7 nAChRactivity.

Yet another aspect of the invention relates to a method of selectivelymodulating to nAChR activity, for example α7 nAChR activity. The methodis useful for treating and/or preventing conditions and disordersrelated to α7 nAChR activity modulation in mammals. More particularly,the method is useful for conditions and disorders related to attentiondeficit disorder, attention deficit hyperactivity disorder (ADHD),Alzheimer's disease (AD), mild cognitive impairment, senile dementia,AIDS dementia, Pick's Disease, dementia associated with Lewy bodies,dementia associated with Down's syndrome, amyotrophic lateral sclerosis,Huntington's disease, diminished CNS function associated with traumaticbrain injury, acute pain, post-surgical pain, chronic pain, inflammatorypain, neuropathic pain, infertility, need for new blood vessel growthassociated with wound healing, need for new blood vessel growthassociated with vascularization of skin grafts, and lack of circulation,more particularly circulation around a vascular occlusion, among othersystemic activities, for example inflammatory response mediated by TNF.

The compounds, compositions comprising the compounds, and methods fortreating or preventing conditions and disorders by administering thecompounds are further described herein.

DETAILED DESCRIPTION OF THE INVENTION Definition of Terms

Certain terms as used in the specification are intended to refer to thefollowing definitions, as detailed below.

The term “acyl”, as used herein, means an alkyl group, as definedherein, appended to the parent molecular moiety through a carbonylgroup, as defined herein. Representative examples of acyl include, butare not limited to, acetyl, 1-oxopropyl, 2,2-dimethyl-1-oxopropyl,1-oxobutyl, and 1-oxopentyl.

The term “acyloxy”, as used herein, means an acyl group, as definedherein, appended to the parent molecular moiety through an oxygen atom.Representative examples of acyloxy include, but are not limited to,acetyloxy, propionyloxy, and isobutyryloxy.

The term “alkenyl”, as used herein, means a straight or branched chainhydrocarbon containing from 2 to 10 carbons and containing at least onecarbon-carbon double bond formed by the removal of two hydrogens.Representative examples of alkenyl include, but are not limited to,ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl,5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, and 3-decenyl.

The term “alkoxy”, as used herein, means an alkyl group as definedherein, appended to the parent molecular moiety through an oxygen atom.Representative examples of alkoxy include, but are not limited to,methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, andhexyloxy.

The term “alkoxyalkoxy”, as used herein, means an alkoxy group, asdefined herein, appended to the parent molecular moiety through anotheralkoxy group, as defined herein. Representative examples of alkoxyalkoxyinclude, but are not limited to, tert-butoxymethoxy, 2-ethoxyethoxy,2-methoxyethoxy, and methoxymethoxy.

The term “alkoxyalkyl”, as used herein, means an alkoxy group, asdefined herein, appended to the parent molecular moiety through an alkylgroup, as defined herein. Representative examples of alkoxyalkylinclude, but are not limited to, tert-butoxymethyl, 2-ethoxyethyl,2-methoxyethyl, and methoxymethyl.

The term “alkoxycarbonyl”, as used herein, means an alkoxy group, asdefined herein, appended to the parent molecular moiety through acarbonyl group, represented by —C(O)—, as defined herein. Representativeexamples of alkoxycarbonyl include, but are not limited to,methoxycarbonyl, ethoxycarbonyl, and tert-butoxycarbonyl.

The term “alkoxyimino”, as used herein, means an alkoxy group, asdefined herein, appended to the parent molecular moiety through an iminogroup, as defined herein. Representative examples of alkoxyiminoinclude, but are not limited to, ethoxy(imino)methyl andmethoxy(imino)methyl.

The term “alkoxysulfonyl”, as used herein, means an alkoxy group, asdefined herein, appended to the parent molecular moiety through asulfonyl group, as defined herein. Representative examples ofalkoxysulfonyl include, but are not limited to, methoxysulfonyl,ethoxysulfonyl and propoxysulfonyl.

The term “alkyl”, as used herein, means a straight or branched chainhydrocarbon containing from 1 to 6 carbon atoms. Representative examplesof alkyl include, but are not limited to, methyl, ethyl, n-propyl,iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl,isopentyl, neopentyl, and n-hexyl.

The term “alkylcarbonyl”, as used herein, means an alkyl group, asdefined herein, appended to the parent molecular moiety through acarbonyl group, as defined herein. Representative examples ofalkylcarbonyl include, but are not limited to, acetyl, 1-oxopropyl,2,2-dimethyl-1-oxopropyl, 1-oxobutyl, and 1-oxopentyl.

The term “alkylcarbonyloxy”, as used herein, means an alkylcarbonylgroup, as defined herein, appended to the parent molecular moietythrough an oxygen atom. Representative examples of alkylcarbonyloxyinclude, but are not limited to, acetyloxy, ethylcarbonyloxy, andtert-butylcarbonyloxy.

The term “alkylsulfonyl”, as used herein, means an alkyl group, asdefined herein, appended to the parent molecular moiety through asulfonyl group, as defined herein. Representative examples ofalkylsulfonyl include, but are not limited to, methylsulfonyl andethylsulfonyl.

The term “alkylthio”, as used herein, means an alkyl group, as definedherein, appended to the parent molecular moiety through a sulfur atom.Representative examples of alkylthio include, but are not limited,methylthio, ethylthio, tert-butylthio, and hexylthio.

The term “alkynyl”, as used herein, means a straight or branched chainhydrocarbon group containing from 2 to 10 carbon atoms and containing atleast one carbon-carbon triple bond. Representative examples of alkynylinclude, but are not limited, to acetylenyl, 1-propynyl, 2-propynyl,3-butynyl, 2-pentynyl, and 1-butynyl.

The term “amido”, as used herein, means an amino, alkylamino, ordialkylamino group appended to the parent molecular moiety through acarbonyl group, as defined herein. Representative examples of amidoinclude, but are not limited to, aminocarbonyl, methylaminocarbonyl,dimethylaminocarbonyl, and ethylmethylaminocarbonyl.

The term “aryl”, as used herein, means a monocyclic or bicyclic aromaticring system. Representative examples of aryl include, but are notlimited to, phenyl and naphthyl.

The aryl groups of this invention are substituted with 0, 1, 2, 3, 4, or5 substituents independently selected from acyl, acyloxy, alkenyl,alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxyimino,alkoxysulfonyl, alkyl, alkylsulfonyl, alkynyl, amino, carboxy, cyano,formyl, haloalkoxy, haloalkyl, halo, hydroxy, hydroxyalkyl, mercapto,nitro, thioalkoxy, —NR_(g)R_(j), (NR_(g)R_(j))alkyl,(NR_(g)R_(j))alkoxy, (NR_(g)R_(j))carbonyl, and (NR_(g)R_(j))sulfonyl,wherein R_(g) and R_(j) are each independently selected from the groupconsisting of hydrogen and alkyl.

The term “arylcarbonyl”, as used herein, means an aryl group, as definedherein, or a benzyl group appended to the parent molecular moietythrough a carbonyl group, represented by —C(O)—, as defined herein.Representative examples of arylcarbonyl include, but are not limited to,phenylcarbonyl and benzylcarbonyl.

The term “aryloxycarbonyl”, as used herein, means an aryl-O— group,wherein the aryl of aryl-O— is as defined herein, or a benzyoxyl groupappended to the parent molecular moiety through a carbonyl group,represented by —C(O)—, as defined herein. Representative examples ofaryloxycarbonyl include, but are not limited to, phenoxycarbonyl andbenzyloxycarbonyl.

The term “arylsulfonyl”, as used herein, means an aryl group, as definedherein, appended to the parent molecular moiety through a sulfonylgroup, as defined herein. Representative examples of arylsulfonylinclude, but are not limited to, phenylsulfonyl,(methylaminophenyl)sulfonyl, (dimethylaminophenyl)sulfonyl, and(naphthyl)sulfonyl.

The term “carbonyl”, as used herein, means a —C(O)— group.

The term “carboxy”, as used herein, means a —CO₂H group.

The term “cyano”, as used herein, means a —CN group.

The term “formyl”, as used herein, means a —C(O)H group.

The term “halo” or “halogen”, as used herein, means —Cl, —Br, —I or —F.

The term “haloalkoxy”, as used herein, means at least one halogen, asdefined herein, appended to the parent molecular moiety through analkoxy group, as defined herein. Representative examples of haloalkoxyinclude, but are not limited to, chloromethoxy, 2-fluoroethoxy,trifluoromethoxy, and pentafluoroethoxy.

The term “haloalkyl”, as used herein, means at least one halogen, asdefined herein, appended to the parent molecular moiety through an alkylgroup, as defined herein. Representative examples of haloalkyl include,but are not limited to, chloromethyl, 2-fluoroethyl, trifluoromethyl,pentafluoroethyl, and 2-chloro-3-fluoropentyl.

The term “heteroaryl” means an aromatic five- or six-membered ringcontaining 1, 2, 3, or 4 heteroatoms independently selected from groupconsisting of nitrogen, oxygen and sulfur. The heteroaryl groups areconnected to the parent molecular moiety through a carbon or nitrogenatom. Representative examples of heteroaryl include, but are not limitedto, furyl, imidazolyl, indazolyl, benzothiozolyl, isoxazolyl,isothiazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl,pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiadiazolyl, thiazolyl,thienyl, triazinyl, and triazolyl.

The heteroaryl groups of the invention are substituted with 0, 1, 2, or3 substituents independently selected from alkenyl, alkoxy,alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxysulfonyl, alkyl,alkylcarbonyl, alkylcarbonyloxy, alkylsulfonyl, alkylthio, alkynyl,carboxy, cyano, formyl, haloalkoxy, haloalkyl, halo, hydroxy,hydroxyalkyl, mercapto, nitro, —NR_(g)R_(j), (NR_(g)R_(j))alkyl,(NR_(g)R_(j))alkoxy, (NR_(g)R_(j))carbonyl, and (NR_(g)R_(j))sulfonyl,wherein R_(g) and R_(j) are each independently selected from the groupconsisting of hydrogen and alkyl.

The term “bicyclic heteroaryl” refers to fused aromatic nine- andten-membered bicyclic rings containing 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of nitrogen, oxygen andsulfur. The bicyclic heteroaryl groups are connected to the parentmolecular moiety through a carbon or nitrogen atom. Representativeexamples of bicyclic heteroaryl rings include, but are not limited to,indolyl, benzothiazolyl, benzofuranyl, isoquinolinyl, and quinolinyl.Bicyclic heteroaryl groups of the invention are substituted with 0, 1,2, or 3 substituents independently selected from alkenyl, alkoxy,alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxysulfonyl, alkyl,alkylcarbonyl, alkylcarbonyloxy, alkylsulfonyl, alkylthio, alkynyl,carboxy, cyano, formyl, haloalkoxy, haloalkyl, halo, hydroxy,hydroxyalkyl, mercapto, nitro, —NR_(g)R_(j), (NR_(g)R_(j))alkyl,(NR_(g)R_(j))alkoxy, (NR_(g)R_(j))carbonyl, and (NR_(g)R_(j))sulfonyl,wherein R_(g) and R_(j) are each independently selected from the groupconsisting of hydrogen and alkyl.

The term “heterocycle” or “heterocyclic” as used herein, means amonocyclic heterocycle or a bicyclic heterocycle. The monocyclicheterocycle is a 3, 4, 5, 6 or 7 membered ring containing at least oneheteroatom independently selected from the group consisting of nitrogen,oxygen and sulfur. The 3 or 4 membered ring contains 1 heteroatomselected from the group consisting of nitrogen, oxygen and sulfur. The 5membered ring contains zero or one double bond and one, two or threeheteroatoms selected from the group consisting of nitrogen, oxygen andsulfur. The 6 or 7 membered ring contains zero, one or two double bondsand one, two or three heteroatoms selected from the group consisting ofnitrogen, oxygen and sulfur. The monocyclic heterocycle is connected tothe parent molecular moiety through any carbon atom or any nitrogen atomcontained within the monocyclic heterocycle. Representative examples ofmonocyclic heterocycle include, but are not limited to, azetidinyl,azepanyl, aziridinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl,1,3-dithiolanyl, 1,3-dithianyl, imidazolinyl, imidazolidinyl,isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl,morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl,piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl,pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, thiadiazolinyl,thiadiazolidinyl, thiazolinyl, thiazolidinyl, thiomorpholinyl,1,1-dioxidothiomorpholinyl (thiomorpholine sulfone), thiopyranyl, andtrithianyl. The bicyclic heterocycle is a monocyclic heterocycle that iseither fused to a cycloalkyl ring, a heteroaryl ring or anotherheterocyclic ring, or is formed by an alkyl chain attached to twonon-adjacent carbons contained within the monocyclic heterocyclic ring.The bicyclic heterocycle is connected to the parent molecular moietythrough any carbon atom or any nitrogen atom contained within themonocyclic heterocycle. Representative examples of bicyclic heterocycleinclude, but are not limited to, azabicyclo[3.1.1]heptane,azabicyclo[3.2.1]octane, 1,3-benzodioxolyl, 1,3-benzodithiolyl,2,3-dihydro-1,4-benzodioxinyl, 2,3-dihydro-1-benzofuranyl,2,3-dihydro-1-benzothienyl, 2,3-dihydro-1H-indolyl, and1,2,3,4-tetrahydroquinolinyl.

The heterocyclic groups of the invention are substituted with 0, 1, 2,or 3 substituents independently selected from alkenyl, alkoxy,alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxysulfonyl, alkyl,alkylcarbonyl, alkylcarbonyloxy, alkylsulfonyl, alkylthio, alkynyl,carboxy, cyano, formyl, haloalkoxy, haloalkyl, halo, hydroxy,hydroxyalkyl, mercapto, nitro, —NR_(g)R_(j), (NR_(g)R_(j))alkyl,(NR_(g)R_(j))alkoxy, (NR_(g)R_(j))carbonyl, and (NR_(g)R_(j))sulfonyl,wherein R_(g) and R_(j) are each independently selected from the groupconsisting of hydrogen and alkyl.

The term “hydroxy”, as used herein, means an —OH group.

The term “hydroxyalkyl”, as used herein, means at least one hydroxygroup, as defined herein, is appended to the parent molecular moietythrough an alkyl group, as defined herein. Representative examples ofhydroxyalkyl include, but are not limited to, hydroxymethyl,2-hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypentyl, and2-ethyl-4-hydroxyheptyl.

The term “mercapto”, as used herein, means a —SH group.

The term “nitro”, as used herein, means a —NO₂ group.

The term “—NR_(g)R_(j)”, as used herein, means two groups, R_(g) andR_(j) which are appended to the parent molecular moiety through anitrogen atom. R_(g) and R_(j) are each independently hydrogen or alkyl.Representative examples of —NR_(g)R_(j) include, but are not limited to,amino, methylamino, dimethylamino, and methylethylamino.

The term “(NR_(g)R_(j))alkyl”, as used herein, means a —NR_(g)R_(j)group, as defined herein, appended to the parent molecular moietythrough an alkyl group, as defined herein. Representative examples of(NR_(g)R_(j))alkyl include, but are not limited to, (amino)methyl,(dimethylamino)methyl, and (ethylamino)methyl.

The term “(NR_(g)R_(j))alkoxy”, as used herein, means a —NR_(g)R_(j)group, as defined herein, appended to the parent molecular moietythrough an alkoxy group, as defined herein. Representative examples of(NR_(g)R_(j))alkoxy include, but are not limited to, (amino)methoxy,(dimethylamino)methoxy, and (diethylamino)ethoxy.

The term “(NR_(g)R_(j))carbonyl”, as used herein, means a —NR_(g)R_(j)group, as defined herein, appended to the parent molecular moietythrough a carbonyl group, as defined herein. Representative examples of(NR_(g)R_(j))carbonyl include, but are not limited to, aminocarbonyl,(methylamino)carbonyl, (dimethylamino)carbonyl, and(ethylmethylamino)carbonyl.

The term “(NR_(g)R_(j))sulfonyl”, as used herein, means a —NR_(g)R_(j)group, as defined herein, appended to the parent molecular moietythrough a sulfonyl group, as defined herein. Representative examples of(NR_(g)R_(j))sulfonyl include, but are not limited to, aminosulfonyl,(methylamino)sulfonyl, (dimethylamino)sulfonyl, and(ethylmethylamino)sulfonyl.

The term “sulfonyl”, as used herein, means a —S(O)₂— group.

The term “thioalkoxy”, as used herein, means an alkyl group, as definedherein, appended to the parent molecular moiety through a sulfur atom.Representative examples of thioalkoxy include, but are no limited to,methylthio, ethylthio, and propylthio.

Although typically it may be recognized that an asterisk is used toindicate that the exact subunit composition of a receptor is uncertain,for example α3β4* indicates a receptor that contains the α3 and β4proteins in combination with other subunits, the term α7 as used hereinis intended to include receptors wherein the exact subunit compositionis both certain and uncertain. For example, as used herein α7 includeshomomeric (α7)₅ receptors and α7* receptors, which denote a nAChRcontaining at least one α7 subunit.

Compounds of the Invention

Compounds of the invention have the formula (I) as described above. Moreparticularly, compounds of formula (I) can include, but are not limitedto, compounds wherein A is N, and n is 1 or 2. Certain preferredcompounds exist wherein A is N; L is O; n is 2.

More particularly, in compounds of formula (I) Ar¹ is selected from:

wherein R₁, R₂, R₃, R₄ and R₅ are independently acyl, acyloxy, alkenyl,alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxyimino,alkoxysulfonyl, alkyl, alkylsulfonyl, alkynyl, amino, carboxy, cyano,formyl, haloalkoxy, haloalkyl, halo, hydroxy, hydroxyalkyl, mercapto,nitro, thioalkoxy, —NR_(g)R_(j), (NR_(g)R_(j))alkyl,(NR_(g)R_(j))alkoxy, (NR_(g)R_(j))carbonyl, or (NR_(g)R_(j))sulfonyl;R_(g) and R_(j) are each independently hydrogen or alkyl. Morepreferably, Ar¹ is

Particularly, the invention includes, but is not limited to, compoundsof formula (I) wherein A is N; R is methyl; L is O; n is 2; Ar¹ is

Ar² in compounds of formula (I) is selected from:

wherein Z₁, Z₂, Z₃ and Z₄ are each independently nitrogen or are carbon,wherein the carbon atom is optionally substituted with a substituentselected from the group consisting of hydrogen, halogen, alkyl, —OR_(c),-alkyl-OR_(c), —NR_(d)R_(e), and -alkyl-NR_(d)R_(e); R_(b) is selectedfrom the group consisting of hydrogen, alkyl and alkylcarbonyl; R_(c) isalkyl; R_(d) and R_(e) are each independently selected from the groupconsisting of hydrogen and alkyl, R₆ and R₇ are each independentlyselected from the group consisting of hydrogen, alkenyl, alkoxy,alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxyimino, alkoxysulfonyl,alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfonyl, alkynyl, carboxy,cyano, formyl, haloalkoxy, haloalkyl, halo, hydrogen, hydroxy,hydroxyalkyl, mercapto, nitro, thioalkoxy, —NR_(g)R_(j),(NR_(g)R_(j))alkyl, (NR_(g)R_(j))alkoxy, (NR_(g)R_(j))carbonyl, and(NR_(g)R_(j))sulfonyl; R_(g) and R_(j) are each independently selectedfrom the group consisting of hydrogen and alkyl.

R is selected from hydrogen, alkyl, cycloalkylalkyl, and arylalky.Preferred compounds are disclosed wherein R is hydrogen and alkyl.Preferably, R is methyl and hydrogen.

Preferred compounds are disclosed wherein Ar² is

More preferably Ar² is

Particularly, the invention relates to compounds of formula (I) whereinA is N; R is selected from methyl and hydrogen; L is O; n is 2; and Ar²is selected from the group of consisting of:

More particularly, the invention relates to compounds of formula (I)wherein A is N; R is methyl or hydrogen; L is O; n is 2; Ar¹ is

and

Ar² is

Compounds for the method of the invention, including but not limited tothose specified in the examples or otherwise specifically named, canmodulate, and often possess an affinity for, nAChRs, and moreparticularly α7 nAChRs. As α7 nAChRs ligands, the compounds of theinvention can be useful for the treatment or prevention of a number ofα7 nAChR-mediated diseases or conditions.

Specific examples of compounds that can be useful for the treatment orprevention of α7 nAChR-mediated diseases or conditions include, but arenot limited to, compounds described in the Compounds of the Inventionand also in the Examples, and also compounds such as:

-   5-{6-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-1H-indole;-   (endo)-3-(6-benzo[b]thiophen-5-yl-pyridazin-3-yloxy)-8-methyl-8-aza-bicyclo[3.2.1]octane;-   (endo)-3-[6-(benzofuran-5-yl)-pyridazin-3-yloxy]-8-methyl-8-aza-bicyclo[3.2.1]octane;-   6-{6-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-1H-indole;-   5-{6-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-1H-indazole;-   1-methyl-5-{6-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-1H-indole;-   5-{6-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-2-trifluoromethyl-1H-indole;-   5-{6-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-1H-indole;-   5-{5-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indole;-   (endo)-3-(6-benzo[b]thiophen-5-yl-pyridin-3-yloxy)-8-methyl-8-aza-bicyclo[3.2.1]octane;-   5-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indole;-   (exo)-3-[6-(benzofuran-5-yl)-pyridin-3-yloxy]-8-methyl-8-aza-bicyclo[3.2.1]octane;-   5-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indazole;-   5-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-2-trifluoromethyl-1H-indole;-   4-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indole;-   5-{6-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-3-yl}-1H-indole;-   (endo)-3-(5-benzo[b]thiophen-5-yl-pyridin-2-yloxy)-8-methyl-8-aza-bicyclo[3.2.1]octane;-   5-{6-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-3-yl}-1H-indole;-   [6-(1H-indol-5-yl)-pyridin-3-yl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl-]amine;-   [6-(benzofuran-5-yl)-pyridin-3-yl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;-   [(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-[6-(2-trifluoromethyl-1H-indol-5-yl)-pyridin-3-yl]-amine;-   [6-(1H-indazol-5-yl)-pyridin-3-yl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;-   [6-(1H-indol-4-yl)-pyridin-3-yl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;-   [(endo)-8-aza-bicyclo[3.2.1]oct-3-yl]-[6-(1H-indol-5-yl)-pyridin-3-yl]-amine;-   [4-(1H-indol-5-yl)-phenyl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;-   [4-(1H-indazol-5-yl)-phenyl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;-   [(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-[4-(1-methyl-1H-indol-5-yl)-phenyl]-amine;-   (4-benzo[b]thiophen-5-yl-phenyl)-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;-   [4-(benzofuran-5-yl)-phenyl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;-   [4-(1H-indol-4-yl)-phenyl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;-   [3-(1H-indol-5-yl)-phenyl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;-   [3-(1H-indol-4-yl)-phenyl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;-   5-{6-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-2-trifluoromethyl-1H-indole;-   4-{6-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-1H-indole;-   5-{6-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-3-yl}-1H-indole;-   5-{6-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-3-yl}-2-trifluoromethyl-1H-indole;-   4-{6-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-1H-indole;-   6-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indole;-   5-{5-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indole;-   4-{5-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indole;-   6-{5-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indole;-   [6-(1H-indol-6-yl)-pyridin-3-yl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;-   5-{6-[(endo)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yloxy]pyridazin-3-yl}-1H-indole;-   (endo)-3-[6-(benzo[b]thiophen-5-yl)pyridazin-3-yloxy]-9-methyl-9-azabicyclo[3.3.1]nonane;-   5-{5-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-pyrrolo[2,3-b]pyridine;-   5-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-pyrrolo[2,3-b]pyridine;-   5-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-3-yl}-1H-indole;-   5-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indole;-   4-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indole;-   6-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indole;-   (endo)-N-(5-(1H-Indol-5-yl)pyridin-3-yl)-8-methyl-8-azabicyclo[3.2.1]octan-3-amine;

(endo)-N-(5-(1H-Indol-4-yl)pyridin-3-yl)-8-methyl-8-azabicyclo[3.2.1]octan-3-amine;

-   (endo)-N-(5-(1H-Indol-6-yl)pyridin-3-yl)-8-methyl-8-azabicyclo[3.2.1]octan-3-amine;-   (endo)-N-{5-[2-(trifluoromethyl)-1H-indol-5-yl]pyridin-3-yl}-8-Methyl-8-azabicyclo[3.2.1]octan-3-amine;-   5-{5-[(endo)-8-Methyl-8-azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-pyrrolo[2,3-b]pyridine;-   5-{5-[(endo)-8-Methyl-8-azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}indolin-2-one;-   5-{5-[(endo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-indole;-   (1R,3r,5S,8s)-3-(6-(1H-Indol-5-yl)pyridin-3-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane    8-oxide;-   (1R,3r,5S,8r)-3-(6-(1H-Indol-5-yl)pyridin-3-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane    8-oxide;-   4-{5-[(endo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-indole;-   5-{5-[(exo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-indole;-   5-{5-[(endo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}indolin-2-one;-   5-{5-[(endo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-pyrrolo[2,3-b]pyridine;-   5-{5-[(exo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-pyrrolo[2,3-b]pyridine,    or pharmaceutically acceptable salts, esters, amides, and prodrugs    thereof.

Compound names are assigned by using AUTONOM naming software, which isprovided by MDL Information Systems GmbH (formerly known as BeilsteinInformationssysteme) of Frankfurt, Germany, and is part of the CHEMDRAW®ULTRA v. 6.0.2 software suite.

Compounds of the invention may exist as stereoisomers wherein,asymmetric or chiral centers are present. These stereoisomers are “R” or“S” depending on the configuration of substituents around the chiralelement. The terms “R” and “S” used herein are configurations as definedin IUPAC 1974 Recommendations for Section E, FundamentalStereochemistry, Pure Appl. Chem., 1976, 45: 13-30.

The attachment of L to the azabicyclic alkane may be considered toencompass both the endo and exo geometries, such as isomer (Ia) and(Ib). The configurational assignment of structures of formula (Ia) areassigned endo in accordance with that described in Stereochemistry ofOrganic Compounds, E. L. Eliel, S. H. Wilen; John Wiley and Sons, Inc.1994. Structures of formula (Ib) are assigned exo using the samemethods.

The N⁺-0⁻ portion of isomer (Ic) and isomer (Id) are diastereomers. Theconfigurational assignment of structures of formula (Ic) are assigned(r) in accordance with that described in Synthesis, 1992, 1080, Becker,D. P.; Flynn, D. L. and as defined in Stereochemistry of OrganicCompounds, E. L. Eliel, S. H. Wilen; John Wiley and Sons, Inc. 1994. Inaddition the configurational assignment of structures of formula (Id)are assigned (s) using the same methods.

The invention contemplates various stereoisomers and mixtures thereofand are specifically included within the scope of this invention.Stereoisomers include enantiomers and diastereomers, and mixtures ofenantiomers or diastereomers. Individual stereoisomers of compounds ofthe invention may be prepared synthetically from commercially availablestarting materials which contain asymmetric or chiral centers or bypreparation of racemic mixtures followed by resolution well-known tothose of ordinary skill in the art. These methods of resolution areexemplified by (1) attachment of a mixture of enantiomers to a chiralauxiliary, separation of the resulting mixture of diastereomers byrecrystallization or chromatography and optional liberation of theoptically pure product from the auxiliary as described in Furniss,Hannaford, Smith, and Tatchell, “Vogel's Textbook of Practical OrganicChemistry”, 5th edition (1989), Longman Scientific & Technical, EssexCM20 2JE, England, or (2) direct separation of the mixture of opticalenantiomers on chiral chromatographic columns or (3) fractionalrecrystallization methods.

Methods for Preparing Compounds of the Invention

The reactions exemplified in the schemes are performed in a solventappropriate to the reagents and materials employed and suitable for thetransformations being effected. The described transformations mayrequire modifying the order of the synthetic steps or selecting oneparticular process scheme over another in order to obtain a desiredcompound of the invention, depending on the functionality present on themolecule.

The methods described below can entail use of various enantiomers. Wherethe stereochemistry is shown in the Schemes, it is intended forillustrative purposes only.

Compounds of formula (8), wherein Ar¹, Ar² are as defined in formula(I), can be prepared as described in Scheme 1. Compounds of formula (1)when treated with a compound of formula (2a), wherein halo is bromide,chloride, or iodide, in the presence of CuI, 1,10-phenanthroline andCs₂CO₃ in a solvent such as, but not limited to, toluene as described inOrg. Lett., 2002, 4, 973, will provide compounds of formula (3).Compounds of formula (3) can also be prepared through the reaction ofcompounds of formula (1) with compounds of formula (2b) in the presenceof a base, such as, but not limited to, KHMDS, in a solvent such as butnot limited to THF, DME and toluene. Compounds of formula (3) whentreated with hexamethylditin or an organo-borane compound of formula(4), such as bis(pinacolato)diboron or bis(catecholato)diboron, whereinR is hydrogen, alkyl or aryl, in the presence of a palladium catalystwill provide the corresponding tin or boronic acid of formula (5),wherein M is —Sn-(Me)₃ or —B(OR)₂. Compounds of formula (5) when treatedwith compounds of formula (6), Ar₂-halo, wherein Ar₂ is a bicyclicheteroaryl ring and halo is bromide, chloride, or iodide, in thepresence of a palladium catalyst to provide compounds of formula (8).Alternatively, compounds of formula (6) when treated withhexamethylditin or a di-borane containing compound of formula (4), suchas bis(pinacolato)diboron and bis(catecholato)diboron, in the presenceof a palladium catalyst will provide a corresponding tin or boronic acidcontaining compound of formula (7), wherein Ar₂ is a bicyclic heteroaryland wherein M is —Sn-(Me)₃ or —B(OR)₂. Compounds of formula (7) whentreated with a compound of formula (3) in the presence of a palladiumcatalyst will provide a compound of formula (8).

Compounds of formula (13), wherein Ar¹ is a nitrogen-containingheteroaryl, for examples pyridazine, pyrimidine, pyrazine, 2-pyridyl,and Ar² is as defined for formula (I), can be prepared as shown inScheme 2. Compounds of formula (9), wherein R^(z) is alkoxyalkyl, alkyl,alkyloxycarbonyl, alkylcarbonyl, aryl, arylalkyloxycarbonyl,cycloalkylalkyl, arylcarbonyl and aryloxycarbonyl and K represents thepotassium, which are prepared from treating hydroxyl containingheterocycles of similar formula with potassium tert-butoxide in solventssuch as but not limited to THF or DMF to provide the potassium oxidecontaining compounds of formula (9). The compounds of formula (9) whentreated with compounds of formula (10), wherein Y¹ and halo are bothbromo, chloro and iodo, and X², X³, X⁴ and X⁵ are independently eithercarbon or nitrogen, for example, dichloropyridazine, will providecompounds of formula (11). Compounds of formula (11) when treated withhexamethylditin or a di-borane containing compound of formula (4) in thepresence of a palladium catalyst according to the procedure outlined inScheme 1 will provide compounds of formula (12). Compounds of formula(12) treated with compounds of formula 6 in the presence of a palladiumcatalyst will provide compounds of formula (13). Alternatively, thecompounds of formula (11) when treated with organo stannane or organoboronic acid containing compounds of formula (7), as described in Scheme1, in the presence of a palladium catalyst will provide a compound offormula (13).

Alternatively, compounds of formula (8) may be prepared as outlined inScheme 3. Compounds of formula (1) when treated with a compound offormula (14), wherein Z³ is bromo, chloro or iodo or is Ar², in thepresence of diethyl azodicarboxylate or di(isopropyl) 1 azodicarboxylateand a phosphine, such as triphenylphosphine, will provide compounds offormula (15). When Z³ is Ar², compounds of formula (15) arerepresentative of the present invention. When Z³ is a halogen, thefurther treatment of the compound according to conditions outlined inSchemes 1-2 outlining the Suzuki type coupling to provide compounds offormula (8) which are representative of the compounds of the presentinvention.

Another method of generating compounds of formula (8) is described inScheme 4. The activated tin or boronic acid compounds of formula (7) canbe coupled with a variety of aryl halides that will provide a method ofgenerating biaryl compounds of formula (17) and of formula (20). Forexample compounds of formula (7) when treated with diiodobenzene offormula (16) in the presence of a palladium catalyst will providecompounds of formula (17). Compounds of formula (17) when treated withcompounds of formula (1) in the presence of cuprous iodide and cesiumcarbonate and 1,10-phenanthroline as described in Scheme 1, will providecompounds of formula (8). Alternatively, compounds of formula (7) whentreated with a compound of formula (18), wherein R^(a) is benzyl oranother appropriate alcohol protecting group, in the presence of apalladium catalyst will provide compounds of formula (19). Thedeprotection of the alcohol protecting group, for example when R^(a) isbenzyl the deprotection is generally achieved utilizing palladium oncarbon and an atmosphere of hydrogen, will provide compounds of formula(20). Compounds of formula (20) when treated with compounds of formula(1) in the presence of triphenylphosphine and diethyldiazocarboxylate ora similar reagent will provide compounds of formula (8).

Compounds of formula (25), which are representative of compounds offormula (I), wherein L is —NH—, can be prepared as shown in Scheme 5.Compounds of formula (21) when treated with compounds of formula (22),wherein halo is bromide, chloride, or iodide, along with sodiumtriacetoxy borohydride and Na₂SO₄ in acetic acid will provide compoundsof formula (23). Alternatively, a compound of formula (23) can beobtained by treating compounds of formula (24) with a compound offormula (2), wherein Y is bromo or iodo, in the presence of palladiumcatalyst, preferably in toluene. Compounds of formula (23) when furthertreated with a tin or diboron of formula (4), such asbis(pinacolato)diboron and bis(catecholato)diboron, under conditionsdescribed in Scheme 2, will provide the corresponding tin or boronicacid compounds of formula (26). Compounds of formula (26) when treatedwith a compound of formula (6) in the presence of a palladium catalyst,will provide the compound of formula (25). Alternatively, the compoundof formula (23) when treated with a tin or boronic acid containingcompound of formula (7) in the presence of a palladium catalyst willalso provide compounds of formula (25).

In addition, compounds of formula (25) can be prepared as shown inScheme 6. Ketone containing compounds of formula (21), when treated withcompounds of formula (27), prepared via the coupling reaction ofhaloarylamine of formula (22) and a suitable tin or boron agent offormula (7) in the presence of a palladium catalyst, followed bytreatment with sodium triacetate borohydride and Na₂SO₄ in acetic acidwill provide compounds of formula (25) as described in Tetrahedron Lett.1996, 37, 6045.

Compounds of formula (31), wherein L is S and Ar¹ and Ar² are as definedin formula (I), can be prepared as shown in Scheme 7. Compounds offormula (29), wherein halo is bromide, chloride, or iodide, whenpretreated with sodium hydride in a solvent such as but not limited toDMF followed by treatment with compounds of formula (28) will providecompounds of formula (30). Compounds of formula (30) when treated with acompound of formula (7) as described in Scheme 1, will provide compoundsof formula (31), which are representative of compounds of formula (I)wherein L is S. Alternatively, the compound of formula (30) when treatedwith a hexamethylditin or diboron reagent of formula (4), such asbis(pinacolato)diboron and bis(catecholato)diboron, in the presence of apalladium catalyst will provide a compound of formula (32). Compounds offormula (32) when treated with compounds of formula (6), wherein halo isbromo, chloro or iodo, in the presence of a palladium catalyst willprovide compounds of formula (31).

Compounds of formula (35) which are representative of compounds offormula (I), wherein L is O, S, or —N(R_(a))—, Ar¹ is as previouslydefined in formula (I), and Ar² is an aminosubstituted benzothiazole areprepared according to the conditions outlined in Scheme 8. Compounds offormula (33) which are obtained by methods described in Schemes 1-7,wherein Ar² is substituted with —NH₂, when treated with bromine and KSCNin acetic acid will provide compounds of formula (34). Compounds offormula (34) can be further treated with the halide of a desired R^(g)group, wherein R^(g) is as defined under the scope compounds of thepresent invention to provide compounds of formula (35).

Compounds of formula (39), wherein L is O, NH, or S; Ar¹ is aspreviously defined in formula (I), Ar² is a benzoimidazole as definedfor compounds of formula (I), are prepared as outlined in Scheme 9.Compounds of formula (36), are obtained by treating compounds of formula(33) of Scheme 8, using conditions known to one skilled in the art thatwill incorporate a nitrogen-protecting group to the nitrogen atom of Ar²wherein P is tert-butyloxycarbonyl, benzyloxycarbonyl, alkoxycarbonyl,alkylcarbonyl, arylcarbonyl or trialkylsilane. Compounds of formula (36)when treated with nitric acid in sulfuric acid will provide compounds offormula (37). Compounds of formula (37) when subjected to reducingconditions such as but not limited to treatment with a palladiumcatalyst and an atmosphere of hydrogen will reduce the nitro group tothe corresponding amine, which is subjected to conditions known to oneskilled in the art that will remove the nitrogen protecting group toprovide compounds of formula (38). Compounds of formula (38) were thenfurther subjected to treatment with an excess of an orthoester offormula (EtO)₃CR^(m) will provide compounds of formula (39) whereinR^(m) is alkyl or aryl.

Benzooxazole-containing compounds of formula (44), wherein L is O, NH,or S, Ar¹ is as previously defined in formula (I), and R^(n) is alkylhydrogen, or aryl, can be prepared as outlined in Scheme 10. Compoundsof formula (40) can be treated with a ditin or diboron reagent offormula (4), such as hexamethylditin, bis(pinacolato)diboron andbis(catecholato)diboron, in the presence of a palladium catalyst toprovide the corresponding tin or boronic acid of formula (41). Compoundsof formula (41) when treated with a halogen containing compound offormula (42) in the presence of a palladium catalyst will providecompounds of formula (43). Compounds of formula (43) when treatedaccording to conditions known to one skilled in the art that will reducenitro groups to the corresponding amine group, followed by treatmentwith a R^(n) substituted ortho ester, wherein R^(n) is hydrogen, alkylor aryl will provide compounds of formula (44).

In addition, compounds of formula (I) wherein A is N can be converted tocompounds of formula (I) wherein A is N⁺—O⁻ by treatment with anoxidizing agent. Examples of the oxidizing agent include, but notlimited to, aqueous hydrogen peroxide and m-chloroperbenzoic acid. Thereaction is generally performed in a solvent such as, but not limitedto, acetonitrile, water, dichloromethane, acetone or mixture thereof,preferably a mixture of acetonitrile and water, at a temperature fromabout 0° C. to about 80° C., for a period of about 1 hour to about 4days.

The compounds and intermediates of the invention may be isolated andpurified by methods well known to those skilled in the art of organicsynthesis. Examples of conventional methods for isolating and purifyingcompounds can include, but are not limited to, chromatography on solidsupports such as silica gel, alumina, or silica derivatized withalkylsilane groups, by recrystallization at high or low temperature withan optional pretreatment with activated carbon, thin-layerchromatography, distillation at various pressures, sublimation undervacuum, and trituration, as described for instance in “Vogel's Textbookof Practical Organic Chemistry”, 5th edition (1989), by Furniss,Hannaford, Smith, and Tatchell, pub. Longman Scientific & Technical,Essex CM20 2JE, England.

The compounds of the invention have at least one basic nitrogen wherebythe compound can be treated with an acid to form a desired salt. Forexample, a compound may be reacted with an acid at or above roomtemperature to provide the desired salt, which is deposited, andcollected by filtration after cooling. Examples of acids suitable forthe reaction include, but are not limited to tartaric acid, lactic acid,succinic acid, as well as mandelic, atrolactic, methanesulfonic,ethanesulfonic, toluenesulfonic, naphthalenesulfonic, carbonic, fumaric,gluconic, acetic, propionic, salicylic, hydrochloric, hydrobromic,phosphoric, sulfuric, citric, or hydroxybutyric acid, camphorsulfonic,malic, phenylacetic, aspartic, glutamic, and the like.

Nitrogen protecting groups can be used for protecting amine groupspresent in the described compounds. Such methods, and some suitablenitrogen protecting groups, are described in Greene and Wuts (ProtectiveGroups In Organic Synthesis, Wiley and Sons, 1999). For example,suitable nitrogen protecting groups include, but are not limited to,tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), benzyl (Bn), acetyl,and trifluoracetyl. More particularly, the Boc protecting group may beremoved by treatment with an acid such as trifluoroacetic acid orhydrochloric acid. The Cbz and Bn protecting groups may be removed bycatalytic hydrogenation. The acetyl and trifluoracetyl protecting groupsmay be removed by a hydroxide ion.

The compounds and processes of the invention will be better understoodby reference to the following Examples, which are intended as anillustration of and not a limitation upon the scope of the invention.

Example 15-{6-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-1H-indoletrifluoroacetate Example 1A(endo)-3-(6-chloro-pyridazin-3-yloxy)-8-methyl-8-aza-bicyclo[3.2.1]octane

A mixture of (endo)-tropine (Aldrich, 706 mg, 5.0 mmol),3,6-dichloropyridazine [Aldrich, 745 mg, 5.0 mmol) and potassiumt-butoxide (Aldrich, 1.12 g, 10 mmol) in THF (anhydrous, Aldrich, 25 mL)was stirred at 60° C. under an atmosphere of nitrogen for 16 hours. Themixture was concentrated under reduced pressure and the residue purifiedby chromatography (150 g SiO₂, EtOAc:MeOH:NH3.H₂O, 90:10:1, R_(f). 0.20)to provide the title compound. ¹H NMR (300 MHz, CD₃OD) δ 2.03-2.36 (m,8H), 2.45 (s, 3H), 3.38 [s (br.), 2H], 5.40 (t, J=5.09 Hz, 1H), 7.20 (d,J=9.16 Hz, 1H), 7.66 (d, J=9.16 Hz, 1H) ppm; MS (DCI/NH₃) m/z 254(M+H)⁺.

Example 1B5-{6-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-1H-indoletrifluoroacetate

The mixture of Example 1A (112 mg, 0.44 mmol),5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indole (Aldrich, 232mg, 0.954 mmol), bis(triphenylphosphine)palladium(II) chloride (Aldrich,7.02 mg, 0.01 mmol) and biphenyl-2-yl-dicyclohexyl-phosphane (StremChemicals, 10.5 mg, 0.03 mmol) in dioxane/EtOH/Na₂CO₃ (aq., 1 M) (v.1/1/1, 3 mL) were heated and microwaved to 150° C. and 300 watts for 15minutes in an Emry™ Creatror microwave. The solid was filtered off witha syringe filter and the organic solution was directly purified bypreparative HPLC (Gilson, column, Xterra® 5:m, 40×100 mm. ElutingSolvent, MeCN/H₂0 containing 0.1% v. TFA (90% to 10% over 25 minutes,Flow rate of 40 mL/minute, uv detector set to 254 nm). The fractionscontaining the desired product were collected and concentrated underreduced pressure and the residue was stirred in etherlethanol (v. 10/1,5 mL) at ambient temperature for 16 hours to provide the title compound.¹H NMR (300 MHz, CD₃OD) δ 2.31-2.60 (m, 8H), 2.85 (s, 3H), 3.97 [s(br.), 2H], 5.53-5.62 (m, 1H), 6.56 (d, J=3.05 Hz, 1H), 7.24-7.34 (m,2H), 7.51 (d, J=8.48 Hz, 1H), 7.74 (dd, J=8.65, 1.86 Hz, 1H), 8.09-8.17(m, 2H) ppm; MS (DCI/NH₃) m/z 335 (M+H)⁺. Anal. Calculated forC₂₀H₂₂N₄O.1.05 CF₃CO₂H.0.50 C₂H₅OH: C, 58.14; H, 5.50; N, 11.74. Found:C, 58.07; H, 5.44; N, 11.75.

Example 2

(endo)-3-(6-Benzo[b]thiophen-5-yl-pyridazin-3-yloxy)-8-methyl-8-aza-bicyclo[3.2.1]octanetrifluoroacetate

The product from Example 1A (121 mg, 0.48 mmol) and2-benzo[b]thiophen-5-yl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane(Maybridge, 219 mg, 0.84 mmol) were treated according to the procedureoutlined in Example 1B to provide the title compound. ¹H NMR (300 MHz,CD₃OD) δ 2.33-2.58 (m, 8H), 2.86 (s, 3H), 3.94-4.02 (m, 2H), 5.57-5.64(m, 1H), 7.34 (d, J=9.15 Hz, 1H), 7.50 (d, J=5.42 Hz, 1H), 7.67 (d,J=5.42 Hz, 1H), 7.98 (dd, J=8.48, 1.70 Hz, 1H), 8.06 (d, J=8.48 Hz, 1H),8.20 (d, J=9.15 Hz, 1H), 8.44 (d, J=1.36 Hz, 1H) ppm. MS (DCI/NH₃): m/z352 (M+H)⁺. Anal. Calculated for C₂₀H₂₁N₃OS.1.10 CF₃CO₂H: C, 55.91; H,4.67; N, 8.81. Found: C, 55.90; H, 4.41; N, 8.59.

Example 3

(endo)-3-[6-(Benzofuran-5-yl)-pyridazin-3-yloxy]-8-methyl-8-aza-bicyclo[3.2.1]octanetrifluoroacetate

The product from Example 1A (131 mg, 0.52 mmol) and1-benzofuran-5-ylboronic acid (Apollo, 166 mg, 1.02 mol) were treatedaccording to the procedure outlined in Example 1B to provide the titlecompound. ¹H NMR (300 MHz, CD₃OD) δ 2.33-2.64 (m, 8H), 2.86 (s, 3H),3.94-4.02 (m, 2H), 5.56-5.63 (m, 1H), 6.96 (d, J=1.36 Hz, 1H), 7.32 (d,J=9.16 Hz, 1H), 7.65 (d, J=8.82 Hz, 1H), 7.84 (d, J=2.37 Hz, 1H), 7.93(dd, J=8.82, 2.03 Hz, 1H), 8.15 (d, J=9.49 Hz, 1H), 8.22 (d, J=1.36 Hz,1H) ppm; MS (DCI/NH₃): m/z 336 (M+H)⁺. Anal. Calculated forC₂₀H₂₁N₃O₂1.1 CF₃CO₂H: C, 57.86; H, 4.83; N, 9.12. Found: C, 58.10; H,4.54; N, 9.06.

Example 46-{6-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-1H-indoletrifluoroacetate

The product of Example 1A (158 mg, 0.62 mmol) was coupled withindole-6-boronic acid (Frontier, 162 mg, 1.01 mol) were treatedaccording to the procedure outlined in Example 1B to provide the titlecompound. ¹H NMR (300 MHz, CD₃OD) δ 2.33-2.59 (m, 8H), 2.85 (s, 3H),3.93-4.01 (m, 2H), 5.58 (t, J=3.05 Hz, 1H), 6.51 (d, J=3.05 Hz, 1H),7.29 (d, J=9.16 Hz, 1H), 7.35 (d, J=3.05 Hz, 1H), 7.58-7.64 (m, 1H),7.66-7.73 (m, 1H), 8.01 (s, 1H), 8.13 (d, J=9.49 Hz, 1H) ppm. MS(DCI/NH₃): m/z 335 (M+H)⁺Anal. Calculated for C₂₀H₂₁N₄O.1.10 CF₃CO₂H: C,57.99; H, 5.06; N, 12.18. Found: C, 58.09; H, 4.95; N, 11.97.

Example 55-{6-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-1H-indazolefumarate Example 5A5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole

A flask containing 5-bromo-1H-indazole (Ref. US 200319951 1, 9.45 g, 48mmol) and bis(pinacolato)diboron (Aldrich, 15.5 g, 61 mmol) in dry DMF(160 mL) was added

KOAc (16.7 g, 170 mmol). The mixture was degassed and purged with N₂three times followed by the addition of PdCl₂(dppf). CH₂Cl₂ (Aldrich,985 mg, 1.21 mmol). The mixture was heated to 90° C. and stirred for 24hours. The mixture was cooled to ambient temperature, diluted with ethylacetate (250 mL), washed with water (2×50 mL). The organic phase wasconcentrated under reduced pressure and the residue was purified bychromatography (400 g SiO₂, hexane:EtOAc 90:10, R_(f)=0.6) to providethe title compound. ¹H NMR (300 MHz, CD₃OD) δ 1.36 (s, 12H), 7.51 (dt,J=8.48, 1.02 Hz, 1H), 7.73 (dd, J=8.48, 1.02 Hz, 1H), 8.08 (d, J=1.02Hz, 1H), 8.23 (t, J=1.02 Hz, 1H) ppm. MS (DCI/NH₃): m/z 245 (M+H)⁺.

Example 5B5-{-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-1H-indazole

A mixture of Example 1A (158 mg, 0.62 mmol) and the product of Example5A (308 mg, 1.26 mol) were treated withbis(triphenylphosphine)palladium(II) chloride (Aldrich, 7.02 mg, 0.01mmol) and biphenyl-2-yl-dicyclohexyl-phosphane (Strem Chemicals, 10.5mg, 0.03 mmol) in dioxane/EtOH/Na₂CO₃ (aq., 1 M) (v. 1/1/1, 3 mL) wereheated and microwaved to 150° C. and 300 watts for 15 minutes in anEmry™ Creator microwave reactor. The mixture was cooled to ambienttemperature, solid was filtered off with a syringe filter and theorganic solution was directly purified by chromatography (40 g SiO₂,EtOAc:MeOH:NH₃H₂O, 90:10:1, R_(f)=0.10) to provide the title compound.¹H NMR (300 MHz, CD₃OD) δ 2.02-2.33 (m, 8H), 2.36 (s, 3H), 3.25 [s(br.), 2H], 5.47 (t, J=4.92 Hz, 1H), 7.23 (d, J=9.16 Hz, 1H), 7.67 (dt,J=8.82, 0.85 Hz, 1H), 8.07 (dd, J=8.82, 1.70 Hz, 1H), 8.10-8.19 (m, 2H),8.36 (dd, J=1.53, 0.85 Hz, 1H) ppm; MS (DCI/NH₃): m/z 336 (M+H)⁺.

Example 5C5-{6-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-1H-indazolefumarate

The product of Example 5B (128 mg, 0.38 mmol) was treated with fumaricacid (46 mg, 0.40 mmol) in EtOAc/EtOH (v. 1:1, 5 mL) at ambienttemperature for 15 hours. The mixture was filtered to provide the titledcompound. ¹H NMR (300 MHz, CD₃OD) 6 2.29-2.61 (m, 8H), 2.86 (s, 3H),3.90-3.99 (m, 2H), 5.59 (t, J=4.92 Hz, 1H), 6.69 (s, 2H), 7.32 (d,J=9.16 Hz, 1H), 7.68 (d, J=8.82 Hz, 1H), 8.08 (dd, J=8.82, 1.70 Hz, 1H),8.15-8.21 (m, 2H), 8.38 (dd, J=1.70, 0.68 Hz, 1H) ppm; MS (DCI/NH3): m/z336 (M+H)⁺. Anal. Calcd. for C₁₉H₂₁N₅O.1.20 C₄H₄O₄: C, 60.22; H, 5.48;N, 14.75. Found: C, 60.03; H, 5.17; N, 14.85.

Example 61-Methyl-5-{6-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-1H-indoletrifluoroacetate

The product of Example 1A (121 mg, 0.48 mmol) andN-methylindole-5-boronic acid (Frontier, 175 mg, 1 .O mol) were treatedaccording to the procedure outlined in Example 1B to provide the titlecompound. ¹H NMR (300 MHz, CD₃OD) δ 2.22-2.70 (m, 8H), 2.86 (s, 3H),3.93-4.03 (m, 2H), 5.53-5.62 (m, 1H), 6.57 (d, J=3.05 Hz, 1H), 7.26 (d,J=3.39 Hz, 1H), 7.37 (d, J=9.49 Hz, 1H), 7.54 (d, J=8.82 Hz, 1H), 7.80(dd, J=8.65, 1.87 Hz, 1H), 8.16 (d, J=1.70 Hz, 1H), 8.21 (d, J=9.16 Hz,1H) ppm; MS (DCI/NH₃): m/z 349 (M+H)⁺. Anal. Calculated forC₂₁H₂₄N₄O.1.60 CF₃CO₂H: C, 54.75; H, 4.86; N, 10.55. Found: C, 54.69; H,4.80; N, 10.58.

Example 75-{6-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-2-trifluoromethyl-1H-indoletrifluoroacetate Example 7A5-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-2-trifluorormethhl-1H-indole

A mixture of 5-Bromo-2-trifluoromethyl-1H-indole (Ref. US 2005043347,6.05 g, 22.9 mmol), bis(pinacolato)diboron (7.74 g, 30.5 mmol), KOAc(8.05 g, 82 mmol) and PdCl₂(dppf) CH₂Cl₂ (901 mg, 1.1 mmol) in anhydrousDMF (242 mL) were processed according to the procedure of outlined inExample 5A to provide the titled compound. ¹H NMR (300 MHz, CD₃OD) δ1.36 (s, 12H), 6.91 (s, 1H), 7.43 (d, J=8.48 Hz, 1H), 7.64 (d, J=8.14Hz, 1H), 8.11 (s, 1H) ppm; MS (DCI/NH₃): 312 (M+H)⁺.

Example 7B (exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl-4-nitro-benzoate

To a mixture of (endo)-tropine (2.82 g, 20.0 mmol), 4-nitrobenzoic acid(3.34 g, 20.0 mmol) and triphenylphosphine (5.24 g, 20.0 mmol) in dryTHF (100 mL) at room temperature was added diisopropyl azodicarboxylate(4.04 g, 20.0 mmol) and the resulting mixture stirred for 40 hours. Themixture was concentrated under reduced pressure and the residue purifiedby chromatography (140 g SiO₂, EtOAc:MeOH:NH₃H₂O, 90:10:1, R_(f)=0.30)to provide the titled compound. ¹H NMR (300 MHz, CD₃OD) δ 1.74-2.23 (m,8H), 2.38 (s, 3H), 3.32-3.38 (m, 2H), 5.23-5.38 (m, 1H), 8.21 (d, J=8.82Hz, 2H), 8.32 (d, J=8.82 Hz, 2H) ppm; MS (DCI/NH₃): 291 (M+H)⁺.

Example 7C (exo)-8-methyl-8-aza-bicyclo[3.2.1]octan-3-ol

The product of Example 7B (5.0 g, 0.017 mol) in ethanol (10 mL) wastreated with NaOH (IN, 200 mL) at room temperature for 40 hours. Themixture was extracted with the mixture of 10% isopropanol in chloroform(3×100 mL) and the combined extracts concentrated under reduced pressureto provide the title compound. ¹H NMR (300 MHz, CD₃OD) δ 1.55-1.69 (m,4H), 1.80 (m, 2H), 1.99-2.09 (m, 2H), 2.28 (s, 3H), 3.14-3.21 (m, 2H),3.79-3.93 (m, 1H) ppm. MS (DCI/NH₃): 142 (M+H)⁺.

Example 7D(exo)-3-(6-chloro-pyridazin-3-yloxy)-8-methyl-8-aza-bicyclo[3.2.1]octane

The product of Example 7D (721 mg, 5.1 mmol) and 3,6-dichlropyridazine(1.04 g, 7.0 mmol) were treated according to the procedure outlined inExample 1A to provide the title compound. ¹H NMR (300 MHz, CD₃OD) δ1.87-2.07 (m, 4H), 2.23-2.31 (m, 2H), 2.37 (m, 2H), 3.60-3.69 (m, 2H),5.54 (m, 1H), 7.15 (d, J=9.16 Hz, 1H), 7.64 (d, J=9.16 Hz, 1H) ppm; MS(DCI/NH₃): 254 (M+H)⁺.

Example 7E5-{6-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-2-trifluoromethyl-1H-indoletrifluoroacetate

The product of Example 7D (128 mg, 0.5 mmol) and the product of Example7A (311 mg, 1.0 mmol) were treated according to the procedure outlinedin Example 1B to provide the title compound. ¹H NMR (300 MHz, CD₃OD) δ2.01-2.73 (m, 8H), 2.85 (s, 3H), 4.01-4.10 (m, 2H), 5.64-5.80 (m, 1H),7.02 (s, 1H), 7.23 (d, J=9.15 Hz, 1H), 7.60 (d, J=8.48 Hz, 1H), 7.95(dd, J=8.48, 1.70 Hz, 1H), 8.13 (d, J=9.49 Hz, 1H), 8.26 (d, J=1.02 Hz,1H) ppm; MS (DCI/NH₃): m/z 403 (M+H)⁺. Anal. Calculated forC₂₁H₂₁F₃N₄O.1.55 CF₃CO₂H: C, 49.98; H, 3.92; N, 9.67. Found: C, 49.93;H, 4.09; N, 9.69.

Example 85-{6-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-1H-indolefumarate

The product of Example 7D (154 mg, 0.61 mmol) and5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-IH-indol (Aldrich, 243mg, 1.0 mmol) were treated with bis(triphenylphosphine)palladium(II)chloride (Aldrich, 7.02 mg, 0.01 mmol) andbiphenyl-2-yl-dicyclohexyl-phosphane (Strem Chemicals, 10.5 mg, 0.03mmol) in dioxane/EtOH/aqeous 1M Na₂CO₃ (v. 1/1/1.3 mL) were heated andmicrowaved to 150° C. and 300 watts for 15 minutes in an Emry™ Creatrormicrowave. The mixture was cooled to ambient temperature, the solid wasfiltered off with a syringe filter and the organic solution was directlypurified by preparative HPLC (Gilson, Xterra® column, 7 μm, 40×100 mm,eluting solvent, MeCN/H₂O (with 0.1 M NH₄HCO₃/NH₄OH, PH=10) (v. 90/10 to10/90 over 25 minutes), flow rate, 40 mL/min., uv, 254 nm) to providethe free base of the titled compound. The free base was treated withfumaric acid (65 mg, 0.57 mmol) according to the procedure of Example 5Cto provide the title compound. ¹H NMR (300 MHz, CD₃OD) δ 2.04-2.50 (m,6H), 2.57-2.69 (m, 2H), 2.85 (s, 3H), 3.99-4.05 (m, 2H), 5.63-5.78 (m,1H), 6.56 (d, J=3.05 Hz, 1H), 6.69 (s, 2H), 7.20 (d, J=9.15 Hz, 1H),7.31 (d, J=3.39 Hz, 1H), 7.51 (d, J=8.48 Hz, 1H), 7.74 (dd, J=8.48, 1.70Hz, 1H), 8.09 (d, J=9.49 Hz, 1H), 8.14 (d, J=1.02 Hz, 1H) ppm; MS(DCI/NH₃): m/z 335 (M+H)⁺; Anal. Calculated for C₂₀H₂₂N₄O.1.20 C₄H₄O₄:C, 62.88; H, 5.70; N, 11.83. Found: C, 62.63; H, 5.70; N, 11.96.

Example 95-{5-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indolebistosylate Example 9A(endo)-3-(6-Chloro-pyridin-3-yloxy)-8-methyl-8-aza-bicyclo[3.2.1]octane

The mixture of (endo)-tropine (Aldrich, 2.82 g, 20 mmol),2-chloro-5-iodopyridine (Aldrich, 2.39 g, 24 mmol), CuI (StremChemicals, 0.19 g, 1 mmol) and 1,10-phenanthroline (Aldrich, 0.36 g, 2mmol), Cs₂CO₃ (Aldrich, 6.52 g, 20 mmol) in toluene (anhydrous, Aldrich,25 mL) was stirred at 110° C. for 40 hours. The mixture allowed to coolto ambient temperature and was diluted with CH₂Cl₂ (100 mL) and washedwith water (2×10 mL). The organic solution was concentrated and thetitle compound was purified by chromatography (SiO₂,CH₂Cl₂:MeOH:NH₃.H₂O, 90:10:1, R_(f). 0.10) to provide the titledcompound. ¹H NMR (300 MHz, CD₃OD) δ 1.97-2.08 (d, J=14.5 Hz, 2H),2.13-2.18 (d, J=2.37 Hz, 2H), 2.45 (s, 3H), 3.35-3.41 (m, 2H), 4.66 (t,J=4.8 Hz, 1H), 7.35-7.42 (m, 2H), 7.96-8.04 (dd, J=2.3, 1.0 Hz, 1H) ppm.MS (DCI/NH₃) m/z 255 (M+H)⁺, 253 (M+H)⁺.

Example 9B5-{5-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indole

The mixture of the product from Example 9A (150 mg, 0.59 mmol),5-indolylboronic acid (Rsycor, 143.3 mg, 0.89 mmol), Pd(PPh₃)₄ (Aldrich,6.8 mg, 0.006 mmol) and K₂CO₃ (2 M, 1 mL) was heated to 85° C. indioxane (4 mL) for 12 hours. The mixture was cooled to ambient, filteredand purified by preparative HPLC [Waters XTerra RP18 column, 30×100 mm,eluting solvents, MeCN/H₂O (0.1 M aqueous ammonium bicarbonate, adjustedto pH 10 with ammonium hydroxide) (v. 90/10 to 10/90 over 20 min.), flowrate 40 mL/min, uv, 250 nm] to provide the titled compound. ¹H NMR (300MHz, CD₃OD) δ1.94-2.06 (m, 2H), 2.06-2.27 (m, 6H), 2.34 (s, 3H), 3.21 [s(br.), 2H], 4.67 (t, J=4.75 Hz, 1H), 6.52 (dd, J=3.05, 1.00 Hz, 1H),7.26 (d, J=3.39 Hz, 1H), 7.40 (dd, J=8.82, 3.05 Hz, 1H), 7.45 (dt,J=8.48, 0.7 Hz, 1H), 7.63 (dd, J=8.65, 1.87 Hz, 1H), 7.77 (dd, J=8.82,0.70 Hz, 1H), 7.99-8.08 (m, 1 H), 8.18 (d, J=3.05 Hz, 1H) ppm. MS(DCI/NH₃) m/z 334 (M+H)⁺.

Example 9C5-{5-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indolebistosylate

The product of Example 9B (40 mg, 0.12 mmol) was treated withptoluenesulfonic acid monohydrate TsOH H₂O (Aldrich, 38 mg, 0.2 mmol) ina mixture of 25% isopropanol in iso-propylacetate (5 mL) at ambienttemperature for 10 hours. The mixture was filtered to provide the titledcompound. ¹H NMR (300 MHz, CD₃OD) δ 2.25-2.56 (m, 13H), 2.77-2.89 (m,4H), 3.87-4.03 (m, 2H), 4.90-2.04 (m, 1H), 6.66 (dd, J=3.1, 0.7 Hz, 1H),7.19 (d, J=8.10 Hz, 4H), 7.43 (d, J=3.39 Hz, 1H), 7.55-7.65 (m, 2H),7.68 (d, J=8.14 Hz, 4H), 8.10-8.17 (m, 1H), 8.22-8.38 (m, 2H), 8.46 (d,J=2.03 Hz, 1H) ppm. MS (DCI/NH₃): m/z 334 (M+H)⁺. Anal. Calculated forC₂₁H₂₃N₃O 2.05 C₇H₈SO₃.2.00H₂O: C, 57.52; H, 6.17; N, 5.72. Found: C,57.88; H, 5.99; N, 5.33.

Example 10(endo)-3-(6-Benzo[b]thiophen-5-yl-pyridin-3-yloxy)-8-methyl-8-aza-bicyclo[3.2.1]octanebistosylate Example 10A2-Benzo[b]thiophen-5-yl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane

A mixture of 5-bromo-benzo[b]thiophene (Maybridge, 4.26 g, 0.0200 mol),bis(pinacolato)diboron (Aldrich, 6.09 g, 0.0240 mol) and potassiumacetate (Aldrich, 2.94 g, 0.0300 mol) in 1,4-dioxane (Aldrich, 50 mL)was degassed and purged with N₂ three times.[1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) PdCl₂ (dppf)CH₂Cl₂ (300 mg, 0.4 mmol, Aldrich) was and the solution was heated to100° C. for 20 hours. The mixture was then cooled to room temperature,diluted with 300 mL of EtOAc and washed with brine (2×20 mL). Theorganic solution was concentrated under reduced pressure and the residuewas chromatographed to provide the title product. ¹H NMR (300 MHz,CDCl₃) δ 1.36-1.41 (S, 12H), 7.35 (d, J=5.50 Hz, 1H), 7.42 (d, J=5.70Hz, 1H), 7.75 (d, J=8.14 Hz, 1H), 7.89 (d, J=8.14 Hz, 1H), 8.31 (s, 1H)ppm. MS (DCI/NH₃) m/z 278 (M+H)⁺.

Example 10B(endo)-3-(6-Benzo[b]thiophen-5-yl-pyridin-3-yloxy)-8-methyl-8-aza-bicyclo[3.2.1]octane

The product from Example 9A (150 mg, 0.59 mmol) and the product of 10A(231.6 mg, 0.89 mmol) was treated with Pd(PPh₃)₄ (Aldrich, 6.8 mg, 0.006mmol) according to the procedure of outlined in Example 9B. The titleproduct was purified by preparative HPLC [Waters XTerra RP18 column,30×100 mm, eluting solvents, MeCN/H₂O (0.1 M aqueous ammoniumbicarbonate, adjusted to pH 10 with ammonium hydroxide) (v. 90/10 to10/90 over 20 min.), flow rate 40 mL/min, uv, 250 nm]. ¹H NMR (300 MHz,CD₃OD) δ 1.93-2.07 (m, 2H), 2.06-2.28 (m, 6H), 2.34 (s, 3H), 3.21 [s(br.), 2H], 4.70 (t, J=5.26 Hz, 1H), 7.37-7.50 (m, 2H), 7.61 (d, J=5.43Hz, 1H), 7.80-7.92 (m, 2H), 7.94-8.02 (m, 1H), 8.25 (d, J=2.71 Hz, 1H),8.34 (d, J=1.36 Hz, 1H) ppm. MS (DCI/NH₃) m/z 351 (M+H)⁺.

Example 10C(endo)-3-(6-Benzo[b]thiophen-5-yl-pyridin-3-yloxy)-8-methyl-8-aza-bicyclo[3.2.1]octanebistosylate

The product of Example 10B (70 mg, 0.20 mmol) was treated withptoluenesulfonic acid monohydrate TsOH H₂O (Aldrich, 38 mg, 0.2 mmol) ina mixture of 25% isopropanol in isopropyl acetate as outlined inExampled 9C. The mixture was filtered to provide the titled compound. ¹HNMR (300 MHz, CD₃OD) δ 2.35 (s, 6H), 2.48-2.62 (m, 8H), 2.78 (s, 3H),3.88-4.05 (m, 2H), 5.02 (t, J=4.58 Hz, 1H), 7.22 (d, J=7.80 Hz, 4H),7.55 (d, J=5.76 Hz, 1H), 7.70 (d, J=8.48 Hz, 4H), 7.75-7.84 (m, 2H),8.12-8.22 (m, 2H), 8.29 (d, J=9.20 Hz, 1H) 8.37 (d, J=1.70 Hz, 1H), 8.56(d, J=3.05 Hz, 1H) ppm. MS (DCI/NH₃): m/z 351 (M+H)⁺. Anal. Calculatedfor C₂₁H₂₃N₂OS 2.00 C₇H₈SO₃.1.00H₂O: C, 58.97; H, 5.66; N, 3.93. Found:C, 58.86; H, 5.61; N, 5.71.

Example 115-{5-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indoletosylate Example 11A

(exo)-3-(6-Chloro-pyridin-3-yloxy)-8-methyl-8-aza-bicyclo[3.2.1]octanetosylate To the mixture of (endo)-tropine (Aldrich, 2.82 g, 20 mmol),2-chloro-5-hydroxypyridine (Aldrich, 1.29 g, 10 mmol) and Ph₃P (Aldrich,5.24 g, 20 mmol) was added diisopropyl azadicarboxylate (Aldrich, 4.04g, 20 mmol) in THF (anhydrous, Aldrich, 100 mL) and the mixture wasstirred for two days. The mixture was concentrated under reducedpressure and the title product was purified by chromatography (SiO₂,CH₂Cl₂:MeOH:NH₃.H₂O, 90:10:1, R_(f). 0.40) as solid (1.98 g, yield,78.3%). ¹H NMR (300 MHz, CD₃OD) δ 1.63-1.92 (m, 4H), 1.97-2.20 (m, 4H),2.33 (s, 3H), 3.34 (s, 2H), 4.51-4.75 (m, 1H), 7.27-7.37 (dd, J=8.80,0.7 Hz, 1H), 7.37-7.49 (dd, J=8.80, 3.00 Hz, 1H), 8.01 (d, J=3.05 Hz,1H) ppm. MS (DCI/NH₃) m/z 255 (M+H)⁺, 253 (M+H)⁺.

Example 11B5-{5-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxyl]-pyridin-2-yl}-1H-indole

The mixture of the product from Example 11A (150 mg, 0.59 mmol),5-Indolylboronic acid (Rsycor, 143.3 mg, 0.89 mmol) and Pd(PPh₃)₄(Aldrich, 6.8 mg, 0.006 mmol) and K₂CO₃ (2 M, 1 mL) in dioxane (4 mL)was stirred at 85° C. for 12 hours according to the procedure ofoutlined in Example 9B. The title product was purified by preparativeHPLC [Waters XTerra RP18 column, 30×100 mm, eluting solvents, MeCN/H₂O(0.1 M aqueous ammonium bicarbonate, adjusted to pH 10 with ammoniumhydroxide) (v. 90/10 to 10/90 over 20 min.), flow rate 40 mL/min, uv,250 nm]. ¹H NMR (300 MHz, CD₃OD) δ 1.61-1.97 (m, 4H), 2.00-2.23 (m, 4H),2.35 (s, 3H), 3.22-3.38 (m, 2H), 4.56-4.78 (m, 1H), 6.51 (d; J=4.07 Hz,1H), 7.26 (d, J=3.39 Hz, 1H), 7.40-7.52 (m, 2H), 7.62 (dd, J=8.48, 1.70Hz, 1H), 7.75 (d, J=8.82 Hz, 1H), 8.03 (s, 1H), 8.21 (d, J=2.37 Hz, 1H)ppm. MS (DCI/NH₃) m/z 334 (M+H)⁺.

Example 11C5-{5-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indoletosylate

The product of Example 11B (50 mg, 0.15 mmol) was treated withp-toluenesulfonic acid monohydrate TsOH.H₂O (Aldrich, 38 mg, 0.2 mmol)in a mixture of 25% isopropanol in isopropyl acetate (5 mL) at ambienttemperature for 10 hours according to the procedure of Example 9C. Themixture was filtered to provide the titled compound. ¹H NMR (300 MHz,CD₃OD) δ 1.90-2.13 (m, 2H), 2.17-2.31 (m, 2H), 2.33-2.42 (m, 5H),2.44-2.58 (m, 2H), 2.83 (s, 3H), 4.02[s (br.), 2H], 4.86-5.03 (m, 1H),6.53 (dd, J=3.22, 0.85 Hz, 1H), 7.22 (d, J=8.14 Hz, 1H), 7.26-7.32 (m,1H), 7.47 (d, J=8.48 Hz, 1H), 7.56-7.66 (m, 2H), 7.70 (dt, J=8.10, 1.80Hz, 2H), 7.82 (d, J=8.82 Hz, 1H), 8.05 (d, J=1.36 Hz, 1H), 8.28 (d,J=3.05 Hz, 1H) ppm. MS (DCI/NH₃): m/z 334 (M+H)⁺. Anal. Calculated forC₂₁H₂₃N₃O.1.00 C₇H₈SO₃.1.00H₂O: C, 64.22; H, 6.35; N, 8.02. Found: C,64.07; H, 6.16; N, 7.69.

Example 12(exo)-3-[6-(Benzofuran-5-yl)-pyridin-3-yloxy]-8-methyl-8-aza-bicyclo[3.2.1]octanebistrifluoroacetate

The product of Example 11A (130 mg, 0.52 mmol) and1-benzofuran-5-ylboronic acid (Maybridge, 166 mg, 1.0 mmol) were treatedaccording to the procedure outlined in Example 1B to provide the titlecompound. ¹H NMR (300 MHz, CD₃OD) δ 1.98-2.58 (m, 8H), 2.84 (s, 3H),3.98-4.09 (m, 2H), 4.93-5.07 (m, 1H), 6.94 (d, J=1.36 Hz, 1H), 7.62 (d,J=8.81 Hz, 1H), 7.73 (dd, J=8.81, 3.05 Hz, 1H), 7.80-7.86 (m, 2H), 7.92(d, J=8.48 Hz, 1H), 8.13 (d, J=1.36 Hz, 1H), 8.38 (d, J=2.37 Hz, 1H)ppm; MS (DCI/NH₃): m/z 335 (M+H)⁺. Anal. Calculated for C₂₁H₂₂N₂O₂2.00CF₃CO₂H: C, 53.39; H, 4.30; N, 4.98. Found: C, 53.28; H, 4.04; N, 4.95.

Example 135-{5-[(exo)-8-Methyl-8-aza-bicyclo[32.1]oct-3-yloxy]-pyridin-2-yl}-1H-indazolehemifumarate

The product of Example 11A (139 mg, 0.55 mmol) and the product ofExample 5A (325 mg, 1.3 mmol) were treated according to the procedureoutlined in Example 8 to provide the title compound. ¹H NMR (300 MHz,CD₃OD) δ 1.97-2.45 (m, 8H), 2.73 (s, 3H), 3.80-3.89 (m, 2H), 4.84-4.96(m, 1H), 6.68 (s, 1H), 7.56 (dd, J=8.82, 3.05 Hz, 1H), 7.62 (d, J=8.82Hz, 1H), 7.84 (d, J=8.82 Hz, 1H), 7.97 (dd, J=8.82, 1.70 Hz, 1H), 8.12(d, J=1.02 Hz, 1H), 8.27 (dd, J=1.53, 0.85 Hz, 1H), 8.32 (d, J=3.05 Hz,1H) ppm; MS (DCI/NH₃): m/z 335 (M+H)⁺.

Example 145-{5-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-2-trifluoromethyl-1H-indolefumarate

The product of Example 11A (130 mg, 0.52 mmol) and the product ofExample 7A (319 mg, 1.0 mmol) were treated according to the procedureoutlined in Example 8 to provide the title compound. ¹H NMR (300 MHz,CD₃OD) δ 1.99-2.53 (m, 8H), 2.83 (s, 3H), 3.96-4.03 (m, 2H), 4.85-5.02(m, 1H), 6.69 (s, 2H), 6.97 (s, 1H), 7.50-7.62 (m, 2H), 7.78-7.88 (m,2H), 8.16 (d, J=1.36 Hz, 1H), 8.31 (d, J=2.71 Hz, 1H) ppm; MS (DCI/NH₃):m/z 402 (M+H)⁺. Anal. Calculated for C₂₂H₂₂F₃N₃O.1.20 C₄O₄H₄: C, 59.53;H, 5.00; N, 7.77. Found: C, 59.26; H, 5.06; N, 7.86.

Example 154-{5-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indolebistrifluoroacetate

The product of Example 11A (130 mg, 0.52 mmol) and indole-4-boronic acid(Apollo, 165 mg, 1.0 mmol) were treated according to the procedureoutlined in Example 1B to provide the title compound. 1H NMR (300 MHz,CD₃OD) δ 2.03-2.64 (m, 8H), 2.85 (s, 3H), 4.00-4.10 (m, 2H), 5.02-5.16(m, 1H), 6.70 (d, J=2.37 Hz, 1H), 7.25-7.40 (m, 2H), 7.44 (d, J=3.05 Hz,1H), 7.59 (d, J=7.80 Hz, 1H), 8.01-8.17 (m, 2H), 8.50 (d, J=2.71 Hz, 1H)ppm; MS (DCI/NH₃): m/z 334 (M+H)⁺; Anal. Calculated for C₂₁H₂₃N₃O.2.00C₂F₃O₂H: C, 53.48; H, 4.49; N, 7.48. Found: C, 53.29; H, 4.17; N, 7.35.

Example 164-{5-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-phenylaminebistrifluoroacetate Example 16A4-{5-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-phenylamine

The product of Example 11A (379 mg, 1.5 mmol) and4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine (Aldrich,552 mg, 2.5 mmol) were processed according to the procedure of Example5B. The mixture was purified by chromatography (140 g SiO₂,EtOAc:MeOH:NH₃H₂O, 90:10:1) to provide the title compound. ^(1H) NMR(300 MHz, CD₃OD) δ 1.76-1.91 (m, 4H), 2.08-2.21 (m, 4H), 3.35-3.42 [s(br.), 2H], 4.62-4.76 (m, 1H), 6.73-6.81 (m, 2H), 7.42 (dd, J=8.81, 3.05Hz, 1H), 7.57-7.68 (m, 3H), 8.15 (d, J=2.37 Hz, 1H) ppm; MS (DCI/NH₃):m/z 310 (M+H)⁺.

Example 16B4-{5-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-phenylaminebistrifluoroacetate

The product of Example 16A (135 mg, 0.44 mmol) was repurified bypreparative HPLC (Gilson, Xterra® column, 5 μm, 40×100 mm. ElutingSolvent, MeCN/H₂O (with 0.1% v. TFA) (v. 90/10 to 10/90 over 25 min.)Flow rate, 40 mL/min., uv, 254 nm). The fractions of the desired productwere collected and concentrated under reduced pressure and the residuewas stirred in Ether/Ethanol (v. 10/1, 5 mL) at room temperature for 16hours. The mixture was filtered to provide the bis trifluoroacetatesalt. ¹H NMR (300 MHz, CD₃OD) δ 1.99-2.56 (m, 8H), 4.03 [s (br.), 2H],4.93-5.07 (m, 1H), 6.96-7.07 (m, 2H), 7.73-7.86 (m, 3H), 7.88-7.98 (m,1H), 8.32 (d, J=3.05 Hz, 1H) ppm; MS (DCI/NH₃) m/z 310 (M+H)⁺; Anal.Calculated for C₁₉H₂₃N₃O.2.30 CF₃CO₂H: C, 49.58; H, 4.46; N, 7.53.Found: C, 49.58; H, 4.36; N, 7.44.

Example 175-{6-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-3-yl}-1H-indoletosylate Example 17A(endo)-3-(5-Bromo-pyridin-2-yloxy)-8-methyl-8-aza-bicyclo[3.2.1]octane

(endo)-Tropine (Aldrich, 282 mg, 2 mmol) was treated with ^(t)BuOK(Aldrich, 224 mg, 2 mmol) in THF (20 mL) at ambient temperature for 1hour followed by the addition of 3,6-dibromopyridine (Aldrich, 569 mg,2.4 mmol). The mixture was stirred at 60° C. for additional 10 hours andthen concentrated under reduced pressure. The residue was dissolved inCHCl₃/isopropanol (10:1, 50 mL) and washed with brine (2×5 mL). Theorganic solution was concentrated under reduced pressure and the titlecompound was purified by chromatography (SiO₂, CH₂Cl₂:MeOH:NH₃H₂O,90:10:1, R_(f). 0.10). ¹H NMR (300 MHz, CD₃OD) δ 1.93 (d, J=14.50 Hz,2H), 2.02-2.23 (m, 6H), 2.31 (s, 3H), 3.17 [s (br.), 2H], 5.16 (t,J=5.26 Hz, 1H), 6.70 (d, J=8.82 Hz, 1H), 7.77 (dd, J=8.81, 2.71 Hz, 1H),8.16 (d, J=2.71 Hz, 1H) ppm. MS (DCI/NH₃): 299 (M+H)⁺, 297 (M+H)⁺.

Example 17B5-{6-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-3-yl}-1H-indole

The mixture of the product from Example 17A (150 mg, 0.50 mmol),5-indolylboronic acid (Rsycor, 121.9 mg, 0.75 mmol), Pd(PPh3)₄ (Aldrich,6.8 mg, 0.006 mmol) and K2C03 (2 M, 1 mL) in dioxane (4 mL) was stirredat 85° C. for 12 hours according to the procedure of outlined in Example9B. The title product was purified by preparative HPLC [Waters XTerraRP18 column, 30×100 mm, eluting solvents, MeCN/H₂O (0.1 M aqueousammonium bicarbonate, adjusted to pH 10 with ammonium hydroxide) (v.90/10 to 10/90 over 20 min.), flow rate 40 mL/min, uv, 250 nm]. ¹H NMR(300 MHz, CD₃OD) δ 2.01 (d, J=14.30 Hz, 2H), 2.06-2.28 (m, 6H), 2.34 (s,3H), 3.17-3.26 (m, 2H), 5.19 (t, J=5.26 Hz, 1H), 6.49 (d, J=2.37 Hz,1H), 6.82 (d, J=8.48 Hz, 1H), 7.26 (d, J=3.05 Hz, 1H), 7.31 (dd, J=8.48,1.70 Hz, 1H), 7.45 (d, J=8.48 Hz, 1H), 7.73 (s, 1H), 7.96 (dd, J=8.65,2.54 Hz, 1H), 8.35 (d, J=2.03 Hz, 1H) ppm. MS (DCI/NH₃) m/z 334 (M+H)⁺.

Example 17C5-{6-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-3-yl}-1H-indolebistosylate

The product of Example 11B (40 mg, 0.15 mmol) was treated withp-toluenesulfonic acid monohydrate TsOH.H₂O (Aldrich, 38 mg, 0.2 mmol)in a mixture of 25% isopropanol in isopropyl acetate (5 mL) at ambienttemperature for 10 hours according to the procedure outlined in Example9C. The mixture was filtered to provide the title compound. ¹H NMR (300MHz, CD₃OD) δ 2.32-2.58 (m, 14H), 2.81-2.88 (s, 3H), 3.89-4.01 (m, 2H),5.27-5.41 (m, 1H), 6.52 (d, J=3.39 Hz, 1H), 7.13 (d, J=8.48 Hz, 1H),7.23 (d, J=7.80 Hz, 4H), 7.35 (dd, J=8.48, 2.03 Hz, 1H), 7.49 (d, J=8.48Hz, 1H), 7.70 (d, J=8.14 Hz, 4H), 7.79 (s, 1H), 8.24 (dd, J=8.65, 2.54Hz, 1H), 8.47 (d, J=2.71 Hz, 1H) ppm. MS (DCI/NH₃): m/z 334 (M+H)⁺.Anal. Calculated for C₂₁H₂₃N₃O.2.20 C₇H₈SO₃.2.00H₂O: C, 58.42; H, 6.01;N, 5.62. Found: C, 58.02; H, 5.84; N, 5.31.

Example 18(endo)-3-(5-Benzo[b]thiophen-5-yl-pyridin-2-yloxy)-8-methyl-8-aza-bicyclo[3.2.1]octanetosylate Example 18A(endo)-3-(5-Benzo[b]thiophen-5-yl-pyridin-2-yloxy)-8-methyl-8-aza-bicyclo[3.2.1]octane

The mixture of Example 17A (150 mg, 0.50 mmol), the product of Example10A (197.0 mg, 0.75 mmol), Pd(PPh₃)₄ (Aldrich, 6.8 mg, 0.006 mmol) andK₂CO₃ (2 M, 1 mL) in dioxane (4 mL) was processed according to theprocedure outlined in Example 9B. The title product was purified bypreparative HPLC [Waters XTerra RP18 column, 30×100 mm, elutingsolvents, MeCN/H₂O (0.1 M aqueous ammonium bicarbonate, adjusted to pH10 with ammonium hydroxide) (v. 90/10 to 10/90 over 20 min.), flow rate40 mL/min, uv, 250 nm]. ¹H NMR (300 MHz, CD₃OD) δ 1.99 (d, J=14.50 Hz,1H), 2.03-2.28 (m, 6H), 2.33 (s, 3H), 3.14-3.25 (m, 2H), 5.23 (t, J=5.26Hz, 1H), 6.86 (d, J=8.48 Hz, 1H), 7.43 (d, J=5.43 Hz, 1H), 7.57 (dd,J=8.48, 1.70 Hz, 1H), 7.61 (d, J=5.43 Hz, 1H), 7.91-8.09 (m, 3H), 8.42(d, J=1.70 Hz, 1H) ppm. MS (DCI/NH₃) m/z 351 (M+H)⁺.

Example 18B(endo)-3-(5-Benzo[b]thiophen-5-yl-pyridin-2-yloxy)-8-methyl-8-aza-bicyclo[3.2.1]octanetosylate

The product of Example 18A (60 mg, 0.17 mmol) was treated withp-toluenesulfonic acid monohydrate TsOH.H₂O (Aldrich, 38 mg, 0.2 mmol)in a mixture of 25% isopropanol in isopropyl acetate (5 mL) at ambienttemperature for 10 hours according to the procedure outlined in Example9C. The mixture was filtered to provide the titled compound. ¹H NMR (300MHz, CD₃OD) δ 2.34-2.45 (m, 9H), 2.48-2.55 (m, 2H), 2.84 (s, 3H),3.88-4.00 (m, 2H), 5.39 (t, J=4.41 Hz, 1H), 7.06 (d, J=8.82 Hz, 1H),7.23 (d, J=7.80 Hz, 2H), 7.45 (d, J=5.43 Hz, 1H), 7.59 (dd, J=8.48, 1.70Hz, 1H), 7.64 (d, J=5.76 Hz, 1H), 7.70 (d, J=8.48 Hz, 2H), 8.00 (d,J=8.48 Hz, 1H), 8.08 (d, J=1.36 Hz, 1H), 8.18 (dd, J=8.82, 2.37 Hz, 1H),8.51 (d, J=2.03 Hz, 1H) ppm. MS (DCI/NH₃): m/z 351 (M+H)⁺. Anal.Calculated for C₂₁H₂₃N₂OS.1.10 C₇H₈SO₃.1.00H₂O: C, 61.79; H, 5.93; N,5.02. Found: C, 61.44; H, 5.63; N, 4.68.

Example 195-{6-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-3-yl}-1H-indolefumarate Example 19A(exo)-3-(5-Bromo-pyridin-2-yloxy)-8-methyl-8-aza-bicyclo[3.2.1]octane

The product of Example 7C (721 mg, 5.1 mmol) and 2,5-dibromopyridine(1.66 g, 7.0 mmol) were treated according to the procedure outlined inExample 1A to provide the title compound. ¹H NMR (300 MHz, CD₃OD) δ1.88-2.47 (m, 8H), 2.74 (s, 3H), 3.82-3.90 (m, 2H), 5.34-5.48 (m, 1H),6.71 (d, J=8.82 Hz, 1H), 7.78 (dd, J=8.82, 2.71 Hz, 1H), 8.20 (d, J=2.37Hz, 1H) ppm; MS (DCI/NH₃): 2997 (M+H)⁺, 297 (M+H)⁺.

Example 19B5-{6-[(exo]-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-3-yl}-1H-indolefumarate

The product of Example 19A (129 mg, 0.434 mmol) and 5-indolylboronicacid (165 mg, 1.02 mmol) were treated according to the procedureoutlined in Example 8 to provide the title compound. ¹H NMR (300 MHz,CD₃OD) δ 1.97-2.12 (m, 2H), 2.20-2.46 (m, 4H), 2.48-2.60 (m, 2H), 2.84(s, 3H), 3.96-4.07 (m, 2H), 5.43-5.60 (m, 1H), 6.49 (d, J=3.05Hz, 1H),6.70 (s, 2H), 6.82 (d, J=8.48 Hz, 1H), 7.23-7.35 (m, 2H), 7.46 (d,J=8.14 Hz, 1H), 7.73 (d, J=1.70 Hz, 1H), 7.95 (dd, J=8.65, 2.54 Hz, 1H),8.37 (d, J=2.03 Hz, 1H) ppm; MS DCI/NH₃): m/z 334 (M+H)⁺; Anal.Calculated for C₂₁H₂₃N₃O.1.10C₄O₄H₄.1.00H₂O: C, 63.67; H, 6.18; N, 8.77.Found: C, 63.77; H, 6.26; N, 8.64.

Example 20[6-(1H-Indol-5-yl)-pyridin-3-yl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-aminebis(hydrochloride) Example 20A(6-Chloro-pyridin-3-yl)-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine

A mixture of tropinone (Aldrich, 2.78 g, 20 mmol),6-chloro-pyridin-3-ylamine (Aldrich, 2.83 g, 22 mmol), Na₂SO₄(anhydrous, Aldrich, 21.3 g, 150 mmol) and NaBH(OAc)₃ (Aldrich, 8.48 g,40 mmol) in HOAc (50 mL) at ambient temperature was stirred for 15hours. The mixture was filtered and the filtrate washed with EtOH (2×10mL). The organic solution was concentrated under reduced pressure andthe title compound obtained by purified using chromatography (SiO₂,CH₂Cl₂:MeOH:NH₃.H₂O, 90:10:2, R_(f). 0.10). ¹H NMR (300 MHz, CD₃OD) δ2.16 (d, J=15.26 Hz, 2H), 2.25-2.35 (m, 2H), 2.37-2.60 (m, 4H), 2.81 (s,3H), 3.65 (t, J=5.93 Hz, 1H), 3.79-3.98 (m, J=2.71 Hz, 1H), 7.09 (dd,J=8.50, 3.00 Hz, 1H), 7.21 (d, J=8.80 Hz, 1H), 7.73 (d, J=2.71 Hz, 1H)ppm. MS (DCI/NH₃) m/z 254 (M+H)⁺, 252 (M+H)⁺.

Example 20B[6-(1H-Indol-5-yl)-pyridin-3-yl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine

The mixture of Example 20A (250 mg, 1.0 mmol), 5-indolylboronic acid(Rsycor, 241.0 mg, 1.50 mmol), bis(triphenylphosphine)palladium(II)chloride (Aldrich, 10.0 mg, 0.01 mmol) andbiphenyl-2-yl-dicyclohexyl-phosphane (Strem Chemicals, 11.0 mg, 0.03mmol) in dioxane/EtOH/1M aqueous Na₂CO₃ (v. 1/1/1 3 mL) were heated andmicrowaved to 130° C. and 300 watts for 15 minutes in an Emry™ Creatormicrowave. The mixture was filtered through a syringe filter and theliquid was purified by preparative HPLC [Waters XTerra RP18 column,30×100 mm, eluting solvents, MeCN/H₂O (0.1 M aqueous ammoniumbicarbonate, adjusted to pH 10 with ammonium hydroxide) (v. 90/10 to10/90 over 20 min.), flow rate 40 mL/min, uv, 250 nm] to provide thetitled compound. ¹H NMR (300 MHz, CD₃OD) δ 1.88 (d, J=15.20 Hz, 2H)2.05-2.18 (m, 4H), 2.18-2.31 (m, 2H), 2.37 (s, 3H), 3.26 [s (br.), 2H)],3.60 (t, J=6.44 Hz, 1H), 6.49 (d, J=3.05 Hz, 1H), 7.05 (dd, J=8.82, 2.71Hz, 1H), 7.24 (d, J=3.05 Hz, 1H), 7.42 (d, J=8.48 Hz, 1H), 7.49-7.64 (m,2H), 7.95 (s, 1 H) ppm. MS (DCI/NH₃) m/z 333 (M+H)⁺.

Example 20C[6-(1H-Indol-5-yl)-pyridin-3-yl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-aminebis(hydrochloride)

The solution of Example 20B (160 mg, 0.48 mmol) in EtOAc (10.0 mL) atambient temperature was treated with 4M hydrochloric acid in dioxane(0.5 mL, 2.0 mmol) for 10 hours. The title compound was obtained byfiltration. ¹H NMR (300 MHz, CD₃OD) δ 2.25 (d, J=15.65 Hz, 2H),2.32-2.53 (m, 4H), 2.54-2.64 (m, 2H), 2.84 (s, 3H), 3.83 (t, J=6.14 Hz,1H), 3.97 [s (br.), 2H], 6.63 (d, J=3.07 Hz, 1H), 7.40-7.41 (m, 1H),7.54 (dd, J=8.60, 1.90 Hz, 1H), 7.62 (d, J=8.60 Hz, 1H), 7.83-7.95 (m,2H), 8.06 (d, J=1.53 Hz, 1H), 8.12 (d, J=8.90 Hz, 1H) ppm. MS (DCI/NH₃):m/z 333 (M+H)⁺. Anal. Calculated for C₂₁H₂₄N₄2.30HCl. 3.35H₂O: C, 52.92;H, 6.98; N, 11.75. Found: C, 52.87; H, 6.78; N, 11.35.

Example 21[6-(Benzofuran-5-yl)-pyridin-3-yl]-[(endo-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-aminefumarate

The product of Example 20A (136 mg, 0.54 mmol) and1-benzofuran-5-ylboronic acid (Aldrich, 185 mg, 1.14 mmol) were treatedaccording to the procedure outlined in Example 8 to provide the titlecompound. NMR (300 MHz, CD₃OD) δ 2.14-2.57 (m, 8H), 2.83 (s, 3H), 3.74(t, J=5.93 Hz, 1H), 3.90 [s (br.), 2H], 6.69 (s, 2H), 6.89 (d, J=1.36Hz, 1H), 7.13 (dd, J=8.65, 2.88 Hz, 1H), 7.54 (d, J=8.82 Hz, 1H), 7.68(d, J=8.82 Hz, 1H), 7.72-7.79 (m, 2H), 7.99-8.07 (m, 2H) ppm; MSDCI/NH₃): m/z 334 (M+H)⁺.

Example 22[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-[6-(2-trifluoromethyl-1H-indol-5-yl)-pyridin-3-yl]-aminebistrifluoroacetate

The product of Example 20A (130 mg, 0.52 mmol) and the product ofExample 7A (262 mg, 0.84 mmol) were treated according to the procedureoutlined in Example 1B to provide the title compound. ¹H NMR (300 MHz,CD₃OD) δ 2.17-2.62 (m, 8H), 2.84 (s, 3H), 3.82 (t, J=5.93 Hz, 1H), 3.96[s (br.), 2 HI, 7.06 (s, 1H), 7.63-7.80 (m, 3H), 7.95 (d, J=2.71 Hz,1H), 8.06 (d, J=9.16 Hz, 1H), 8.15 (d, J=1.36 Hz, 1H) ppm; MS DCI/NH₃):m/z 401 (M+H)⁺; Anal. Calculated for C₂₂H₂₂F₃N₃O.2.00 CF₃CO₂H. 0.70NH₄OH: C, 47.75; H, 4.24; N, 7.92. Found: C, 47.69; H, 3.91; N, 8.14.

Example 23[6-(1H-Indazol-5-yl)-pyridin-3-yl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-aminefumurate

The product of Example 20A (128 mg, 0.51 mmol) and the product ofExample 5A (205 mg, 0.84 mmol) were treated according to the procedureoutlined in Example 8 to provide the title compound. ¹H NMR (300 MHz,CD₃OD) δ 2.11-2.55 (m, 8H), 2.79 (s, 3H), 3.73 (t, J=5.93 Hz, 1H), 3.85[s (br.), 2H], 6.67 (s, 3H), 7.13 (dd, J=8.65, 2.88 Hz, 1H), 7.59 (d,J=8.82 Hz, 1H), 7.70 (d, J=8.82 Hz, 1H), 7.90 (dd, J=8.82, 1.70 Hz, 1H),8.04 (d, J=2.71 Hz, 1H), 8.09 (s, 1H), 8.18 (s, 1H) ppm; MS DCI/NH₃):m/z 334 (M+H)⁺; Anal. Calculated for C₂₀H₂₃N₅ 1.50 C₄O₄H₄ 1.00 NH₄OH: C,57.55; H, 6.32; N, 15.49. Found: C, 57.46; H, 6.26; N, 15.55.

Example 24[6-(1H-Indol-4-yl)-pyridin-3-yl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-aminefumarate

The product of Example 20A (130 mg, 0.52 mmol) and indole-4-boronic acid(Apollo, 165 mg, 1.0 mmol) were treated according to the procedureoutlined in Example 8 to provide the title compound. ¹H NMR (300 MHz,CD₃OD) δ 2.16-2.60 (m, 8H), 2.84 (s, 3H), 3.76 (t, J=5.76 Hz, 1H),3.88-3.95 [s (br.), 2 HI, 6.69 (s, 2H), 6.70 (d, J=3.39 Hz, 1H),7.14-7.32 (m, 4H), 7.40 (d, J=7.80 Hz, 1H), 7.68 (d, J=8.48 Hz, 1H),8.06 (d, J=2.71 Hz, 1H) ppm; MS DCI/NH₃): m/z 333 (M+H)⁺; Anal.Calculated for C₂₁H₂₄N₄ 1.40 C₄O₄H₄ 0.90H₂O: C, 62.50; H, 6.19; N,10.96. Found: C, 62.40; H, 6.17; N, 11.04.

Example 25[(endo)-8-aza-bicyclo[3.2.1]oct-3-yl]-[6-(1H-indol-5-yl)-pyridin-3-yl]-amineExample 25A(endo)-3-(6-Chloro-pyridin-3-ylamino)-8-aza-bicyclo[3.2.1]octane]-8-carboxylicacid tert-butyl ester

The mixture of 3-oxo-8-aza-bicyclo[3.2.1]octane-8-carboxylic acidtert-butyl ester (Fluka, 3.50 g, 15.50 mmol), 6-chloro-pyridin-3-ylamine(Aldrich, 2.20 g, 17.1 mmol), Na₂SO₄ (anhydrous, Aldrich, 16.6 g, 116mmol) and NaBH(OAc)₃ (Aldrich, 6.59 g, 31.1 mmol) in HOAc (40 mL) wasstirred at ambient temperature for 15 hours according to the procedureoutlined in Example 20A. The title compound was purified bychromatography (SiO₂, hexane:EtOAc, 50:50, R_(f). 0.40). ¹H NMR (300MHz, CD₃OD) δ 1.41-1.56 (m, 9H), 1.58-2.90 (m, 8H) 4.13-4.33 (m, 1H),4.37-4.54 (m, 2H), 7.00 (dd, J=8.81, 3.05 Hz, 0.5H), 7.15 (d, J=8.14 Hz,0.5H), 7.26 (dd, J=8.30, 3.10 Hz, 0.5H) 7.41 (d, J=8.48 Hz, 0.5H), 7.68(d, J=3.05 Hz, 0.5H) 7.84 (d, J=2.37 Hz, 0.5H) ppm. MS (DCI/NH₃) m/z 340(M+H)⁺, 338 (M+H)⁺.

Example 25B[(endo)-8-Aza-bicyclo[3.2.1]oct-3-yl]-(6-chloro-pyridin-3-yl)-amine

The product of Example 25A (2.92 g, 8.7 mmol) was treated withtrifluoroacetic acid (5 mL) in dichloromethane (20 mL) at ambienttemperature for 4 hours. The mixture was concentrated under reducedpressure and the residue purified by chromatography (SiO₂,CH₂Cl₂:MeOH:NH₃.H₂O, 90:10:2, R_(f). 0.10) to provide the titlecompound. ¹H NMR (300 MHz, CD₃OD) δ 1.71-1.94 (m, 4H) 2.03-2.22 (m, 4H),3.42-3.64 (m, 3H), 6.98 (dd, J=8.82, 3.05 Hz, 1H), 7.14 (d, J=8.14 Hz,1H), 7.65 (d, J=3.05 Hz, 1H) ppm. MS (DCI/NH₃) m/z 238 (M+H)+, 240(M+H)⁺.

Example 25C[(endo)-8-aza-bicyclo[3.2.1]oct-3-yl]-[6-(1H-indol-5-yl)-pyridin-3-yl]-amine

The product of Example 20A (250 mg, 1.0 mmol), 5-indolylboronic acid(Rsycor, 241.0 mg, 1.50 mmol), bis(triphenylphosphine)palladium(II)chloride (Aldrich, 10.0 mg, 0.01 mmol) andbiphenyl-2-yl-dicyclohexyl-phosphane (Strem Chemicals, 11.0 mg, 0.03mmol) in dioxane/EtOH/1M aqueous Na₂CO₃ (1/1/1 3 mL) were heated andmicrowaved to 130° C. and 300 watts for 15 minutes in an Emry™ Creatrormicrowave. The solid was filtered off with a syringe filter and theliquid was purified by preparative HPLC [Waters XTerra RP18 column,30×100 mm, eluting solvents, MeCN 1H₂O (0.1 M aqueous ammoniumbicarbonate, adjusted to pH 10 with ammonium hydroxide) (v. 90/10 to10/90 over 20 min.), flow rate 40 mL/min, uv, 250 nm] to provide thetitled compound. ¹H NMR (300 MHz, CD₃OD) δ 1.96-2.17 (m, 4H), 2.20-2.52(m, 4H), 3.71 (t, J=6.1 Hz, 1H) 3.80-3.92 (m, 2H), 6.49 (d, J=2.37 Hz,1H), 7.10 (dd, J=8.82, 3.05 Hz, 1H), 7.25 (d, J=3.05 Hz, 1H), 7.42 (d,J=8.48 Hz, 1H), 7.56 (dd, J=8.48, 1.70 Hz, 1H), 7.63 (d, J=8.48 Hz, 1H),7.92-8.00 (s, 1H) ppm. MS (DCI/NH₃) m/z 319 (M+H)⁺.

Example 26[6-(4-Amino-3-methyl-phenyl)-pyridin-3-yl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-aminefumarate Example 26A[2-methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-trifluoroacetamide

A mixture of N-(4-Bromo-2-methyl-phenyl)-2,2,2-trifluoro-acetamide refUS 2005-0043347, 4.23 g, 15.0 mmol), bis(pinacolato)diboron (Aldrich,5.07 g, 20 mmol), KOAc (Aldrich, 5.27 g, 53.7 mmol) andPdCl₂(dppf):CH₂Cl₂(Aldrich, 203 mg, 0.25 mmol) in anhydrous dioxane (50mL) at 100° C. for 72 hours. The mixture was cooled to ambienttemperature, diluted with EtOAc (150 mL), washed with water (2×25 mL).The organic solution was concentrated under reduced pressure and theresidue was purified by chromatography (140 g SiO₂, hexane:EtOAc, 80:20,R_(f). 0.6) to provide the titled compound. NMR (300 MHz, CDCl₃) δ 1.35(s, 12H), 2.31 (s, 3H), 7.66-7.80 (m, 3H), 7.90 (d, J=8.14 Hz, 1H) ppm;MS (DCI/NH₃): 347 (M+NH₄)⁺.

Example 26B[6-(4-Amino-3-methyl-phenyl)-pyridin-3-yl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-aminefumarate

The product of Example 20A (130 mg, 0.52 mmol) and the product ofExample 26A (277 mg, 0.84 mmol) were treated according to the procedureoutlined in Example 8 to provide the title compound. NMR (300 MHz,CD₃OD) δ 2.12-2.57 (m, 11H), 2.82 (s, 3H), 3.71 (t, J=6.10 Hz, 1H),3.85-3.94 (m, 2H), 6.69 (s, 2H), 6.77 (d, J=8.14 Hz, 1H), 7.10 (dd,J=8.65, 2.88 Hz, 1H), 7.42 (dd, J=8.14, 2.37 Hz, 1H), 7.47 (s, 1H), 7.53(d, J=8.82 Hz, 1H), 7.92 (d, J=2.71 Hz, 1H) ppm; MS DCI/NH₃): m/z 323(M+H)⁺.

Example 27[4-(1H-Indol-5-yl)-phenyl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-aminefumarate Example 27A(4-Bromo-phenyl)-(3-endo-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amine

Tropinone (Aldrich, 2.78 g, 20 mmol) and p-bromoaniline (Aldrich, 3.78g, 22 mmol) were treated according to the procedure outlined in Example20A to provide the title compound. The title compound was purified bychromatography (140 g SiO₂, EtOAc:MeOH (v. 2% NH₃.H₂O), 50:50, R_(f).0.25). NMR (300 MHz, MeOH-D4) δ 1.71-1.82 (m, 2H), 2.00-2.22 (m, 6H),2.29 (s, 3H), 3.14 [s (br.), 2H], 3.46 (t, J=6.61 Hz, 1H), 6.46 (d,J=8.81 Hz, 2H), 7.17 (d, J=9.15 Hz, 2H) ppm; MS (DCI/NH₃): 297 (M+H)⁺295(M+H)⁺.

Example 27B[4-(1H-Indol-5-yl)-phenyl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-aminefumarate

The product of Example 27A (134 mg, 0.45 mmol) and5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indol (Aldrich, 198mg, 0.81 mmol) were treated according to the procedure outlined inExample 8 to provide the title compound. ¹H NMR (300 MHz, CD₃OD) δ2.16-2.60 (m, 8H), 2.82 (s, 3H), 3.72 (t, J=5.76 Hz, 1H), 3.89 [s (br.),2H], 6.44 (d, J=2.37 Hz, 1H), 6.66-6.74 (m, 5.3H), 7.21 (d, J=3.39 Hz,1H), 7.26-7.32 (m, 1H), 7.35-7.41 (m, 1H), 7.46 (d, J=8.82 Hz, 2H), 7.67(d, J=1.02 Hz, 1H) ppm; MS DCI/NH₃): m/z 332 (M+H)⁺; Anal. Calculatedfor C₂₂H₂₅N₃.1.65 C₄O₄H₄: C, 65.68; H, 6.09; N, 8.03. Found: C, 65.62;H, 6.40; N, 8.14.

Example 28[4-(1H-Indazol-5-yl)-phenyl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-aminefumarate

The product of Example 27A (134 mg, 0.45 mmol) and the product ofExample 5A (265 mg, 1.08 mmol) were treated according to the procedureoutlined in Example 8 to provide the title compound. ¹H NMR (300 MHz,CD₃OD) δ 2.14-2.61 (m, 8H), 2.82 (s, 3H), 3.72 (t, J=5.93 Hz, 1H), 3.89[s (br.), 2H], 6.67-6.77 (m, 5H), 7.45-7.52 (m, 2H), 7.52-7.58 (m, 1H),7.59-7.65 (m, 1H), 7.87 (s, 1H), 8.04 (s, 1H) ppm; MS DCI/NH₃): m/z 333(M+H)⁺; Anal. Calculated for C₂₁H₂₄N₄.1.48 C₄O₄H₄:C, 64.12; H, 5.98; N,11.11. Found: C, 64.00; H, 5.98; N, 11.22.

Example 29[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-[4-(1-methyl-1H-indol-5-yl)-phenyl]-aminefumarate

The product of Example 27A (128 mg, 0.43 mmol) andN-methylindole-5-boronic acid (Frontier, 142 mg, 0.81 mmol) were treatedaccording to the procedure outlined in Example 8 to provide the titlecompound. ¹H NMR (300 MHz, CD₃OD) δ 2.12-2.63 (m, 8H), 2.82 (s, 3H),3.72 (t, J=5.93 Hz, 1H), 3.80 (s, 3H), 3.88 [s (br.), 2H], 6.42 (d,J=3.05 Hz, 1H), 6.66-6.74 (m, 4H), 7.13 (d, J=3.05 Hz, 1H), 7.36 (d,J=1.0 Hz, 2H), 7.46 (d, J=8.48 Hz, 2H), 7.67 (t, J=1.20 Hz, 1H) ppm; MSDCI/NH₃): m/z 346 (M+H)⁺. Anal. Calculated for C₂₃H₂₇N₃.1.10 C₄O₄H₄: C,69.55; H, 6.69; N, 8.88. Found: C, 69.29; H, 6.76; N, 8.85.

Example 30(4-Benzo[b]thiophen-5-yl-phenyl-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-aminetrifluoroacetate

The product of Example 27A (129 mg, 0.44 mmol) and2-benzo[b]thiophen-5-yl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane(Maybridge, 189 mg, 0.73 mmol) were treated according to the procedureoutlined in Example 1B to provide the title compound. ¹H NMR (300 MHz,CD₃OD) δ 2.17-2.60 (m, 8H), 2.82 (s, 3H), 3.73 (t, J=5.76 Hz, 1H), 3.90[s (br.), 2H], 6.73 (d, J=8.82 Hz, 2H), 7.38 (d, J=5.76 Hz, 1H),7.48-7.59 (m, 4H), 7.88 (d, J=8.48 Hz, 1H), 7.97 (d, J=1.70 Hz, 1H) ppm;MS DCI/NH₃): m/z 349 (M+H)⁺; Anal. Calculated for C₂₂H₂₄N₂S.1.10C₂F₃O₂H: C, 61.33; H, 5.34; N, 5.91. Found: C, 61.03; H, 5.34; N, 5.76.

Example 31[4-(Benzofuran-5-yl)-phenyl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-aminefumarate

The product of Example 27A (135 mg, 0.46 mmol) and5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzofuran (Maybridge,189 mg, 0.77 mmol) were treated according to the procedure outlined inExample 8 to provide the title compound. ¹H NMR (300 MHz, CD₃OD) δ2.15-2.60 (m, 8H), 2.82 (s, 3H), 3.72 (t, J=5.93 Hz, 1H), 3.88 [s (br.),2H], 6.65-6.76 (m, 4H), 6.83 (d, J=2.71 Hz, 1H), 7.40-7.52 (m, 4H),7.69-7.75 (m, 2H) ppm; MS DCI/NH₃): m/z 333 (M+H)⁺; Anal. Calculated forC₂₂H₂₄N₂O.1.15 C₄O₄H₄: C, 68.57; H, 6.19; N, 6.01. Found: C, 68.42; H,6.17; N, 6.02.

Example 32[4-(1H-Indol-4-yl]-phenyl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-aminefumarate

The product of Example 27A (125 mg, 0.42 mmol) and indole-4-boronic acid(Apollo, 131 mg, 0.81 mmol) were treated according to the procedureoutlined in Example 8 to provide the title compound. ¹H NMR (300 MHz,CD₃OD) δ 2.11-2.68 (m, 8H), 2.83 (s, 3H), 3.74 (t, J=8.31 Hz, 1H), 3.89[s (br.), 2 HI 6.58 (dd, J=3.39, 1.02 Hz, 1H), 6.68 (s, 2H), 6.74 (d,J=8.82 Hz, 2H), 6.99 (dd, J=7.12, 1.02 Hz, 1H), 7.08-7.15 (m, 1H), 7.23(d, J=3.39 Hz, 1H), 7.29 (d, J=8.14 Hz, 1H), 7.51 (d, J=8.81 Hz, 2H)ppm; MS DCI/NH₃): m/z 332 (M+H)⁺; Anal. Calculated for C₂₂H₂₅N₃ 1.00C₄O₄H₄: C, 69.78; H, 6.53; N, 9.39. Found: C, 70.17; H, 6.69; N, 9.58.

Example 33[3-(1H-Indol-5-yl)-phenyl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-aminefumarate Example 33A(3-Bromo-phenyl)-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine

Tropinone (696 mg, 5.0 mmol) and m-bromoaniline (946 mg, 5.5 mmol) weretreated according to the procedure outlined in Example 20A to providethe title compound. The title compound was purified by chromatography[140 g SiO₂, EtOAc:MeOH (v. 2% NH₃.H₂O), 50:50, R_(f)=0.25]. ¹H NMR (300MHz, MeOH-D₄) δ 1.72-2.23 (m, 8H), 2.29 (s, 3H), 3.14 [s (br.), 2H],3.47 (t, J=6.44 Hz, 1H), 6.46-6.52 (ddd, J=8.20, 2.00, 1.00 Hz, 1H),6.64-6.72 (m, 2H), 6.92-7.02 (t, J=8.10 Hz, 1H) ppm; MS (DCI/NH₃): 297(M+H)⁺, 295 (M+H)⁺.

Example 33B[3-(1H-Indol-5-yl)-phenyl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-aminefumarate

The product of Example 33A (128 mg, 0.43 mmol) and indole-5-boronic acid(165 mg, 1.0 mmol) were treated according to the procedure outlined inExample 8 to provide the title compound. ¹H NMR (300 MHz, CD₃OD) δ2.19-2.61 (m, 8H), 2.81 (s, 3H), 3.75 (t, J=5.76 Hz, 1H), 3.83-3.92 (m,2H), 6.47 (dd, J=3.05, 0.70 Hz, 1H), 6.55 (ddd, J=7.10, 2.60, 0.70 Hz,1H), 6.68 (s, 2H), 6.89 (t, J=2.03 Hz, 1H), 6.96 (ddd, J=7.80, 1.70,1.00 Hz, 1H), 7.20 (t, J=7.80 Hz, 1H), 7.24 (d, J=7.10 Hz, 1H), 7.34(dd, J=8.50, 1.70 Hz, 1H), 7.39 (t, J=8.40 Hz, 1H), 7.74 (dd, J=1.70,0.70 Hz 1H) ppm; MS DCI/NH₃): m/z 332 (M+H)⁺; Anal. Calculated forC₂₂H₂₅N₃.1.10 C₄H₄O₄.0.40 C₄H₈O₂: C, 68.03; H, 6.65; N, 8.50. Found: C,67.68; H, 6.85; N, 8.78.

Example 34[3-(1H-Indol-4-yl)-phenyl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-aminetrifluoroacetate

The product of Example 33A (128 mg, 0.43 mmol) and indole-4-boronic acid(Apollo, 168 mg, 1.0 mmol) were treated according to the procedureoutlined in Example 1B to provide the title compound. ¹H NMR (300 MHz,CD₃OD) δ 2.22-2.64 (m, 8H), 2.81 (s, 3H), 3.74 (t, J=5.42 Hz, 1H),3.87-3.93 (m, 2H), 6.57-6.67 (m, 2H), 6.92 (t, J=2.10 Hz, 1H), 6.99 (dt,J=7.80, 1.00 Hz, 1H) 7.14 (t, J=7.56 Hz, 1H), 7.21-7.28 (m, 2H), 7.35(d, J=8.14 Hz, 1H) ppm; MS DCI/NH₃): m/z 332 (M+H)⁺; Anal. Calculatedfor C₂₂H₂₅N₃.1.10 CF₃CO₂H.0.60 EtOH: C, 62.96; H, 6.18; N, 8.67. Found:C, 62.85; H, 5.98; N, 8.65.

Example 355-{6-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-2-trifluoromethyl-1H-indoletrifluoroacetate

The product of Example 1A (89 mg, 0.35 mmol) and the product of Example7A (299 mg, 0.96 mmol) were treated according to the procedure outlinedin Example 1B to provide the title compound. ¹H NMR (300 MHz, CD₃OD) δ2.22-2.67 (m, 8H), 2.86 (s, 3H), 3.93-4.01 [s (br), 2H], 5.55-5.62 (m,1H), 7.02 (t, J=1.02 Hz, 1H), 7.32 (d, J=9.15 Hz, 1H), 7.60 (d, J=8.81Hz, 1H), 7.94 (dd, J=8.82, 1.70 Hz, 1H), 8.16 (d, J=9.49 Hz, 1H), 8.26(d, J=1.36 Hz, 1H) ppm; MS DCI/NH₃): m/z 403 (M+H)⁺; Anal. Calculatedfor C₂₁H₂₁F₃N₄O.1.53 CF₃CO₂H: C, 50.09; H, 3.94; N, 9.71. Found: C,50.07; H, 3.94; N, 9.66.

Example 364-{6-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-1H-indolefumarate

The product of Example 7D (129 mg, 0.51 mmol) and indole-4-boronic acid(Apollo, 161 mg, 1.0 mmol) were treated according to the procedureoutlined in Example 8 to provide the title compound. ¹H NMR (300 MHz,CD₃OD) δ 2.05-2.50 (m, 6H), 2.66 (ddd, J=14.92, 5.76, 3.05 Hz, 2H), 2.85(s, 3H), 4.03 (dd, J=3.73, 3.05 Hz, 2H), 5.67-5.83 (m, 1H), 6.79 (dd,J=3.22, 0.85 Hz, 1H), 7.22-7.30 (m, 2H), 7.37 (d, J=3.05 Hz, 1H), 7.41(dd, J=7.29, 0.85 Hz, 1H), 7.54 (d, J=8.14 Hz, 1H), 8.08 (d, J=9.15 Hz,1H) ppm; MS DCI/NH₃): m/z 335 (M+H)⁺; Anal. Calculated forC₂₀H₂₂N₄O.1.20 C₄O₄: C, 62.88; H, 5.70; N, 11.83. Found: C, 62.90; H,5.53; N, 11.79.

Example 375-{6-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-3-yl}-1H-indolefumarate Example 37A(exo)-3-(5-Bromo-pyridin-2-yloxy)-8-methyl-8-aza-bicyclo[3.2.1]octane

The product of Example 7C (721 mg, 5.1 mmol) and 2,5-dibromo-pyridine(Aldrich, 1.66 g, 7.0 mmol) were treated according to the procedureoutlined in Example 1A to provide the title compound. ¹H NMR (300 MHz,CD₃OD) δ 1.90-2.46 (m, 8H), 2.74 (s, 3H), 3.81-3.90 (m, 2H), 5.34-5.48(m, 1H), 6.71 (d, J=8.82 Hz, 1H), 7.78 (dd, J=8.82, 2.71 Hz, 1H), 8.20(d, J=2.37 Hz, 1H) ppm; MS DCI/NH₃): m/z 299 (M+H)⁺297 (M+H)⁺.

Example 37B5-{6-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-3-yl}-1H-indolefumarate

The product of Example 37A (129 mg, 0.43 mmol) and indole-5-boronic acid(Ryscor Inc., 165 mg, 1.0 mmol) were treated according to the procedureoutlined in Example 8 to provide the title compound. ¹H NMR (300 MHz,CD₃OD) δ 1.96-2.62 (m, 8H), 2.84 (s, 3H), 3.97-4.04 (m, 2H), 5.44-5.58(m, 1H), 6.49 (dd, J=3.22, 0.85 Hz, 1H), 6.70 (s, 2H), 6.82 (d, J=8.48Hz, 1H), 7.27 (d, J=3.05 Hz, 1H), 7.30 (dd, J=8.48, 1.70 Hz, 1H), 7.46(d, J=8.14 Hz, 1H), 7.73 (d, J=1.70 Hz, 1H), 7.95 (dd, J=8.65, 2.54 Hz,1H), 8.37 (d, J=2.03 Hz, 1H) ppm; MS DCI/NH₃): m/z 334 (M+H)⁺; Anal.Calculated for C₂₁H₂₃N₃O.1.10 C₄H₄O₄.1.00H₂O: C, 63.67; H, 6.18; N,8.77. Found: C, 63.77; H, 6.26; N, 8.64.

Example 385-{6-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-3-yl}-2-trifluoromethyl-1H-indolebisfumarate

The product of Example 37A (129 mg, 0.43 mmol) and5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-2-trifluoromethyl-1H-indole(Aldrich, 319 mg, 1.02 mmol) were treated according to the procedureoutlined in Example 8 to provide the title compound. ¹H NMR (300 MHz,CD₃OD) δ 1.92-2.63 (m, 8H), 2.85 (s, 3H), 4.02 [s (br), 2H], 5.46-5.61(m, 1H), 6.71 (s, 4H), 6.84 (d, J=8.48 Hz, 1H), 6.95 (s, 1H), 7.47-7.59(m, 2H), 7.85 (s, 1H), 7.97 (dd, J=8.65, 2.54 Hz, 2H), 8.40 (d, J=2.03Hz, 1H) ppm; MS DCI/NH₃): m/z 402 (M+H)⁺. Anal. Calculated forC₂₂H₂₂F₃N₃O.2.00C₄H₄O₄: C, 56.87; H, 4.77; N, 6.63. Found: C, 56.98; H,5.09; N, 6.29.

Example 394-{6-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-1H-indolefumarate

The product of Example 7D (129 mg, 0.51 mmol) was coupled withindole-4-boronic acid (Apollo, 161 mg, 1.0 mmol) to give the free baseof the title compound (150 mg, 0.45 mmol). It was then was treated withfumaric acid (52.0 mg, 0.45 mmol) according to the procedure of Exampleof 5C to give the title compound as white solid. ¹H NMR (300 MHz, CD₃OD)δ 2.05-2.49 (m, 6H) 2.60-2.71 (m, 2H) 2.85 (s, 3H) 4.01-4.07 (m, 2H)5.69-5.81 (m, 1H) 6.69 (s, 2H) 6.79 (dd, J=3.22, 0.85 Hz, 1H) 7.23-7.29(m, 2H) 7.37 (d, J=3.05 Hz, 1H) 7.41 (dd, J=7.29, 0.85 Hz, 1H) 7.54 (d,J=8.14 Hz, 1H) 8.08 (d, J=9.15 Hz, 1H) ppm. MS (DCI/NH₃): m/z 335(M+H)⁺. Anal. Calculated for C₂₀H₂₂N₄O.1.2C₄O₄H₄: C, 62.88; H, 5.70; N,11.83. Found: C, 62.90; H, 5.53; N, 11.79.

Example 406-{5-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indolehydrochloride Example 40A6-{5-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indole

Under N₂, the mixture of the product from Example 11A (240 mg, 0.95mmol) was coupled with 6-indolylboronic acid (Frontier Scientific, 229mg, 1.42 mmol) according to the procedure of Example 11B to provide thetitle product. ¹H NMR (300 MHz, CD₃OD) δ 1.72-1.93 (m, 4H), 2.00-2.25(m, 4H), 2.39 (s, 3H), 3.23-3.35 (m, 2H), 4.56-4.82 (m, 1H), 7.29 (d,J=3.05 Hz, 1H), 7.46 (d, J=2.71 Hz, 1H), 7.47-7.51 (m, 1H), 7.53 (d,J=1.36 Hz, 1H), 7.60 (d, J=8.52 Hz, 1H), 7.76 (d, J=8.82 Hz, 1H), 7.88(s, 1H), 8.22 (d, J=3.05 Hz, 1H) ppm; MS (DCI/NH₃) m/z 334 (M+H)⁺.

Example 40B6-{5-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indolehydrochloride

The product of Example 40A (210 mg, 0.63 mmol) was treated with HCl(Aldrich, 4 M in dioxane, 0.5 mL, 2.0 mmol) EtOAc (10 mL) at ambienttemperature for 10 hours and concentrated under reduced pressure toprovide the title compound. ¹H NMR (300 MHz, CD₃OD) δ 2.14-2.32 (m, 2H),2.26-2.49 (m, 4H), 2.49-2.65 (m, 2H), 2.85 (s, 3H), 3.99-4.18 (m, 2H),5.07-5.31 (m, 1H), 6.60 (d, J=4.07 Hz, 1H), 7.46-7.56 (m, 2H), 7.82 (d,J=8.48 Hz, 1H), 7.98 (s, 1H), 8.34 (s, 1H), 8.35 (d, J=2.71 Hz, 1H),8.55 (d, J=2.37 Hz, 1H) ppm. MS (DCI/NH₃): m/z 334 (M+H)⁺. Anal.Calculated for C₂₁H₂₃N₃O.1.00 HCl.1.20H₂O: C, 64.42; H, 6.80; N, 10.73.Found: C, 64.54; H, 6.61; N, 10.89.

Example 415-{5-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl)-1H-indoletosylate Example 41A 5-Bromo-pyrazin-2-ylamine

To the solution of 2-aminopyrazine (Aldrich, 4.75 g, 50 mmol) inanhydrous MeCN (Aldrich, 50 mL) was slowly added the solution ofN-bromosuccinimide (Aldrich, 8.90 g, 50 mmol) in MeCN (anhydrous, 50 mL)at 0-10° C. The reaction mixture was then stirred at ambient temperatureand quenched with saturated Na₂S₂O₃ (5.0 mL). The mixture wasconcentrated and the residue was extracted with EtOAc (3×50 mL). Thecombined extracts were concentrated and the title compound was purifiedby chromatography (SiO₂, EtOAc/hexane=1/1, v. R_(f)=0.50). ¹H NMR (300MHz, CDCl₃) δ 7.77 (d, J=1.36 Hz, 1H), 8.09 (d, J=1.36 Hz, 1H) ppm; m/z174 (M+H)⁺, 174 (M+H)⁺.

Example 41B 5-Bromo-2-iodopyrazine

Under N₂, to the mixture of the product of Example 41A (7.50 g, 43 mmol)in DME (anhydrous, Aldrich, 200 mL) was added CsI (Aldrich, 11.20 g, 43mmol), iodine (Aldrich, 5.52 g, 21.6 mmol), CuI (Stream, 2.52 g, 13.2mmol) and isoamyl nitrite (34.8 mL, 259.2 mmol) at ambient temperature.It was then heated to 60° C. and stirred for 30 min. till no gasevolution was observed. After being cooled down to room temperature, thedark mixtures was poured into a flask containing EtOAc (200 mL) andsaturated NH4Cl (200 mL), stirred for 10 min. The organic layer wasseparated and the aqueous layer was extracted with EtOAc (2×1000 mL).The combined organic solution was washed with 5% of Na₂S₂O₃ aqueous(2×50 mL), brine (50 mL) and dried over MgS04. The drying agents werefiltered off and the organic solution was concentrated to provide thetitle compound. ¹H NMR (300 MHz, CDCl₃) δ 8.50 (d, J=1.36 Hz, 1H), 8.62(d, J=1.36 Hz, 1H) ppm; m/z 284 (M+H)⁺, 286 (M+H)⁺.

Example 41C(endo)-3-(5-Iodo-pyrazin-2-yloxy)-8-methyl-8-aza-bicyclo[3.2.1]octane

Under N₂, the mixture of (endo)-tropine (Aldrich, 1.54 g, 11 mmol) wastreated with potassium t-butoxide (Aldrich, 0.96 g, 10 mmol) in THF(anhydrous, Aldrich, 50 mL) at ambient temperature for 1 h. The productof Example 41B (2.85 g, 10.0 mmol) and was added. The brown mixture wasstirred at ambient temperature for 4 hours and quenched with water (5mL). The mixture was concentrated and the residue was purified bychromatography (150 g SiO₂, EtOAc:MeOH:NH₃.H₂O, 90:10:1, R_(f). 0.20) togive the title compound. ¹H NMR (300 MHz, CD₃OD) δ 6 2.16-2.60 (m, 8H),2.84 (s, 3H), 3.78-4.05 (m, 2H), 5.17-5.40 (m, 1H), 8.14 (d, J=1.36 Hz,1H), 8.42 (d, J=1.36 Hz, 1H) ppm; MS (DCI/NH₃) m/z 346 (M+H)⁺.

Example 41D5-{5-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indole

The product from Example 41C (200 mg, 0.58 mmol), was coupled with5-indolylboronic acid (Rsycor, 143.3 mg, 0.89 mmol) according to theprocedure of 1 Example 9B to provide the title product. ¹H NMR (300 MHz,CD₃OD) 6 1.94-2.05 (m, 2H), 2.07-2.29 (m; 6H), 2.34 (s, 3H), 3.15-3.27(m, 2H), 5.29 (t, J=5.09 Hz, 1H), 6.53 (d, J=2.37 Hz, 1H), 7.27 (d,J=3.39 Hz, 1H), 7.47 (d, J=8.48 Hz, 1H), 7.68 (dd, J=8.48, 1.70 Hz, 1H),8.11 (s, 1H), 8.17 (d, J=1.70 Hz, 1H), 8.58 (d, J=1.36 Hz, 1H) ppm. MS(DCI/NH₃) m/z 335 (M+H)⁺.

Example 41E5-{5-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indoletosylate

The product of Example 41D (90 mg, 0.27 mmol) was treated withptoluenesulfonic acid monohydrate TsOH.H₂O (Aldrich, 57 mg, 0.3 mmol) inEtOAcIEtOH (v. 4:1, 5 mL) at ambient temperature for 10 hour. Themixture was concentrated under reduced pressure to provide the titlecompound. ¹H NMR (300 MHz, CD₃OD) δ 2.36 (s, 3H), 2.38-2.48 (m, 4H),2.48-2.61 (m, 4H), 2.84 (s, 3H), 3.84-4.05 (m, 2H), 5.41 (t, J=4.41 Hz,1H), 7.23 (d, J=7.80 Hz, 2H), 7.30 (s, 1H), 7.49 (d, J=8.48 Hz, 1H),7.65-7.77 (m, 4H), 8.13 (d, J=1.70 Hz, 1H), 8.29 (s, 1H) ppm. MS(DCI/NH₃):m/z 335 (M+H)⁺. Anal. Calculated for C₂₀H₂₂N₄O.1.38C₇H₈SO₃.0.80H₂O: C, 60.74; H, 5.95; N, 9.55. Found: C, 61.00; H, 5.63;N, 9.17.

Example 424-{5-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indolebistosylate Example 42A4-{5-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indole

The product from Example 41C (200 mg, 0.58 mmol), was coupled with4-indolylboronic acid (Apollo, 143.3 mg, 0.89 mmol) according to theprocedure of Example 9B to provide the title compound. ¹H NMR (300 MHz,CD₃OD) δ 1.97-2.06 (m, 2H), 2.08-2.30 (m, 6H), 2.34 (s, 3H), 3.16-3.28(m, 2H), 5.33 (t, J=5.09 Hz, 1H), 6.82 (d, J=3.39 Hz, 1H), 7.22 (t,J=7.50 Hz, 1H), 7.34 (d, J=3.05 Hz, 1H), 7.40 (d, J=7.46 Hz, 1H), 7.47(d, J=8.14 Hz, 1H), 8.27 (d, J=1.36 Hz, 1H), 8.61 (d, J=1.36 Hz, 1H)ppm. MS (DCI/NH₃) m/z 335 (M+H)⁺.

Example 42B4-{5-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indolebistosylate

The product of Example 42A (40 mg, 0.12 mmol) was treated withptoluenesulfonic acid monohydrate TsOH.H₂O (Aldrich, 27 mg, 0.15 mmol)in EtOAc/EtOH (v. 4:1, 5 mL) at ambient temperature for 10 hours. Themixture was concentrated under reduced pressure to provide the titlecompound. ¹H NMR (300 MHz, CD₃OD) δ 2.36 (s, 6H) 2.40-2.48 (m, 4H),2.50-2.64 (m, 2H), 2.85 (s, 3H), 3.87-4.04 (m, 2H), 5.26-5.63 (m, 1H),7.19-7.29 (m, 6H), 7.35 (s, 1H), 7.42 (d, J=6.44 Hz, 1H), 7.49 (d,J=8.14 Hz, 1H), 7.71 (d, J=8.48 Hz, 4H), 8.38 (d, J=1.36 Hz, 1H), 8.68(d, J=1.36 Hz, 1H) ppm. MS (DCI/NH₃): m/z 335 (M+H)⁺. Anal. Calculatedfor C₂₀H₂₂N₄O.2.00 C₇H₈SO₃.0.50H₂O: C, 59.37; H, 5.71; N, 8.15. Found:C, 59.56; H, 6.10; N, 8.17.

Example 436-{5-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indoletosylate Example 43A6-{5-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indole

The product from Example 41C (200 mg, 0.58 mmol), was coupled with6-indolylboronic acid (Frontier Scientific, 143.3 mg, 0.89 mmol)according to the procedure of Example 9B to provide the title product.¹H NMR (300 MHz, CD₃OD) δ 1.93-2.05 (m, 2H), 2.08-2.28 (m, 6H), 2.33 (s,3H), 3.13-3.26 (m, 2H), 5.29 (t, J=4.92 Hz, 1H), 6.47 (d, J=3.05 Hz,1H), 7.30 (d, J=3.39 Hz, 1H), 7.54-7.68 (m, 2H), 7.96 (s, 1H), 8.19 (d,J=1.36Hz, 1H), 8.60 (d, J=1.36 Hz, 1H) ppm. MS (DCI/NH₃) m/z 335 (M+H)⁺.

Example 43B6-{5-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indoletosylate

The product of Example 43A (80 mg, 0.24 mmol) was treated withptoluenesulfonic acid monohydrate TsOH.H₂O (Aldrich, 57 mg, 0.30 mmol)in EtOAc/EtOH (v. 4:1, 5 mL) at ambient temperature for 10 hours. Themixture was concentrated under reduced pressure to provide the titlecompound. ¹H NMR (300 MHz, CD₃OD) δ 2.36 (s, 3H), 2.37-2.48 (m, 6H),2.47-2.63 (m, 2H), 2.84 (s, 3H), 3.83-4.02 (m, 2H), 5.27-5.50 (m, 1H),6.48 (d, J=2.37 Hz, 1H), 7.32 (t, J=1.70 Hz, 1H), 7.53-7.67 (m, 2H),7.71 (d, J=8.14 Hz, 2H), 7.99 (s, 1H), 8.29 (d, J=1.36 Hz, 1H), 8.64 (d,J=1.36 Hz, 1H) ppm. MS (DCI/NH₃): m/z 335 (M+H)⁺. Anal. Calculated forC₂₀H₂₂N₄O.1.15 C₇H₈SO₃.0.75H₂O: C, 61.71; H, 6.04; N, 10.26. Found: C,61.74; H, 5.72; N, 9.87.

Example 44[6-(1H-Indol-6-yl)-pyridin-3-yl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-aminetrifluoroacetate

The product of Example 20A (139 mg, 0.55 mmol) was coupled withindole-6-boronic acid (Frontier Scientific, 165 mg, 1.02 mmol) accordingto the procedure of Example 8 to provide the title compound. ¹H NMR (300MHz, CD₃OD) δ 2.18-2.63 (m, 8H) 2.84 (s, 3H) 3.82 (t, J=6.10 Hz, 1H)3.96 (s, 2H) 6.57 (dd, J=3.05, 0.68 Hz, 1H) 7.41-7.47 (m, 2H) 7.74-7.93(m, 4H) 8.10 (d, J=9.16 Hz, 1H) ppm. MS (DCI/NH₃): m/z 333 (M+H)⁺. Anal.Calculated for C₂₁H₂₄N₄.2.45 CF₃CO₂H: C, 50.85; H, 4.36; N, 9.16. Found:C, 50.72; H, 4.43; N, 9.25.

Example 455-{6-[(endo)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yloxy]pyridazin-3-yl}-1H-indoletrifluoroacetate Example 45A(endo)-9-Methyl-9-azabicyclo[3.3.1]nonan-3-ol

(endo)-9-methyl-9-azabicyclo[3.3.1]nonan-3-wola s prepared according tothe procedure as described in WO 03062235. ¹H NMR (300 MHz, CD₃OD) δ1.22-1.32 (m, 2H), 1.35-1.47 (m, 3H), 1.98 (tt, J=13.60, 5.21 Hz, 2H),2.30-2.56 (m, 6H), 2.87-2.96 (m, 2H), 4.04-4.15 (m, 1H) ppm. MS(DCI/NH₃): m/z 156 (M+H)+.

Example 45B(endo)-3-(6-chloropyridazin-3-yloxy)-9-methyl-9-azabicyclo[3.3.1]nonane

The product of Example 45A (467 mg, 3.0 mmol) was coupled with3,6-dichloropyridazine (614 mg, 3.3 mmol) according to the procedure ofExample 1A. ¹H NMR (300 MHz, CD₃OD) δ 1.59 (ddd, J=14.41, 6.27, 6.10 Hz,1H), 1.77 (dd, J=14.92, 5.76 Hz, 2H), 2.06-2.28 (m, 4H), 2.52-2.82 (m,3H), 2.90 (s, 3H), 3.51 (t, J=5.76 Hz, 2H), 5.55 (tt, J=6.91, 1.74 Hz,1H), 7.26 (d, J=9.16 Hz, 1H), 7.69 (d, J=9.16 Hz, 1H) ppm. MS (DCI/NH₃):m/z 268 (M+H)⁺.

Example 45C5-{6-[(endo)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yloxy]pyridazin-3-yl}-1H-indoletrifluoroacetate

The product of Example 45B (145 mg, 0.54 mmol) was coupled withindole-5-boronic acid (Ryscor, 165 mg, 1.02 mmol) according to theprocedure of Example 1B to provide the title compound. ¹H NMR (300 MHz,CD₃OD) δ 1.57-1.1 (m, 2H) 1.95-2.47 (m, 5H) 2.67-2.92 (m, 3H) 2.98-3.06(m, 3H) 3.65 (t, J=5.09 Hz, 2H) 5.61 (t, J=6.95 Hz, 1H) 6.59 (d, J=3.05Hz, 1H) 7.34 (d, J=3.05 Hz, 1H) 7.37-7.43 (m, 1H) 7.55 (d, JS.48 HZ, 1H)7.74 (dd, JS.65, 1.86 HZ, 1H) 8.18 (d, J=1.70 HZ, 1H) 8.20-8.27 (m, 1H)ppm. MS (DCI/NH₃): m/z 349 (M+H)⁺. Anal. Calculated for C₂₁H₂₄N₄O.2.10CF₃CO₂H: C, 51.48; H, 4.47; N, 9.53. Found: C, 51.31; H, 4.33; N, 9.36.

Example 46(endo)-3-[6-(Benzo[b]thiophen-5-yl)pyridazin-3-yloxy]-9-methyl-9-azabicyclo[3.3.1]nonanetrifluoroacetate

The product of Example 45B (145 mg, 0.54 mmol) was coupled with theproduct of 10A (280 mg, 1.02 mmol) according to the procedure of Example1B to provide the title compound. ¹H NMR (300 MHz, CD₃OD) δ 1.56-1.81(m, 2H), 1.94-2.48 (m, 5H), 2.68-2.92 (m, 3H), 2.98-3.08 (m, 3H), 3.65(t, J=5.09 Hz, 2H), 5.66 (t, J=6.95 Hz, 1H), 7.34 (d, J=9.16 Hz, 1H),7.50 (d, J=5.76 Hz, 1H), 7.68 (d, J=5.76 Hz, 1H), 7.96-8.02 (m, 1H),8.04-8.10 (m, 1H), 8.20 (d, J=9.49 Hz, 1H), 8.45 (d, J=1.36 Hz, 1H) ppm.MS (DCI/NH₃): m/z 366 (M+H)⁺. Anal. Calculated for C₂₁H₂₃N₃O.S1.13CF₃CO₂H: C, 56.51; H, 4.92; N, 8.50. Found: C, 56.56; H, 4.75; N, 8.44.

Example 475-{5-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-pyrrolo[2,3-b]pyridinebistosylate Example 47A5-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine

5-Bromo-1H-pyrrolo[2,3-b]pyridin (eC hemgenx, 0.90 g, 4.57 mmol) wascoupled with bis(pinacolato)diboron (Aldrich, 1.27 g, 5.0 mmol)according to the procedure of Example 10A. ¹H NMR (300 MHz, CDCl₃) δ1.37 (s, 12H) 6.52 (d, J=3.73 Hz, 1H), 7.38 (d, J=3.73 Hz, 1H), 8.34 (d,J=1.36 Hz, 1H), 8.49 (d, J=1.70 Hz, 1H) ppm; m/z 245 (M+H)⁺.

Example 47B5-{5-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-pyrrolo[2,3-b]pyridinetosylate

The product from Example 41C (207 mg, 0.60 mmol), was coupled with theproduct of Example 47A (200.0 mg, 0.82 mmol) according to the procedureof Example 10B. ¹H NMR (300 MHz, CD₃OD) δ 1.98-2.09 (m, 2H), 2.10-2.32(m, 6H), 2.40 (s, 3H), 5.32 (t, J=5.09 Hz, 1H), 6.58 (d, J=3.39 Hz, 1H),7.44 (d, J=3.73 Hz, 1H), 8.25 (d, J=1.36 Hz, 1H), 8.53 (d, J=2.03 Hz,1H), 8.65 (d, J=1.36 Hz, 1H), 8.78 (d, J=2.03 Hz, 1H) ppm. MS (DCI/NH₃)m/z 336 (M+H)⁺.

Example 47C5-{5-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-pyrrolo[2,3-b]pyridinebistosylate

The product of Example 47B (90 mg, 0.27 mmol) was treated withptoluenesulfonic acid monohydrate TsOH.H₂0 (Aldrich, 95 mg, 0.5 mmol) inEtOAc/EtOH (v. 4:1, 10 mL) at ambient temperature for 10 hours. Themixture was concentrated under reduced pressure to provide the titlecompound. ¹H NMR (300 MHz, CD₃OD) δ 2.35 (s, 6H), 2.38-2.45 (m, 2H),2.45-2.61 (m, 6H), 2.85 (s, 3H), 3.85-4.07 (m, 2H), 5.46 (t, J=4.75 Hz,1H), 6.97 (d, J=3.39 Hz, 1H), 7.22 (d, J=7.80 Hz, 4H) 7.70 (d, J=8.14Hz, 4H), 7.76 (d, J=3.73 Hz, 1H), 8.42 (d, J=1.36 Hz, 1H), 8.85 (d,J=1.36 Hz, 1H), 9.04 (d, J=1.70 Hz, 1H), 9.27 (d, J=1.70 Hz, 1H) ppm. MS(DCI/NH₃): m/z 336 (M+H)⁺. Anal. Calculated for C₁₉H₂₁N₅O.2.17C₇H₈SO₃.1.00H₂O: C, 56.48; H, 5.59; N, 9.63. Found: C, 56.48; H, 5.37;N, 9.67.

Example 485-{5-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-pyrrolo[2,3-b]pyridinebistosylate Example 48A5-{5-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-pyrrolo[2,3-b]pyridine

The product from Example 11A (152 mg, 0.60 mmol), was coupled with theproduct of Example 47A (200.0 mg, 0.82 mmol) according to the procedureof Example 9B. ¹H NMR (300 MHz, CD₃OD) δ 1.76-1.92 (m, 4H), 2.06-2.20(m, 4H), 2.36 (s, 3H), 3.18-3.31 (m, 2H), 4.64-4.79 (m, 1H), 6.57 (d,J=3.39 Hz, 1H), 7.43 (d, J=3.73 Hz, 1H), 7.8 1 (d, J=8.82 Hz, 1H), 8.29(d, J=3.05 Hz, 1H), 8.45 (d, J=2.03 Hz, 1H), 8.72 (d, J=2.03 Hz, 1H)ppm. MS (DCI/NH₃) m/z 335 (M+H)⁺.

Example 48B5-{5-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-pyrrolo[2,3-b]pyridinebistosylate

The product of Example 48A (100 mg, 0.30 mmol) was treated withptoluenesulfonic acid monohydrate TsOH.H₂0 (Aldrich, 95 mg, 0.5 mmol) inEtOAc/EtOH (v. 4:1, 10 mL) at ambient temperature for 10 hours. Themixture was concentrated under reduced pressure to provide the titlecompound. ¹H NMR (300 MHz, CD₃OD) δ 2.18-2.47 (m, 2H), 2.15-2.40 (m,10H), 2.46-2.60 (m, 2H), 2.85 (s, 3H), 3.99-4.06 (m, 2H), 4.95-5.19 (m,1H), 6.83 (d, J=3.39 Hz, 1H), 7.22 (d, J=8.14 Hz, 4H), 7.66 (d, J=3.39Hz, 1H), 7.70 (d, J=8.48 Hz, 4H), 8.09 (d, J=8.82 Hz, 1H), 8.48 (d,J=2.71 Hz, 1H), 8.87 (d, J=2.03 Hz, 1H), 8.91 (d, J=2.03 Hz, 1H) ppm. MS(DCI/NH₃): m/z 335 (M+H)⁺. Anal. Calculated for C₂₀H₂₂N₄O.2.14C₇H₈SO₃.0.50H₂O: C, 59.01; H, 5.68; N, 7.87. Found: C, 58.88; H, 5.63;N, 7.47.

Example 495-{5-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-3-yl}-1H-indoletri(hydrochloride) Example 49A(exo)-3-(5-Chloro-pyridin-3-yloxy)-8-methyl-8-aza-bicyclo[3.2.1]octane

(endo)-Tropine (Aldrich, 0.56 g, 4.0 mmol), was coupled with3-chloro-5-hydroxy-pyridine (Aldrich, 0.26 g, 2.0 mmol), in the presenceof DIAD (di-isopropyl azadicarboxylate, Aldrich, 0.81 g, 4.0 mmol) andPh3P (Aldrich, 1.14 g, 4.0 mmol) in THF (anhydrous, Aldrich, 20 mL) atambient temperature for two days. The reaction mixture was concentrated.The title product was purified by chromatography (SiO₂,CH₂Cl₂:MeOH:NH₃.H₂O, 90:10:1, R_(f). 0.45). NMR (300 MHz, CD₃OD)1.66-1.91 (m, 4H), 1.98-2.19 (m, 4H), 2.33 (s, 3H), 3.22-3.28 (m, 2H),4.58-4.79 (m, 1H), 7.49 (dd, J=2.37, 1.70 Hz, 1H), 8.11 (d, J=1.70 Hz,1H), 8.15 (d, J=2.37 Hz, 1H) ppm. MS (DCI/NH₃) m/z 255 (M+H)⁺, 253(M+H)⁺.

Example 49B5-{5-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-3-yl}-1H-indole

Under N₂, the mixture of the product from Example 49A (250 mg, 1.00mmol) was coupled with 5-Indolylboronic acid (Rsycor, 240.0 mg, 1.50mmol) according to the procedure of Example 9B. ¹H NMR (300 MHz, CD₃OD)δ 1.71-1.92 (m, 4H), 2.02-2.21 (m, 4H), 2.34 (s, 3H), 3.23-3.30 (m, 2H),4.63-4.80 (m, 1H), 6.54 (d, J=3.05 Hz, 1H), 7.29 (d, J=3.39 Hz, 1H),7.38 (dd, J=8.48, 2.03 Hz, 1H), 7.47-7.53 (m, 1H), 7.58-7.64 (m, 1H),7.83 (d, J=1.36 Hz, 1H), 8.15 (d, J=2.71 Hz, 1H), 8.39 (d, J=1.70 Hz,1H) ppm. MS (DCI/NH₃) m/z 334 (M+H)⁺.

Example 49C5-{5-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-3-yl}-1H-indoletri(hydrochloride)

The product of Example 49B (90 mg, 0.27 mmol) was treated with HCl(Aldrich, 4 M in dioxane, 0.25 mL, 1.0 mmol) in ^(i)PrOAc/^(i)PrOH (v.4:1, 5 mL) at ambient temperature for 2 hours to provide the titlecompound. ¹H NMR (300 MHz, CD₃OD) δ 2.01-2.66 (m, 8H), 2.83 (s, 3H),3.92-4.09 (m, 2H), 4.98-5.15 (m, 1H), 6.61 (d, J=3.05 Hz, 1H), 7.33-7.40(m, 1H), 7.50-7.63 (m, 2H), 8.04-8.10 (m, 2H), 8.44 (d, J=1.70 Hz, 1H),8.80 (s, 1H) ppm. MS (DCI/NH₃): m/z 334 (M+H)⁺. Anal. Calculated forC₂₁H₂₃N₃O.3.00 HCl. 4.60H₂O: C, 47.98; H, 6.14; N, 7.85. Found: C,47.62; H, 6.38; N, 7.62.

Example 505-{5-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indoletosylate Example 50A(exo)-3-(5-Iodo-pyrazin-2-yloxy)-8-methyl-8-aza-bicyclo[3.2.1]octane

Under N₂, the mixture of product from 7C (0.42 g, 3.0 mmol) was treatedwith potassium t-butoxide (Aldrich, 0.32 g, 3.3 mmol) in THF (anhydrous,Aldrich, 50 mL) at ambient temperature for 1 hours. The product ofExample 41B (1.00 g, 3.5 mmol) and was added. The mixture was stirred atambient temperature for 4 hours and quenched with water (5 mL). Themixture was concentrated and the residue was purified by chromatography(150 g SiO₂, EtOAc:MeOH:NH₃.H₂O, 90:10:1, R_(f). 0.40) to provide thetitle compound. ¹H NMR (300 MHz, CD₃OD) δ 1.90-2.25 (m, 4H), 2.31-2.60(m, 4H), 2.84 (s, 3H), 3.94-4.11 (m, 2H), 5.32-5.57 (m, 1H), 8.06 (d,J=1.36 Hz, 1H), 8.42 (d, J=1.36 Hz, 1H) ppm; MS (DCI/NH₃) m/z 346(M+H)⁺.

Example 50B5-{5-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indole

The product from Example 50A (200 mg, 0.58 mmol), was coupled with5-indolylboronic acid (Rsycor, 143.3 mg, 0.89 mmol) according to theprocedure of Example 9B. ¹H NMR (300 MHz, CD₃OD) δ 1.95-2.17 (m, 2H),2.16-2.31 (m, 2H), 2.36-2.47 (m, 2H), 2.48-2.67 (m, 2H), 2.85 (s, 3H),3.90-4.17 (m, 1H), 5.36-5.69 (m, 1H), 6.53 (d, J=3.39 Hz, 1H), 7.29 (d,J=3.05 Hz, 1H), 7.48 (d, J=8.48 Hz, 1H) 7.69 (dd, J=8.48, 1.70 Hz, 1H),8.13 (s, 1H) 8.20 (d, J=1.36 Hz, 1H), 8.62 (d, J=1.36 Hz, 1H) ppm. MS(DCI/NH₃) m/z 335 (M+H)⁺.

Example 50C5-{5-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indoletosylate

The product of Example 50B (170 mg, 0.50 mmol) was treated withptoluenesulfonic acid monohydrate TsOH.H₂0 (Aldrich, 100 mg, 0.51 mmol)in EtOAc/EtOH (v. 4:1, 5 mL) at ambient temperature for 10 hours. Themixture was concentrated under reduced pressure to provide the titlecompound. ¹H NMR (300 MHz, CD₃OD) δ 2.01-2.15 (m, 2H), 2.16-2.30 (m,2H), 2.36 (s, 3H), 2.39-2.49 (m, 2H), 2.52-2.67 (m, 2H), 2.84 (s, 3H),3.96-4.13 (m, 2H), 5.43-5.70 (m, 1H), 7.23 (d, J=8.14 Hz, 2H), 7.30 (s,1H), 7.49 (d, J=8.48 Hz, 1H), 7.62-7.75 (m, 4H), 8.12 (s, 1H), 8.22 (d,J=1.36 Hz, 1H), 8.68 (d, J=1.36 Hz, 1H) ppm. MS (DCI/NH₃): m/z 335(M+H)⁺.

Example 514-{5-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indoletosylate Example 51A4-{5-[(exo]-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indole

The product from Example 50A (200 mg, 0.58 mmol), was coupled with4-indolylboronic acid (Apollo, 143.3 mg, 0.89 mmol) according to theprocedure of Example 9B. ¹H NMR (300 MHz, CD₃OD) δ 2.02-2.28 (m, 4H),2.34-2.48 (m, 2H), 2.50-2.65 (m, 2H), 2.86 (s, 3H), 3.96-4.07 (m, 2H),5.45-5.68 (m, 1H), 6.82 (d, J=4.07 Hz, 1H), 7.23 (t, J=7.60 Hz 1H), 7.35(d, J=3.39 Hz, 1H), 7.41 (d, J=6.44 Hz, 1H), 7.48 (d, J=8.14 Hz, 1H),8.29 (d, J=1.36 Hz, 1H), 8.65 (d, J=1.36 Hz, 1H) ppm. MS (DCI/NH₃) m/z335 (M+H)⁺.

Example 51B4-{5-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-yl]-1H-indoletosylate

The product of Example 51A (120 mg, 0.36 mmol) was treated withptoluenesulfonic acid monohydrate TsOH.H₂O (Aldrich, 68 mg, 0.36 mmol)in EtOAc/EtOH (v. 4:1, 5 mL) at ambient temperature for 10 hours. Themixture was concentrated under reduced pressure to provide the titlecompound. ¹H NMR (300 MHz, CD₃OD) δ 2.02-2.17 (m, 2H), 2.18-2.32 (m,2H), 2.36 (s, 3H), 2.38-2.50 (m, 2H), 2.52-2.69 (m, 2H), 2.85 (s, 3H),4.00-4.11 (m, 2H), 7.17-7.28 (m, 1H), 7.35 (s, 1H), 7.42 (d, J=7.12 Hz,1H), 7.49 (d, J=8.14 Hz, 1H), 7.70 (d, J=8.14 Hz, 1H), 8.30 (d, J=1.70Hz, 1H), 8.67 (d, J=1.36 Hz, 1H) ppm. MS (DCI/NH₃): m/z 335 (M+H)⁺.

Example 526-{5-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indoletosylate Example 52A6-{5-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indole

The product from Example 41C (200 mg, 0.58 mmol), was coupled with6-indolylboronic acid (Frontier Scientific, 143.3 mg, 0.89 mmol)according to the procedure of Example 9B. ¹H NMR (300 MHz, CD₃OD) δ1.97-2.16 (m, 2H), 2.14-2.26 (m, 2H), 2.31-2.65 (m, 4H), 2.81 (s, 3H),3.84-4.05 (m, 2H), 5.33-5.71 (m, 1H), 6.47 (d, J=3.05 Hz, 1H), 7.31 (d,J=3.05 Hz, 1H), 7.48-7.73 (m, 2H), 7.99 (s, 1H), 8.20 (d, J=1.36 Hz,1H), 8.63 (d, J=1.36 Hz, 1H) ppm. MS (DCI/NH₃) m/z 335 (M+H)⁺.

Example 52B6-{5-[(exo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indoletosylate

The product of Example 52A (90 mg, 0.27 mmol) was treated withptoluenesulfonic acid monohydrate TsOH.H₂0 (Aldrich, 57 mg, 0.30 mmol)in EtOAc/EtOH (v. 4:1, 5 mL) at ambient temperature for 10 hours. Themixture was concentrated under reduced pressure to provide the titlecompound. ¹H NMR (300 MHz, CD₃OD) δ 2.01-2.14 (m, 2H), 2.16-2.31 (m,2H), 2.36 (s, 3H), 2.39-2.51 (m, 2H), 2.50-2.65 (m, 2H), 2.84 (s, 3H),3.98-4.08 (m, 2H), 5.41-5.68 (m, 1H), 6.48 (d, J=2.37 Hz, 1H), 7.23 (d,J=7.80 Hz, 2H), 7.32 (s, 1H), 7.55-7.67 (m, 2H), 7.71 (d, J=8.48 Hz,2H), 7.99 (s, 1H), 8.22 (d, J=1.36 Hz, 1H), 8.65 (d, J=1.36 Hz, 1H) ppm.MS (DCI/NH₃): m/z 335 (M+H)⁺.

Example 53(endo)-N-(5-(1H-Indol-5-yl)pyridin-3-yl)-8-methyl-8-azabicyclo[3.2.1]octan-3-amineExample 53A(endo)-N-(5-Bromopyridin-3-yl)-8-methyl-8-azabicyclo[3.2.1]octan-3-amine

8-Methyl-8-azabicyclo[3.2.1]octan-3-one (Aldrich, 695 mg, 5.0 mmol)reacted with bromopyridin-3-amine (950 mg, 5.5 mmol) according to theprocedure of Example 20A to give the title compound (650 mg, yield,44%). ¹H NMR (300 MHz, CD₃OD) δ 1.54-2.25 (m, 8H), 2.29 (s, 3H), 3.16 [s(broad), 2H], 3.50 (t, J=6.61 Hz, 1H), 7.08 (t, J=2.20 Hz, 1H), 7.79 (d,J=1.70 Hz, 1H), 7.85 (d, J=2.37 Hz, 1H) ppm; MS (DCI/NH₃): m/z 298(M+H)⁺, 296 (M+H)⁺.

Example 53B(endo)-N-(5-(1H-Indol-5-yl)pyridin-3-yl)-8-methyl-8-azabicyclo[3.2.1]octan-3-aminep-tosylate

The product of Example 53A (150 mg, 0.5 mmol) was coupled withindole-5-boronic acid (Frontier, 150 mg, 0.93 mmol) according to theprocedure of Example 9B to provide the free base of the title compound(82 mg, yield, 50%), which was treated with p-toluenesulfonic acidhydrate (Aldrich, 47 mg, 0.25 mmol) in EtOAc/EtOH (v. 10:1, 5 mL) atroom temperature for 16 hours. The precipitate was collected and driedto give the title compound (99.3 mg, yield, 67.2%). ¹H NMR (300 MHz,CD₃OD) δ 2.15-2.30 (m, 2H), 2.30-2.42 (m, 5.5H), 2.42-2.63 (m, 4H), 2.82(s, 3H), 3.81 (t, J=5.9 Hz, 1H), 3.93 [s (broad), 2H), 6.54 (d, J=2.4Hz, 1H), 7.21 (d, J=8.1 Hz, 3H), 7.32 (d, J=3.1 Hz, 1H), 7.39 (dd,J=8.4, 1.7 Hz, 1H), 7.47-7.59 (m, 2H), 7.70 (d, J=8.5 Hz, 3H), 7.86 (d,J=1.7 Hz, 1H), 7.90 (d, J=2.4 Hz, 1H), 8.23 (d, J=1.7 Hz, 1H) ppm. MSDCI/NH₃): m/z 333 (M+H)⁺. Anal. Calculated for C₂₁H₂₄N₄.1. 50C₇H₈O₃S.1.20H₂O: C, 61.78; H, 6.32; N, 9.15. Found: C, 61.78; H, 6.19; N, 8.99.

Example 54 (endo)-N-(5-(1H-Indol-4-yl)pyridin-3-yl)-8-methy1-8-azabicyclo[3.2.1]octan-3-amine p-tosylate Example 54A(endo)-N-(5-(1H-Indol-4-yl)pyridin-3-yl)-8-methyl-8-azabicyclo[3.2.1]octan-3-amine

The product of Example 53A (150 mg, 0.5 mmol) was coupled withindole-4-boronic acid (Frontier, 150 mg, 0.93 mmol) according to theprocedure of Example 9B to provide the title compound (80 mg, yield,48%), ¹H NMR (300 MHz, CD₃OD) δ 1.78-1.96 (m, 2H), 2.05-2.16 (m, 4H),2.17-2.30 (m, 2H), 2.33 (s, 3H), 3.21 [s (broad), 2H], 3.63 (t, J=6.8Hz, 1H), 6.57 (d, J=3.4 Hz, 1H), 7.08 (d, J=7.1 Hz, 1H), 7.15-7.26 (m,2H), 7.31 (d, J=3.1 Hz, 1H), 7.42 (d, J=7.8 Hz, 1H), 7.89 (d, J=2.7 Hz,1H), 8.05 (d, J=1.7 Hz, 1H) ppm; MS DCI/NH₃): m/z 333 (M+H)⁺.

Example 54B(endo)-N-(5-(1H-Indol-4-yl)pyridin-3-yl)-8-methyl-8-azabicyclo[3.2.1]octan-3-aminep-tosylate

The product of Example 54A (80 mg, 0.24 mmol) was treated withptoluenesulfonic acid hydrate (Aldrich, 47 mg, 0.25 mmol) in EtOAc/EtOH(v. 10:1, 5 mL) at room temperature for 16 hours. The precipitate wascollected and dried to give the title compound (85.3 mg, yield, 58.5%).¹H NMR (300 MHz, CD₃OD) δ 2.17-2.31 (m, 2H), 2.31-2.41 (m, 5.8H),2.41-2.60 (m, 4H), 2.82 (s, 3H), 3.79 (t, J=5.9 Hz, 1H), 3.93 [s(broad), 2H), 7.16 (dd, J=7.5, 1.0 Hz, 1H), 7.21-7.27 (m, 5.2H), 7.37(d, J=3.1 Hz, 1H), 7.50 (d, J=8.1 Hz, 1.0H), 7.62-7.66 (m, 1.0H), 7.70(d, J=8.1 Hz, 3.2H), 7.99 (d, J=2.4 Hz, 1H), 8.24 (d, J=1.4 Hz, 1H) ppm.MS DCI/NH₃): m/z 333 (M+H)⁺. Anal. Calculated forC₂₁H₂₄N₄.1.60C₇H₈O₃S.1.20H₂O: C, 61.43; H, 6.28; N, 8.90. Found: C, 61.72; H, 6.26; N, 8.64.

Example 55(endo)-N-(5-(1H-Indol-6-yl)pyridin-3-yl)-8-methyl-8-azabicyclo[3.2.1]octan-3-aminep-tosylate Example 55A(endo)-N-(5-(1H-Indol-6-yl)pyridin-3-yl)-8-methyl-8-azabicyclo[3.2.1]octan-3-amine

The product of Example 53A (150 mg, 0.5 mmol) was coupled withindole-6-boronic acid (Frontier, 150 mg, 0.93 mmol) according to theprocedure of Example 9B to provide the free base of the title compound(102 mg, yield, 60%). ¹H NMR (300 MHz, CD₃OD) δ 1.80-1.98 (m, 2H),2.06-2.19 (m, 4H), 2.19-2.32 (m, 2H), 2.35 (s, 3H), 3.24 [s (broad),2H), 3.64 (t, J=6.8 Hz, 1H), 6.47 (d, J=3.4 Hz, 1H), 7.16-7.21 (m, 1H),7.22-7.34 (m, 2H), 7.57-7.67 (m, 2H), 7.83 (d, J=2.7 Hz, 1H), 8.06 (d,j=2.0 Hz, 1H) ppm; MS DCI/NH₃): m/z 333 (M+H)⁺.

Example 55B(endo)-N-(5-(1H-Indol-6-yl)pyridin-3-yl)-8-methyl-8-azabicyclo[3.2.1]octan-3-aminep-tosylate

The product of Example 55A (102 mg, 0.3 mmol) was treated withptoluenesulfonic acid hydrate (Aldrich, 57 mg, 0.30 mmol) in EtOAc/EtOH(v. 10:1, 5 mL) at room temperature for 16 hours. The precipitate wascollected and dried to give the title compound (137.2 mg, yield, 59.4%).¹H NMR (300 MHz, CD₃OD) 2.16-2.64 (m, 12.2H), 2.82 (s, 3H), 3.78 (t,J=6.3 Hz, 1H), 3.92 [s (broad), 2H), 6.48 (d, J=4.1 Hz, 1H), 7.22 (d,J=7.8 Hz, 2.8H), 7.27 (dd, J=8.1, 1.7 Hz, 1H), 7.30 (d, J=3.1 Hz, 1H),7.31-7.34 (m, 1H), 7.61-7.66 (m, 2H), 7.70 (d, J=8.1 Hz, 2.8H), 7.88 (d,J=2.4 Hz, 1H), 8.17 (d, J=1.7 Hz, 1H) ppm. MS DCI/NH₃): m/z 333 (M+H)⁺.Anal. Calculated for C₂₁H₂₄N₄.1.40C₇H₈O₃S.0.70H₂O: C, 63.11; H, 6.29; N,9.56. Found: C, 63.17; H, 6.61; N, 9.43.

Example 56(endo)-N-{5-[2-(trifluoromethyl)-1H-indol-5-yl]pyridin-3-yl}-8-Methyl-8-azabicyclo[3.2.1]octan-3-aminefumarate

The product of Example 9A (1 10 mg, 0.4 mmol) was coupled with theproduct of Example 7A (300 mg, 0.97 mmol) according to the proceduredescribed in Example 9B to provide the free base of the title compound(38 mg, yield, 22.5%), which was (38 mg 0.09 mmol) was then treated withfumaric acid (12 mg, 0.1 mmol) in EtOAc/EtOH (v. 10:1, 5 mL) at roomtemperature for 16 hours. The precipitate was filtered and dried to givethe title compound (50.4 mg, yield, 99%). ¹H NMR (300 MHz, CD₃OD) S2.28-2.37 (m, 4H), 2.42-2.57 (m, 4H), 2.84 (s, 3H), 3.02 broad), 2 HI,4.80-4.90 (m, 1H) 6.72 (s, 2.6H), 6.97 (s, 1H), 7.47-7.57 (m, 2H), 7.85(d, J=8.8 Hz, 2H), 8.17 (s, 1H) 8.30 (s, 1H) ppm. MS DCI/NH₃): m/z 402(M+H)⁺. Anal. Calculated for C₂₂H₂₂F₃N₄O.1.30C₄O₄H₄: C, 59.15; H, 4.96;N, 7.61. Found: C, 59.29; H, 5.07; N, 7.37.

Example 575-{5-[(endo)-8-Methyl-8-azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-pyrrolo[2,3-b]pyridinetosylate Example 57A5-{5-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-pyrrolo[2,3-b]pyridine

The product of Example 9A (200 mg, 0.80 mmol), was coupled with theproduct of Example 47A (244.0 mg, 1.0 mmol) according to the procedureof Example 9B. to provide the title compound (190 mg, yield, 71%). ¹HNMR (300 MHz, CD₃OD) δ 1.93-2.27 (m, 8H), 2.33 (s, 3H), 3.20 [s(broad.), 2H], 4.69 (t, J=5.1 Hz, 1H), 6.57 (d, J=3.4 Hz, 1H), 7.39-7.48(m, 2H), 7.83 (d, J=8.5 Hz, 1H), 8.25 (d, J=2.7 Hz, 1H), 8.46 (d, J=2.0Hz, 1H), 8.73 (d, J=2.4 Hz, 1H) ppm. MS (DCI/NH₃) m/z 335 (M+H)⁺.

Example 57B5-{5-[(endo)-8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-pyrrolo[2,3-b]pyridinetosylate

The product of Example 48A (80 mg, 0.24 mmol) was treated withptoluenesulfonic acid monohydrate TsOH.H₂0 (Aldrich, 57 mg, 0.3 mmol) inEtOAc/EtOH (v. 4:1, 10 mL) at ambient temperature for 10 hours. Theprecipitated solid was filtered and dried to provide the title compound(100 mg, yield, 79.6%). ¹H NMR (300 MHz, CD₃OD) δ 2.27-2.69 (m, 11H),2.84 (s, 3H), 3.84-4.08 (m, 2H), 4.84-4.94 (m, 1H), 6.62 (d, J=3.4 Hz,1H), 7.23 (d, J=8.1 Hz, 2H), 7.47 (d, J=3.7 Hz, 1H), 7.56 (dd, J=8.8,3.1 Hz, 1H), 7.71 (d, J=8.1 Hz, 2H), 7.92 (d, J=8.8 Hz, 1H), 8.36 (d,J=2.7 Hz, 1H), 8.56 (d, J=2.0 Hz, 1H), 8.77 (d, J=2.0 Hz, 1H) ppm. MS(DCI/NH₃): m/z 335 (M+H)⁺. Anal. Calculated for C₂₀H₂₂N₄O.1.10C₇H₈SO₃.0.80H₂O: C, 61.81; H, 6.07; N, 10.41. Found: C, 62.15; H, 5.92;N, 10.05.

Example 585-{5-[(endo)-8-Methyl-8-azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}indolin-2-onebis(hydrochloric acid) Example 58A5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-2-one

Under N₂, 5-Bromoindolin-2-one (Aldrich, 2.11 g, 10.0 mmol) was coupledwith bis(pinacolato)dibon (Frontier Scientific, 3.05 g, 12 mmol) in thepresence of KOAc (Aldrich, 1.50 g, 15.0 mmol) under the catalysis ofPdCl₂(dppf). CH₂Cl₂(Aldrich, 163 mg, 0.2 mmol) in anhydrous dioxane(Aldrich, 50 mL) at 85° C. for 15 hours. After the reaction wascompleted, it was cooled down to ambient temperature and diluted withEtOAc (100 mL). The mixture was then washed with brine (2×10 mL) andconcentrated. The residue was purified with chromatography on silica gel(EtOAc/hexanes, v. 1:1, R_(f)=0.5) to provide the title compound (2.43g, yield, 93.8%). ¹H NMR (300 MHz, CD₃OD) δ 1.24 (s, 12H), 3.51 (s, 2H),6.88 (d, J=8.5 Hz, 1H), 7.52-7.75 (m, 2H) ppm. MS (DCI/NH₃): m/z 260(M+H)⁺.

Example 58B5-{5[(endo)-8-Methyl-8-azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}indolin-2-one

The product of Example 9A (200 mg, 0.80 mmol), was coupled with theproduct of Example 58A (260 mg, 1.0 mmol) according to the procedure ofExample 9B. to provide the title compound (130 mg, yield, 46.4%). ¹H NMR(300 MHz, CD₃OD) δ 1.93-2.04 (m, 2H), 2.06-2.15 (m, J=2.4 Hz, 4H),2.14-2.25 (m, 2H), 2.33 (s, 3H), 3.20 [s (broad), 2H], 4.67 (t, J=5.1Hz, 1H), 6.96 (d, J=8.1 Hz, 1H), 7.38 (dd, J=8.8, 3.1 Hz, 1H), 7.69-7.80(m, 3H), 8.18 (d, J=3.1 Hz, 1H) ppm. MS (DCI/NH₃) m/z 350 (M+H)⁺.

Example 58C5-{5-[(endo)-8-Methyl-8-azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}indolin-2-onebis(hydrochloric acid)

The product of Example 48A (80 mg, 0.24 mmol) was treated withptoluenesulfonic acid monohydrate TsOH.H₂0 (Aldrich, 57 mg, 0.3 mmol) inEtOAc/EtOH (v. 4:1, 10 mL) at ambient temperature for 10 hours. Theprecipitated solid was filtered and dried to provide the title compound(100 mg, yield, 79.6%). ¹H NMR (300 MHz, CD₃OD) δ 2.31-2.67 (m, 8H),2.85 (s, 3H), 3.68 (s, 2H), 3.90-4.08 (m, 2H), 5.03 (t, J=4.6 Hz, 1H),7.14 (d, J=9.2 Hz, 1H), 7.73-7.82 (m, 2H), 8.22-8.34 (m, 2H), 8.53 (d,J=2.4 Hz, 1H) ppm. MS (DCI/NH₃) m/z 350 (M+H)⁺. Anal. Calculated forC₂₁H₂₃N₃O₂.2.00 HCl.3.0H₂O: C, 52.95; H, 6.56; N, 8.82. Found: C, 52.67;H, 6.47; N, 8.62.

Example 595-{5-[(endo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-indolebis(hydrochloric acid Example 59A(endo)-3-(6-Chloropyridin-3-yloxy)-8-azabicyclo[3.2.1]octane

To a solution of the product of Example 9A (253 mg, 1.0 mmol) inanhydrous 1,2-dichloroethane (Aldrich, 10 mL) was added 1-chloroethylcarbonochloridate (Aldrich, 286 mg, 2.0 mmol). The mixture was heated toreflux for 15 hours. It was then concentrated, the residue was dilutedwith 5 mL of methanol. The solution was stirred at 65° C. for 1 h. andthen concentrated. The residue was purified with chromatography onsilica gel (CH₂Cl₂:MeOH:NH₃.H₂O, v. 90:10:2, R_(f)=0.1) to give thetitle compound (180 mg, yield, 75%). ¹H NMR (300 MHz, CD₃OD) δ 2.03-2.62(m, 8H), 4.01-4.14 (m, 2H), 4.75-4.82 (m, 1H), 7.37-7.42 (m, 1H), 7.44(d, J=3.1 Hz, 1H), 8.03-8.13 (m, 1H) ppm. MS (DCI/NH₃) m/z 241 (M+H)⁺,239 (M+H)⁺.

Example 59B5-{5-[(endo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-indole

The product of Example 59A (180 mg, 0.75 mmol), was coupled with1H-indol-5-ylboronic acid (160 mg, 1.0 mmol) according to the procedureof Example 9B. to provide the title compound (120 mg, yield, 50.1%). ¹HNMR (300 MHz, CD₃OD) δ 1.77-1.94 (m, 2H), 1.96-2.07 (m, 2H), 2.07-2.30(m, 4H), 3.46-3.59 (m, 2H), 4.73 (t, J=4.9 Hz, 1H), 6.51 (d, J=4.1 Hz,1H), 7.26 (d, J=3.1 Hz, 1H), 7.39 (dd, J=8.8, 3.1 Hz, 1H), 7.45 (d,J=8.5 Hz, 1H), 7.62 (dd, J=8.5, 1.7 Hz, 1H), 7.77 (d, J=8.8 Hz, 1H),8.03 (d, J=1.7 Hz, 1H), 8.17 (d, J=2.7 Hz, 1H) ppm. MS (DCI/NH₃) m/z 320(M+H)⁺.

Example 59C5-{5-[(endo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-indolebis(hydrochloric acid

The product of Example 59B (120 mg, 0.38 mmol) was treated with HCl (4M, in dioxane, 0.2 mL, 0.8 mmol) in EtOAc (5.0 mL) at ambienttemperature for 10 hours. The precipitated solid was filtered and driedto provide the title compound (130 mg, yield, 79.6%). ¹H NMR (300 MHz,CD₃OD) δ 2.09-2.26 (m, 2H), 2.28-2.43 (m, 2H), 2.40-2.59 (m, 4H),4.02-4.23 (m, 2H), 5.02 (t, J=4.4 Hz, 1H), 6.65 (d, J=3.1 Hz, 1H), 7.42(d, J=3.4 Hz, 1H), 7.57-7.71 (m, 2H), 8.15 (s, 1H), 8.19 (dd, J=9.1, 2.7Hz, 1H), 8.29 (d, J=9.1 Hz, 1H), 8.44 (d, J=2.7 Hz, 1H) ppm. MS(DCI/NH₃) m/z 320 (M+H)⁺. Anal. Calculated for C₂₀H₂₁N₃O.2.00HCl.1.18H₂O: C, 58.08; H, 6.18; N, 10.16. Found: C, 57.73; H, 6.37; N,9.95.

Example 60(1R,3r,5S,8s)-3-(6-(1H-Indol-5-yl)pyridin-3-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane8-oxide

3-Chlorobenzoperoxoic acid (Aldrich, 70-75%, 240 mg, 1.0 mmol) was addedto a solution of product of Example 9B (333 mg, 1.0 mmol) in MeOH (10mL). It was then stirred at ambient temperature for 4 hours. Thesolution was directly purified by preparative HPLC [Gilson, column,Xterra® 5 μm, 40×100 mm. Eluting Solvent, MeCN/H₂O (0.1 M aqueousammonium bicarbonate, adjusted to pH 10 with ammonium hydroxide)(v.10/90 to 75/25 over 20 minutes, Flow rate of 40 mL/minute, uvdetector set to 250 nm]. The fractions with lower rention time werecollected and concentrated under reduced pressure to provide the titlecompound (130 mg, yield, 37.2%). ¹H NMR (300 MHz, CD₃OD) δ 2.19-2.42 (m,4H), 2.45-2.74 (m, 4H), 3.34 (s, 3H), 3.57-3.70 (m, 2H), 4.72 (t, J=5.3Hz, 1H), 6.52 (d, J=2.4 Hz, 1H), 7.27 (d, J=3.1 Hz, 1H), 7.40-7.52 (m,2H), 7.64 (dd, J=8.5, 1.7 Hz, 1H), 7.80 (d, J=8.8 Hz, 1H), 8.05 (d,J=2.0 Hz, 1H), 8.23 (d, J=3.1 Hz, 1H) ppm; MS (DCI/NH₃) m/z 350 (M+H)⁺.

Example 61(1R,3r,5S,8r)-3-(6-(1H-Indol-5-yl)pyridin-3-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane8-oxide

3-Chlorobenzoperoxoic acid (Aldrich, 70-75%, 240 mg, 1.0 mmol) was addedto a solution of product of Example 9B (333 mg, 1.0 mmol) in MeOH (10mL). It was then stirred at ambient temperature for 4 hours. Thesolution was directly purified by preparative HPLC [Gilson, column,XterraB 5 pm, 40×100 mm. Eluting Solvent, MeCN/H₂O (0.1 M aqueousammonium bicarbonate, adjusted to pH 10 with ammonium hydroxide) (v.10/90 to 75/25 over 20 minutes, Flow rate of 40 mL/minute, uv detectorset to 250 nm]. The fractions with higher rention time were collectedand concentrated under reduced pressure to provide the title compound (110 mg, yield, 3 1.5%). ¹H NMR (300 MHz, CD₃OD) δ 1.96-2.07 (m, 2H),2.19-2.37 (m, 2H), 2.44-2.59 (m, 2H), 3.06 (dt, J=15.3, 4.2 Hz, 2H),3.24 (s, 3H), 3.47-3.59 (m, 2H), 4.71-4.81 (m, 1H), 6.52 (d, J=3.1 Hz,1H), 7.27 (d, J=3.4 Hz, 1H), 7.42-7.50 (m, 2H), 7.64 (dd, J=8.5, 1.7 Hz,1H), 7.80 (d, J=8.8 Hz, 1H), 8.05 (d, J=1.7 Hz, 1H), 8.24 (d, J=3.1 Hz,1H) ppm; MS (DCI/NH₃) m/z 350 (M+H)⁺.

Example 624-{5-[(endo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-indoletrifluoroacetate

The product of Example 59A (120 mg, 0.50 mmol), was coupled with1H-indol-4-ylboronic acid (Frontier, 121 mg, 0.75 mmol) according to theprocedure of Example 9B. The crude mixture was purified with preparativeHPLC (Gilson, column, Xterra® 5 μm, 40×100 mm. Eluting Solvent, MeCN/H₂Ocontaining 0.1% v. TFA (90% to 10% over 25 minutes, Flow rate of 40mL/minute, uv detector set to 254 nm). The fractions containing thedesired product were collected and concentrated under reduced pressureand the residue was stirred in ether/ethanol (v. 10/1, 5 mL) at ambienttemperature for 16 hours to provide the title compound. (80 mg, yield,29.2%). NMR (300 MHz, CD₃OD) δ 2.06-2.24 (m, 2H), 2.25-2.60 (m, 6H),4.00-4.33 (m, 2H), 4.90-5.02 (m, 1H), 6.72 (dd, J=3.39, 1.02 Hz, 1H),7.25-7.32 (m, 1H), 7.34-7.39 (m, 1H), 7.43 (d, J=3.05 Hz, 1H), 7.58 (dt,J=7.80, 1.02 Hz, 1H), 7.93 (dd, J=8.99, 2.88 Hz, 1H), 8.11 (d, J=8.82Hz, 1H), 8.46 (d, J=2.71 Hz, 1H) ppm. MS (DCI/NH₃) m/z 320 (M+H)⁺. Anal.Calc. for C₂₀H₂₁N₃O.2.00CF₃CO₂H.0.50H₂O: C, 51.80; H, 4.35; N, 7.55.Found: C, 51.84; H, 4.28; N, 7.30.

Example 635-{5-[(exo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-indolebis(hydrochloric acid Example 63A(exo)-3-(6-Chloropyridin-3-yloxy)-8-azabicyclo[3.2.1]octane

To a solution of the product of Example 11A (2.52 g, 9.97 mmol) in1,2-dichloroethane (25 ml) (anhydrous) was added 1-chloroethylcarbonochloridate (5.54 ml, 49.9 mmol). The mixture was then heated to100° C. for 50 h. It was then cooled down to ambient temperature, 25 mLof MeOH was added. The mixture was then heated to reflux for 1 hour. Itis concentrated and the crude was purified with chromatography on silicagel (CH₂Cl₂:MeOH:NH₃H₂O, v. 90:10:2, R_(f)=0.15) to give the titlecompound (180 mg, yield, 75%). ¹H NMR (300 MHz, CD₃OD) δ 1.56-1.71 (m,2H), 1.74-1.94 (m, 4H), 2.01-2.26 (m, 2H), 3.46-3.73 (m, 2H), 4.58-4.76(m, 1H), 7.32 (d, J=8.1 Hz, 1H), 7.43 (dd, J=8.8, 3.0 Hz, 1H), 8.01 (d,J=2.7 Hz, 1H) ppm. MS (DCI/NH₃) m/z 241 (M+H)⁺, 239 (M+H)⁺.

Example 63B5-{5-[(exo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-indole

The product of Example 63A (0.24 g, 1.0 mmol) was coupled with1H-indol-5-ylboronic acid (Frontier, 0.241 g, 1.50 mmol) according tothe procedure of Example 9B to provide the title compound (0.25 g,yield, 79%). ¹H NMR (300 MHz, CD₃OD) δ 1.69-1.83 (m, 2H), 1.86-1.99 (m,4H), 2.1.8-2.32 (m, 2H), 3.67-3.87 (m, 2H), 4.69-4.82 (m, 1H), 6.52 (d,J=2.37 Hz, 1H), 7.27 (d, J=3.05 Hz, 1H), 7.45 (dt, J=8.48, 0.85 Hz, 1H),7.49 (dd, J=8.82, 3.05 Hz, 2H), 7.62 (dd, J=8.48, 1.70 Hz, 2H), 7.76 (d,J=8.14 Hz, 2H), 8.03 (d, J=1.36 Hz, 2H), 8.22 (d, J=2.37 Hz, 1H) ppm; MS(DCI/NH₃) m/z 320 (M+H)₊.

Example 63C5-{5-[(exo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-indolebis(hydrochloric acid)

The product of Example 63B (0.25 g, 0.79 mmol) was treated with HCl(Aldrich, 4 M in dioxane, 0.5 mL, 2.0 mmol) in EtOAc/EtOH (v. 10/1, 10mL). The precipitated solid was filtered and dried to give the titlecompound (0.20 g, yield, 64.9%). ¹H NMR (300 MHz, CD₃OD) δ1.94-2.13 (m,2H), 2.12-2.35 (m, 4H), 2.42-2.68 (m, 2H), 4.09-4.37 (m, 2H), 5.05-5.28(m, 1H), 6.67 (d, J=3.39 Hz, 1H), 7.43 (d, J=3.05 Hz, 1H), 7.57-7.72 (m,2H), 8.16 (s, 1H), 8.27-8.39 (m, 2H), 8.52 (d, J=2.37 Hz, 1H) ppm; MS(DCI/NH₃) m/z 320 (M+H)⁺. Anal. Calc. for C₂₀H₂₁N₃O.2.00HCl.0.90H₂O: C,58.80; H, 6.12; N, 10.29. Found: C, 58.50; H, 5.86; N, 10.08.

Example 645-{5-[(endo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}indolin-2-one

The product of Example 59A (119 mg, 0.50 mmol), was coupled with theproduct of Example 58A (194 mg, 0.75 mmol) according to the procedure ofExample 9B to provide the title compound (150 mg, yield, 89.0%). ¹H NMR(300 MHz, DMSO-D₆) δ 1.86-2.42 (m, 8H), 3.54 (s, 2H), 3.89-4.06 (m, 2H),4.83 (t, J=4.07 Hz, 1H), 6.88 (d, J=7.80 Hz, 1H), 7.47 (dd, J=8.82, 3.05Hz, 1H), 7.78-7.94 (m, 3H), 8.32 (d, J=2.71 Hz, 1H), 10.50 (s, 1H) ppm;MS (DCI/NH₃) m/z 336 (M+H)⁺.

Example 655-{5-[(endo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-pyrrolo[2,3-b]pyridine

The product of Example 59A (200 mg, 0.80 mmol), was coupled with theproduct of Example 47A (183 mg, 0.75 mmol) according to the procedure ofExample 9B to provide the title compound (80 mg, yield, 49.9%). ¹H NMR(300 MHz, DMSO-D₆) δ 1.89-2.16 (m, 4H), 2.17-2.40 (m, 4H), 3.78-4.26 (m,2H), 4.86 (t, J=4.24 Hz, 1H), 6.51 (dd, J=3.39, 1.70 Hz, 1H), 7.46-7.58(m, 2H), 7.97 (d, J=8.82 Hz, 1H), 8.39 (d, J=2.71 Hz, 1H), 8.52 (d,J=2.03 Hz, 1H), 8.88 (d, J=2.03 Hz, 1H), 11.70 (s, 1H) ppm; MS (DCI/NH₃)m/z 321 (M+H)⁺.

Example 665-{5-[(exo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-pyrrolo[2,3-b]pyridine

The product of Example 63A (200 mg, 0.80 mmol) was coupled with theproduct of Example 47A (183 mg, 0.75 mmol) according to the procedure ofExample 9B to provide the title compound (120 mg, yield, 74.9%). ¹H NMR(300 MHz, DMSO-D₆) δ 1.82-2.18 (m, 6H), 2.18-2.40 (m, 2H), 3.91-4.30 (m,2H), 4.71-5.30 (m, 1H), 6.51 (dd, J=3.39, 1.70 Hz, 1H), 7.47-7.55 (m,1H), 7.61 (dd, J=8.82, 3.05 Hz, 1H), 7.94 (d, J=8.82 Hz, 1H), 8.42 (d,J=2.71 Hz, 1H), 8.52 (d, J=2.03 Hz, 1H), 8.88 (d, J=2.03 Hz, 1H), 11.71(s, 1H) ppm; MS (DCI/NH₃) m/z 321 (M+H)⁺.

Compositions of the Invention

The invention also provides pharmaceutical compositions comprising atherapeutically effective amount of a compound of formula (I) incombination with a pharmaceutically acceptable carrier. The compositionscomprise compounds of the invention formulated together with one or morenon-toxic pharmaceutically acceptable carriers. The pharmaceuticalcompositions can be formulated for oral administration in solid orliquid form, for parenteral injection or for rectal administration.

The term “pharmaceutically acceptable carrier,” as used herein, means anontoxic, inert solid, semi-solid or liquid filler, diluent,encapsulating material or formulation auxiliary of any type. Someexamples of materials which can serve as pharmaceutically acceptablecarriers are sugars such as lactose, glucose and sucrose; starches suchas corn starch and potato starch; cellulose and its derivatives such assodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate;powdered tragacanth; malt; gelatin; talc; cocoa butter and suppositorywaxes; oils such as peanut oil, cottonseed oil, safflower oil, sesameoil, olive oil, corn oil and soybean oil; glycols; such a propyleneglycol; esters such as ethyl oleate and ethyl laurate; agar; bufferingagents such as magnesium hydroxide and aluminum hydroxide; alginic acid;pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol,and phosphate buffer solutions, as well as other nontoxic compatiblelubricants such as sodium lauryl sulfate and magnesium stearate, as wellas coloring agents, releasing agents, coating agents, sweetening,flavoring and perfuming agents, preservatives and antioxidants can alsobe present in the composition, according to the judgment of one skilledin the art of formulations.

The pharmaceutical compositions of this invention can be administered tohumans and other mammals orally, rectally, parenterally,intracisternally, intravaginally, intraperitoneally, topically (as bypowders, ointments or drops), bucally or as an oral or nasal spray. Theterm “parenterally,” as used herein, refers to modes of administration,including intravenous, intramuscular, intraperitoneal, intrasternal,subcutaneous, intraarticular injection and infusion.

Pharmaceutical compositions for parenteral injection comprisepharmaceutically acceptable sterile aqueous or nonaqueous solutions,dispersions, suspensions or emulsions and sterile powders forreconstitution into sterile injectable solutions or dispersions.Examples of suitable aqueous and nonaqueous carriers, diluents, solventsor vehicles include water, ethanol, polyols (propylene glycol,polyethylene glycol, glycerol, and the like, and suitable mixturesthereof), vegetable oils (such as olive oil) and injectable organicesters such as ethyl oleate, or suitable mixtures thereof. Suitablefluidity of the composition may be maintained, for example, by the useof a coating such as lecithin, by the maintenance of the requiredparticle size in the case of dispersions, and by the use of surfactants.

These compositions can also contain adjuvants such as preservativeagents, wetting agents, emulsifying agents, and dispersing agents.Prevention of the action of microorganisms can be ensured by variousantibacterial and antifungal agents, for example, parabens,chlorobutanol, phenol, sorbic acid, and the like. It also can bedesirable to include isotonic agents, for example, sugars, sodiumchloride and the like. Prolonged absorption of the injectablepharmaceutical form can be brought about by the use of agents delayingabsorption, for example, aluminum monostearate and gelatin.

In some cases, in order to prolong the effect of a drug, it is oftendesirable to slow the absorption of the drug from subcutaneous orintramuscular injection. This can be accomplished by the use of a liquidsuspension of crystalline or amorphous material with poor watersolubility. The rate of absorption of the drug can depend upon its rateof dissolution, which, in turn, may depend upon crystal size andcrystalline form. Alternatively, dissolving or suspending the drug in anoil vehicle can administer a parenterally administered drug form.

Suspensions, in addition to the active compounds, can contain suspendingagents, for example, ethoxylated isostearyl alcohols, polyoxyethylenesorbitol and sorbitan esters, microcrystalline cellulose, aluminummetahydroxide, bentonite, agar-agar, tragacanth, and mixtures thereof.

If desired, and for more effective distribution, the compounds of theinvention can be incorporated into slow-release or targeted-deliverysystems such as polymer matrices, liposomes, and microspheres. They maybe sterilized, for example, by filtration through a bacteria-retainingfilter or by incorporation of sterilizing agents in the form of sterilesolid compositions, which may be dissolved in sterile water or someother sterile injectable medium immediately before use.

Injectable depot forms are made by forming microencapsulated matrices ofthe drug in biodegradable polymers such as polylactide-polyglycolide.Depending upon the ratio of drug to polymer and the nature of theparticular polymer employed, the rate of drug release can be controlled.Examples of other biodegradable polymers include poly(orthoesters) andpoly(anhydrides) Depot injectable formulations also are prepared byentrapping the drug in liposomes or microemulsions which are compatiblewith body tissues.

The injectable formulations can be sterilized, for example, byfiltration through a bacterial-retaining filter or by incorporatingsterilizing agents in the form of sterile solid compositions which canbe dissolved or dispersed in sterile water or other sterile injectablemedium just prior to use.

Injectable preparations, for example, sterile injectable aqueous oroleaginous suspensions can be formulated according to the known artusing suitable dispersing or wetting agents and suspending agents. Thesterile injectable preparation also can be a sterile injectablesolution, suspension or emulsion in a nontoxic, parenterally acceptablediluent or solvent such as a solution in 1,3-butanediol. Among theacceptable vehicles and solvents that can be employed are water,Ringer's solution, U.S.P. and isotonic sodium chloride solution. Inaddition, sterile, fixed oils are conventionally employed as a solventor suspending medium. For this purpose any bland fixed oil can beemployed including synthetic mono- or diglycerides. In addition, fattyacids such as oleic acid are used in the preparation of injectables.

Solid dosage forms for oral administration include capsules, tablets,pills, powders, and granules. In such solid dosage forms, one or morecompounds of the invention is mixed with at least one inertpharmaceutically acceptable carrier such as sodium citrate or dicalciumphosphate and/or a) fillers or extenders such as starches, lactose,sucrose, glucose, mannitol, and salicylic acid; b) binders such ascarboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone,sucrose, and acacia; c) humectants such as glycerol; d) disintegratingagents such as agar-agar, calcium carbonate, potato or tapioca starch,alginic acid, certain silicates, and sodium carbonate; e) solutionretarding agents such as paraffin; f) absorption accelerators such asquaternary ammonium compounds; g) wetting agents such as cetyl alcoholand glycerol monostearate; h) absorbents such as kaolin and bentoniteclay; and i) lubricants such as talc, calcium stearate, magnesiumstearate, solid polyethylene glycols, sodium lauryl sulfate, andmixtures thereof. In the case of capsules, tablets and pills, the dosageform may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers insoft and hard-filled gelatin capsules using lactose or milk sugar aswell as high molecular weight polyethylene glycols.

The solid dosage forms of tablets, dragees, capsules, pills, andgranules can be prepared with coatings and shells such as entericcoatings and other coatings well-known in the pharmaceutical formulatingart. They can optionally contain opacifying agents and can also be of acomposition that they release the active ingredient(s) only, orpreferentially, in a certain part of the intestinal tract in a delayedmanner. Examples of materials useful for delaying release of the activeagent can include polymeric substances and waxes.

Compositions for rectal or vaginal administration are preferablysuppositories which can be prepared by mixing the compounds of thisinvention with suitable nonirritating carriers such as cocoa butter,polyethylene glycol or a suppository wax which are solid at ambienttemperature but liquid at body temperature and therefore melt in therectum or vaginal cavity and release the active compound.

Liquid dosage forms for oral administration include pharmaceuticallyacceptable emulsions, microemulsions, solutions, suspensions, syrups andelixirs. In addition to the active compounds, the liquid dosage formsmay contain inert diluents commonly used in the art such as, forexample, water or other solvents, solubilizing agents and emulsifierssuch as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethylacetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyleneglycol, dimethylformamide, oils (in particular, cottonseed, groundnut,corn, germ, olive, castor, and sesame oils), glycerol,tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid estersof sorbitan, and mixtures thereof.

Besides inert diluents, the oral compositions can also include adjuvantssuch as wetting agents, emulsifying and suspending agents, sweetening,flavoring, and perfuming agents.

Dosage forms for topical or transdermal administration of a compound ofthis invention include ointments, pastes, creams, lotions, gels,powders, solutions, sprays, inhalants or patches. A desired compound ofthe invention is admixed under sterile conditions with apharmaceutically acceptable carrier and any needed preservatives orbuffers as may be required. Ophthalmic formulation, eardrops, eyeointments, powders and solutions are also contemplated as being withinthe scope of this invention.

The ointments, pastes, creams and gels may contain, in addition to anactive compound of this invention, animal and vegetable fats, oils,waxes, paraffins, starch, tragacanth, cellulose derivatives,polyethylene glycols, silicones, bentonites, silicic acid, talc and zincoxide, or mixtures thereof.

Powders and sprays can contain, in addition to the compounds of thisinvention, lactose, talc, silicic acid, aluminum hydroxide, calciumsilicates and polyamide powder, or mixtures of these substances. Sprayscan additionally contain customary propellants such aschlorofluorohydrocarbons.

Compounds of the invention also can be administered in the form ofliposomes. As is known in the art, liposomes are generally derived fromphospholipids or other lipid substances. Liposomes are formed by mono-or multi-lamellar hydrated liquid crystals that are dispersed in anaqueous medium. Any non-toxic, physiologically acceptable andmetabolizable lipid capable of forming liposomes may be used. Thepresent compositions in liposome form may contain, in addition to thecompounds of the invention, stabilizers, preservatives, and the like.The preferred lipids are the natural and synthetic phospholipids andphosphatidylcholines (lecithins) used separately or together.

Methods to form liposomes are known in the art. See, for example,Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, NewYork, N.Y., (1976), p. 33 et seq.

Dosage forms for topical administration of a compound of this inventioninclude powders, sprays, ointments and inhalants. The active compound ismixed under sterile conditions with a pharmaceutically acceptablecarrier and any needed preservatives, buffers or propellants. Ophthalmicformulations, eye ointments, powders and solutions are also contemplatedas being within the scope of this invention. Aqueous liquid compositionsof the invention also are particularly useful.

The compounds of the invention can be used in the form ofpharmaceutically acceptable salts, esters, or amides derived frominorganic or organic acids. The term “pharmaceutically acceptable salts,esters and amides,” as used herein, include salts, zwitterions, estersand amides of compounds of formula (I) which are, within the scope ofsound medical judgment, suitable for use in contact with the tissues ofhumans and lower animals without undue toxicity, irritation, allergicresponse, and the like, are commensurate with a reasonable benefitfriskratio, and are effective for their intended use.

The term “pharmaceutically acceptable salt” refers to those salts whichare, within the scope of sound medical judgment, suitable for use incontact with the tissues of humans and lower animals without unduetoxicity, irritation, allergic response, and the like, and arecommensurate with a reasonable benefit/risk ratio. Pharmaceuticallyacceptable salts are well-known in the art. The salts can be prepared insitu during the final isolation and purification of the compounds of theinvention or separately by reacting a free base function with a suitableorganic acid.

Representative acid addition salts include, but are not limited toacetate, adipate, alginate, citrate, aspartate, benzoate,benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate,digluconate, fumarate, glycerophosphate, hemisulfate, heptanoate,hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide,2-hydroxyethansulfonate (isethionate), lactate, maleate,methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate,pectinate, persulfate, 3-phenylpropionate, picrate, pivalate,propionate, succinate, tartrate, thiocyanate, phosphate, glutamate,bicarbonate, p-toluenesulfonate and undecanoate.

Also, the basic nitrogen-containing groups can be quaternized with suchagents as lower alkyl halides such as methyl, ethyl, propyl, and butylchlorides, bromides and iodides; dialkyl sulfates such as dimethyl,diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl,lauryl, myristyl and stearyl chlorides, bromides and iodides; arylalkylhalides such as benzyl and phenethyl bromides and others. Water oroil-soluble or dispersible products are thereby obtained.

Examples of acids which can be employed to form pharmaceuticallyacceptable acid addition salts include such inorganic acids ashydrochloric acid, hydrobromic acid, sulphuric acid and phosphoric acidand such organic acids as oxalic acid, maleic acid, succinic acid, andcitric acid.

Basic addition salts can be prepared in situ during the final isolationand purification of compounds of this invention by reacting a carboxylicacid-containing moiety with a suitable base such as the hydroxide,carbonate or bicarbonate of a pharmaceutically acceptable metal cationor with ammonia or an organic primary, secondary or tertiary amine.Pharmaceutically acceptable salts include, but are not limited to,cations based on alkali metals or alkaline earth metals such as lithium,sodium, potassium, calcium, magnesium, and aluminum salts, and the like,and nontoxic quaternary ammonia and amine cations including ammonium,tetramethylammonium, tetraethylammonium, methylamine, dimethylamine,trimethylamine, triethylamine, diethylamine, ethylamine and the such as.Other representative organic amines useful for the formation of baseaddition salts include ethylenediamine, ethanolamine, diethanolamine,piperidine, and piperazine.

The term “pharmaceutically acceptable ester,” as used herein, refers toesters of compounds of the invention which hydrolyze in vivo and includethose that break down readily in the human body to leave the parentcompound or a salt thereof. Examples of pharmaceutically acceptable,non-toxic esters of the invention include C₁-to-C₆ alkyl esters andC₅-to-C₇ cycloalkyl esters, although C₁-to-C₄ alkyl esters arepreferred. Esters of the compounds of formula (I) can be preparedaccording to conventional methods. Pharmaceutically acceptable esterscan be appended onto hydroxy groups by reaction of the compound thatcontains the hydroxy group with acid and an alkylcarboxylic acid such asacetic acid, or with acid and an arylcarboxylic acid such as benzoicacid. In the case of compounds containing carboxylic acid groups, thepharmaceutically acceptable esters are prepared from compoundscontaining the carboxylic acid groups by reaction of the compound withbase such as triethylamine and an alkyl halide, alkyl trifilate, forexample with methyl iodide, benzyl iodide, cyclopentyl iodide. They alsocan be prepared by reaction of the compound with an acid such ashydrochloric acid and an alkylcarboxylic acid such as acetic acid, orwith acid and an arylcarboxylic acid such as benzoic acid.

The term “pharmaceutically acceptable amide,” as used herein, refers tonon-toxic amides of the invention derived from ammonia, primary C₁-to-C₆alkyl amines and secondary C₁-to-C₆ dialkyl amines. In the case ofsecondary amines, the amine can also be in the form of a 5- or6-membered heterocycle containing one nitrogen atom. Amides derived fromammonia, C₁-to-C₃ alkyl primary amides and C₁-to-C₂ dialkyl secondaryamides are preferred. Amides of the compounds of formula (I) can beprepared according to conventional methods. Pharmaceutically acceptableamides can be prepared from compounds containing primary or secondaryamine groups by reaction of the compound that contains the amino groupwith an alkyl anhydride, aryl anhydride, acyl halide, or aroyl halide.In the case of compounds containing carboxylic acid groups, thepharmaceutically acceptable esters are prepared from compoundscontaining the carboxylic acid groups by reaction of the compound withbase such as triethylamine, a dehydrating agent such as dicyclohexylcarbodiimide or carbonyl diimidazole, and an alkyl amine, dialkylamine,for example with methylamine, diethylamine, piperidine. They also can beprepared by reaction of the compound with an acid such as sulfuric acidand an alkylcarboxylic acid such as acetic acid, or with acid and anarylcarboxylic acid such as benzoic acid under dehydrating conditions aswith molecular sieves added. The composition can contain a compound ofthe invention in the form of a pharmaceutically acceptable prodrug.

The term “pharmaceutically acceptable prodrug” or “prodrug,” as usedherein, represents those prodrugs of the compounds of the inventionwhich are, within the scope of sound medical judgment, suitable for usein contact with the tissues of humans and lower animals without unduetoxicity, irritation, allergic response, and the like, commensurate witha reasonable benefit/risk ratio, and effective for their intended use.Prodrugs of the invention can be rapidly transformed in vivo to a parentcompound of formula (I), for example, by hydrolysis in blood. A thoroughdiscussion is provided in T. Higuchi and V. Stella, Pro-drugs as NovelDelivery Systems, V. 14 of the A.C.S. Symposium Series, and in Edward B.Roche, ed., Bioreversible Carriers in Drug Design, AmericanPharmaceutical Association and Pergamon Press (1987).

The invention contemplates pharmaceutically active compounds eitherchemically synthesized or formed by in vivo biotransformation tocompounds of formula (I).

Determination of Biological Activity

To determine the effectiveness of representative compounds of thisinvention as α7 nAChRs, the compounds of the invention were evaluatedaccording to the [³H]-DPPB binding or the [³H]-methyllycaconitin (MLA)binding assay (both measures of α7 NNR binding) and considering the[³H]-cytisine binding assay (measure of α4β2 interactions), which wereperformed as described below.

[³H]-Cytisine Binding

Binding conditions were modified from the procedures described inPabreza L A, Dhawan, S, Kellar K J, [³H]-Cytisine Binding to NicotinicCholinergic Receptors in Brain, Mol. Pharm. 39: 9-12, 1991. Membraneenriched fractions from rat brain minus cerebellum (ABS Inc.,Wilmington, Del.) were slowly thawed at 4° C., washed and resuspended in30 volumes of BSS-Tris buffer (120 mM NaClf5 mM KCl 12 mM CaCl₂/2 mMMgCl₂/50 mM Tris-Cl, pH 7.4, 4° C.). Samples containing 100-200 pg ofprotein and 0.75 nM [3H]-cytisine (30 C_(i)/mmol; Perkin ElmerfNEN LifeScience Products, Boston, Mass.) were incubated in a final volume of 500μL for 75 minutes at 4° C. Seven log-dilution concentrations of eachcompound were tested in duplicate. Non-specific binding was determinedin the presence of 10 μM (−)-nicotine. Bound radioactivity was isolatedby, vacuum filtration onto prewetted glass fiber filter plates(Millipore, Bedford, Mass.) using a 96-well filtration apparatus(Packard Instruments, Meriden, Conn.) and were then rapidly rinsed with2 mL of ice-cold BSS buffer (120 mM NaCl 15 mM KCl 12 mM CaCl₂/2 mMMgCl₂). Packard MicroScint-20®-scintillation cocktail (40 μL) was addedto each well and radioactivity determined using a Packard TopCount®instrument. The IC₅₀ values were determined by nonlinear regression inMicrosoft Excel® software. K_(i) values were calculated from the IC₅₀susing the Cheng-Prusoff equation, where K_(i)=IC₅₀/1+[Ligand]/K_(D)].

[³H]-Methyllycaconitine (MLA) Binding

Binding conditions were similar to those for [3H]-cytisine binding.Membrane enriched fractions from rat brain minus cerebellum (ABS Inc.,Wilmington, Del.) were slowly thawed at 4° C., washed and resuspended in30 volumes of BSS-Tris buffer (120 mM NaCl, 5 mM KCl, 2 mM CaCl₂, 2 mMMgCl₂, and 50 mM Tris-Cl, pH 7.4, 22° C.). Samples containing 100-200 μgof protein, 5 nM [3H]-MLA (25 C_(i)/mmol; Perkin Elmer/NEN Life ScienceProducts, Boston, Mass.) and 0.1% bovine serum albumin (BSA, Millipore,Bedford, Mass.) were incubated in a final volume of 500 μL for 60minutes at 22° C. Seven log-dilution concentrations of each compoundwere tested in duplicate. Nonspecific binding was determined in thepresence of 10 μM MLA. Bound radioactivity was isolated by vacuumfiltration onto glass fiber filter plates prewetted with 2% BSA using a96-well filtration apparatus (Packard Instruments, Meriden, Conn.) andwere then rapidly rinsed with 2 mL of ice-cold BSS. PackardMicroScint-20® scintillation cocktail (40 pL) was added to each well andradioactivity was determined using a Packard TopCount® instrument. TheIC₅₀ values were determined by nonlinear regression in Microsoft Excel®software. K_(i) values were calculated from the IC₅₀s using theCheng-Prusoff equation, where K_(i)=IC₅₀/1+[Ligand]/K_(D)].

[³H]-DPPB Binding

[³H]-DPPB,[³H]-(S,S)-2,2-dimethyl-5-(6-phenyl-pyridazin-3-yl)-5-aza-2-azonia-bicyclo[2.2.1]heptaneiodide, binding to the α7 nAChR subtype was determined using membraneenriched fractions from rat brain minus cerebellum or human cortex (ABSInc., Wilmington, Del.). Pellets were thawed at 4° C., washed andresuspended with a Polytron at a setting of 7 in 30 volumes of BSS-Trisbuffer (120 mM NaCl, 5 mM KCl, 2 mM CaCl₂, 2 mM MgCl₂, and 50 mMTris-Cl, pH 7.4, 4° C.). Seven log-dilution concentrations of testcompounds containing 100-200 μg of protein, and 0.5 nM [³H]-DPPB (62.8Ci/mmol; R46V, Abbott Labs) were incubated in a final volume of 500 μlfor 75 minutes at 4° C. in duplicate. Non-specific binding wasdetermined in the presence of 10 μM methyllycaconitine. Boundradioactivity was collected on Millipore MultiScreen® harvest plates FBpresoaked with 0.3% PEI using a Packard cell harvester, washed with 2.5ml ice-cold buffer, and radioactivity was determined using a PackardTopCount Microplate beta counter. IC₅₀ values were determined bynonlinear regression in Microsoft® Excel or Assay Explorer. K_(i) valueswere calculated from the IC₅₀s using the Cheng-Prusoff equation, whereK_(i)=IC₅₀/1+[Ligand]/K_(D)[³H] was obtained according to thepreparation procedures described below.

[Methyl-³H]2,2-Dimethyl-5-(6-phenyl-pyridazin-3-yl)-5-aza-2-azonia-bicyclo[2.2.1]heptaneiodide Preparation

[Methyl-³]2,2-dimethyl-5-(6-phenyl-pyridazin-3-yl)-5-aza-2-azonia-bicyclo[2.2.1]heptane;iodide used in the [³H]-DPPB binding assay above was prepared accordingto the following procedures.

Step 1: Preparation of t-Butyl(S,S)-5-(6-Phenyl-pyridazin-3-yl)-2,5-diaza-bicyclo[2.2.1]heptane-2-carboxylate

Triethylamine (20 mL) was added to a suspension of t-butyl(S,S)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (3.43 g, 17.3 mmol,Aldrich Chemical Company) and 3-chloro-6-phenylpyridazine (3.30 g, 17.3mmol, Aldrich Chemical Company) in toluene (50 mL) and the mixture washeated under nitrogen at 100° C. for 7 days. The dark mixture was cooledto room temperature, and the resulting precipitate was isolated byfiltration, washed with toluene (15 mL) and dried under vacuum toprovide the title compound as an off-white solid (3.00 g). The filtratewas concentrated and the residue wa purified by column chromatography onsilica gel, eluting with ethyl acetate, to provide additional product(0.41 g, total yield 3.41 g, 56%): MS (DCI/NH3) m/z 353 (M+H)+.

Step 2: Preparation of (S,S)-2-Methyl5-(6-phenyl-pyridazin-3-yl)-2,5-diaza-bicyclo[2.2.1]heptane

The product obtained from Step 1 (3.41 g, 9.7 mmol) was dissolved informic acid (20 mL) and treated with formalin (37% by weight, 1 .O g,12.3 mmol). The mixture was heated at 100° C. for 1 h, and the brownsolution was cooled to room temperature and concentrated under vacuum.The residue was purified by column chromatography on silica gel, elutingwith CH2Cl2-CH3OH—NH4OH (95:5:1) to provide the title compound as anoff-white solid (2.50 g, 96%): MS (DCI/NH3) m/z 267 (M+H)+.

Step 3: Preparation of[³H]-(S,S)-2,2-Dimethyl-5-(6-phenyl-pyridazin-3-yl)-5-aza-2-azonia-bicyclo[2.2.1]heptaneiodide ([³H]-DPPB)

[³H]Methyl iodide in toluene (250 mCi in 0.1 mL, 85Ci/mmol, AmericanRadiolabeled Chemicals, Inc.) was combined with a solution of theproduct obtained from Step 2 in dichloromethane (0.788 mg, 2.96 mmole in0.45 mL). The vial was capped and the mixture was allowed to reactovernight at room temperature. Methanol was added and the solvents wereevaporated to give 42 mCi. The product was taken up in methanol for HPLCpurification.

Step 4: Purification by High Performance Liquid Chromatography (HPLC)

About 7 mCi of [³H]was evaporated to dryness and the residue wasdissolved in total about 4.5 ml acetonitrile:water:TFA (15:85:0.1).Approximately 0.9 mL per injection were made onto a Phenomenex LunaC18(2) column (5 micron, 250 mm×4.6 mm ID) using an Agilent HPLC system.[3H]-DPPB was eluted by a gradient mobile phase from 10% B to 20% B in20 min where Mobile Phase A=0.1% trifluoroacetic acid in water andMobile Phase B=0.1% trifluoroacetic acid in acetonitrile at a flow rateof approximately 1 mL/min. Peak detection and chromatograms wereobtained with an Agilent variable wavelength UV detector set at 275 nm.The fractions containing [3H]-DPPB were collected at approximately 14minutes using an Agilent fraction collector. The fractions were combinedand the solvents were evaporated in vacuo. The residue was dissolved in200 proof ethanol (2 mL) to give 0.7 mCi.

Step 5: Determination of Purity and Specific Activity

[³H]-DPPB was assayed using an Agilent 1100 series HPLC systemconsisting of a quaternary pump, an autosampler, and a photodiode arrayUV detector. A Packard Radiomatic A 500 radioactivity detector wasconnected to the HPLC system. For radiodetection, a 500 mL flow cell anda 3:1 ratio of Ultima-Flo M scintillation cocktail to HPLC mobile phasewere used. The analyses were performed using a Phenomenex Luna¹⁸(2)column (5 microns, 250 mm×4.6 mm ID). The mobile phase consisted of agradient starting with 10% B and ramping to 20% B in 20 minutes followedby ramping to 90% B in 1 minute and hold at 90% B for 9 minutes, whereMobile Phase A=0.1% trifluoroacetic acid in water and Mobile PhaseB=0.1% trifluoroacetic acid in acetonitrile. The flow rate was set atapproximately 1 mL/min and the UV detection was set at 275 nm.

The radiochemical purity of [³H]was found to be >9˜8%. The specificactivity was determined to be 62.78 Ci/mmol by mass spectroscopy.

Compounds of the invention had K_(i) values of from about 1 nanomolar toabout 10 micromolar when tested by the [³H]-MLA assay, many having aK_(i) of less than 1 micromolar. [³H]-Cystine binding values ofcompounds of the invention ranged from about 1 nanomolar to at least 100micromolar. Alternatively, the K_(i) value as measured by [³H]-DPPBassay can be used in place of the K_(i MLA).

Methods of the Invention

Compounds and compositions of the invention are useful for modulatingthe effects of nAChRs, and more particularly α7 nAChRs. In particular,the compounds and compositions of the invention can be used for treatingand preventing disorders modulated by α7 nAChRs. Typically, suchdisorders can be ameliorated by selectively modulating the α7 nAChRs ina mammal, preferably by administering a compound or composition of theinvention, either alone or in combination with another active agent, forexample, as part of a therapeutic regimen. Also, some compounds of theinvention possess affinity at the α4 β2 nAChRs in addition to α7 nAChRs,and selective compounds with dual affinities at both receptor subtypesalso are expected to have beneficial effects. The compounds of theinvention, including but not limited to those specified in the examples,possess an affinity for nAChRs, and more particularly α7 nAChRs. As α7nAChRs ligands, the compounds of the invention can be useful for thetreatment and prevention of a number of α7 nAChR-mediated diseases orconditions.

For example, α7 nAChRs have been shown to play a significant role inenhancing cognitive function, including aspects of learning, memory andattention (Levin, E. D., J. Neurobiol. 53: 633-640, 2002). As such, α7ligands are suitable for the treatment of cognitive disorders including,for example, attention deficit disorder, attention deficit hyperactivitydisorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment,senile dementia, AIDS dementia, Pick's Disease, dementia associated withLewy bodies, and dementia associated with Down's syndrome, as well ascognitive deficits associated with schizophrenia.

In addition, α7-containing nAChRs have been shown to be involved in theneuroprotective effects of nicotine both in vitro (Jonnala, R. B. andBuccafusco, J. J., J. Neurosci. Res. 66: 565-572, 2001) and in vivo(Shimohama, S. et al., Brain Res. 779: 359-363, 1998). Moreparticularly, neurodegeneration underlies several progressive CNSdisorders, including, but not limited to, Alzheimer's disease,Parkinson's disease, amyotrophic lateral sclerosis, Huntington'sdisease, dementia with Lewy bodies, as well as diminished CNS functionresulting from traumatic brain injury. For example, the impairedfunction of α7 nAChRs by P-amyloid peptides linked to Alzheimer'sdisease has been implicated as a key factor in development of thecognitive deficits associated with the disease (Liu, Q.-S., Kawai, H.,Berg, D. K., PNAS 98: 4734-4739, 2001). The activation of α7 nAChRs hasbeen shown to block this neurotoxicity (Kihara, T. et al., J. Biol.Chem. 276: 13541-13546, 2001). As such, selective ligands that enhanceα7 activity can counter the deficits of Alzheimer's and otherneurodegenerative diseases. Schizophrenia is a complex disease that ischaracterized by abnormalities in perception, cognition, and emotions.Significant evidence implicates the involvement of α7 nAChRs in thisdisease, including a measured deficit of these receptors in postmortempatients (Leonard, S. Eur. J. Pharmacol. 393: 237-242, 2000). Deficitsin sensory processing (gating) are one of the hallmarks ofschizophrenia. These deficits can be normalized by nicotinic ligandsthat operate at the α7 nAChR (Adler L. E. et al., Schizophrenia Bull.24: 189-202, 1998; Stevens, K. E. et al., Psychopharmacology 136:320-327, 1998). Thus, α7 ligands demonstrate potential in the treatmentschizophrenia. Angiogenesis, a process involved in the growth of newblood vessels, is important in beneficial systemic functions, such aswound healing, vascularization of skin grafts, and enhancement ofcirculation, for example, increased circulation around a vascularocclusion. Non-selective nAChR agonists like nicotine have been shown tostimulate angiogenesis (Heeschen, C. et al., Nature Medicine 7: 833-839,2001). Improved angiogenesis has been shown to involve activation of theα7 nAChR (Heeschen, C. et al, J. Clin. Invest. 110: 527-536, 2002).Therefore, nAChR ligands that are selective for the α7 subtype offerimproved potential for stimulating angiogenesis with an improved sideeffect profile.

A population of α7 nAChRs in the spinal cord modulate serotonergictransmission that have been associated with the pain-relieving effectsof nicotinic compounds (Cordero-Erausquin, M. and Changeux, J.-P. PNAS98:2803-2807, 2001). The α7 nAChR ligands demonstrate therapeuticpotential for the treatment of pain states, including acute pain,post-surgical pain, as well as chronic pain states includinginflammatory pain and neuropathic pain. Moreover, α7 nAChRs areexpressed on the surface of primary macrophages that are involved in theinflammation response, and that activation of the α7 receptor inhibitsrelease of TNF and other cytokines that trigger the inflammationresponse (Wang, H. et al Nature 421: 384-388, 2003). Therefore,selective α7 ligands demonstrate potential for treating conditionsinvolving TNF-mediated diseases, for example, rheumatoid arthritis,Crohn's disease, ulcerative colitis, inflammatory bowel disease, organtransplant rejection, acute immune disease associated with organtransplantation, chronic immune disease associated with organtransplantation, septic shock, toxic shock syndrome, sepsis syndrome,depression, and rheumatoid spondylitis.

The mammalian sperm acrosome reaction is an exocytosis process importantin fertilization of the ovum by sperm. Activation of an α7 nAChR on thesperm cell has been shown to be essential for the acrosome reaction(Son, J.-H. and Meizel, S. Biol. Reproduct. 68: 1348-1353 2003).Consequently, selective α7 agents demonstrate utility for treatingfertility disorders.

Compounds of the invention are particularly useful for treating andpreventing a condition or disorder affecting cognition,neurodegeneration, and schizophrenia.

Cognitive impairment associated with schizophrenia often limits theability of patients to function normally, a symptom not adequatelytreated by commonly available treatments, for example, treatment with anatypical antipsychotic. (Rowley, M. et al., J. Med. Chem. 44: 477-501,2001). Such cognitive deficit has been linked to dysfunction of thenicotinic cholinergic system, in particular with decreased activity atα7 receptors.

(Friedman, J. I. et al., Biol Psychiatry, 51: 349-357, 002). Thus,activators of α7 receptors can provide useful treatment for enhancingcognitive function in schizophrenic patients who are being treated withatypical antipsychotics. Accordingly, the combination of an α7 nAChRligand and an atypical antipsychotic would offer improved therapeuticutility. Specific examples of suitable atypical antipsychotics include,but are not limited to, clozapine, risperidone, olanzapine, quietapine,ziprasidone, zotepine, iloperidone, and the like.

Actual dosage levels of active ingredients in the pharmaceuticalcompositions of this invention can be varied so as to obtain an amountof the active compound(s) that is effective to achieve the desiredtherapeutic response for a particular patient, compositions and mode ofadministration. The selected dosage level will depend upon the activityof the particular compound, the route of administration, the severity ofthe condition being treated and the condition and prior medical historyof the patient being treated. However, it is within the skill of the artto start doses of the compound at levels lower than required to achievethe desired therapeutic effect and to gradually increase the dosageuntil the desired effect is achieved.

When used in the above or other treatments, a therapeutically effectiveamount of one of the compounds of the invention can be employed in pureform or, where such forms exist, in pharmaceutically acceptable salt,ester, amide or prodrug form.

Alternatively, the compound can be administered as a pharmaceuticalcomposition containing the compound of interest in combination with oneor more pharmaceutically acceptable carriers. The phrase“therapeutically effective amount” of the compound of the inventionmeans a sufficient amount of the compound to treat disorders, at areasonable benefit/risk ratio applicable to any medical treatment. Itwill be understood, however, that the total daily usage of the compoundsand compositions of the invention will be decided by the attendingphysician within the scope of sound medical judgment.

The specific therapeutically effective dose level for any particularpatient will depend upon a variety of factors including the disorderbeing treated and the severity of the disorder; activity of the specificcompound employed; the specific composition employed; the age, bodyweight, general health, sex and diet of the patient; the time ofadministration, route of administration, and rate of excretion of thespecific compound employed; the duration of the treatment; drugs used incombination or coincidental with the specific compound employed; andlike factors well-known in the medical arts. For example, it is wellwithin the skill of the art to start doses of the compound at levelslower than required to achieve the desired therapeutic effect and togradually increase the dosage until the desired effect is achieved.

The total daily dose of the compounds of this invention administered toa human or lower animal range from about 0.010 mg/kg body weight toabout 1 g/kg body weight.

More preferable doses can be in the range of from about 0.010 mg/kg bodyweight to about 100 mg/kg body weight. If desired, the effective dailydose can be divided into multiple doses for purposes of administration.Consequently, single dose compositions may contain such amounts orsubmultiples thereof to make up the daily dose.

Compounds of the invention are α7 nAChRs ligands that modulate functionof α7 nAChRs by altering the activity of the receptor or signaling. Thecompounds can be inverse agonists that inhibit the basal activity of thereceptor or antagonists that completely block the action ofreceptor-activating agonists. The compounds also can be partial agoniststhat partially block or partially activate the α7 nAChR receptor oragonists that activate the receptor. Binding to α7 receptor also triggerkey signaling processes involving various kinases and phosphatases andprotein-protein interactions that are important to effects on memory,cytoprotection, gene transcription and disease modification. Therefore,the administration of a therapeutically effective amount of a compoundof formula (I) to a mammal provides a method of selectively modulatingthe effects of α4β2, α7, or both α4β2 and α7 nicotinic acetylcholinereceptors.

Furthermore, the administration of a therapeutically effective amount ofa compound of formula (I) to a mammal provides a method of treating orpreventing a condition or disorder selected from the group consisting ofattention deficit disorder, attention deficit hyperactivity disorder(ADHD), Alzheimer's disease (AD), mild cognitive impairment, seniledementia, AIDS dementia, Pick's Disease, dementia associated with Lewybodies, dementia associated with Down's syndrome, amyotrophic lateralsclerosis, Huntington's disease, diminished CNS function associated withtraumatic brain injury, acute pain, post-surgical pain, chronic pain,inflammatory pain, neuropathic pain, infertility, need for new bloodvessel growth associated with wound healing, need for new blood vesselgrowth associated with vascularization of skin grafts, and lack ofcirculation, more particularly circulation around a vascular occlusion,rheumatoid arthritis, Crohn's disease, ulcerative colitis, inflammatorybowel disease, organ transplant rejection, acute immune diseaseassociated with organ transplantation, chronic immune disease associatedwith organ transplantation, septic shock, toxic shock syndrome, sepsissyndrome, depression, and rheumatoid spondylitis. More preferred, theadministration of a therapeutically effective amount of a compound offormula (I) to a mammal provides a method of treating cognitivedisorders, neurodegeneration, and schizophrenia. Furthermore, compoundsof formula (I) may also be administered in combination with an atypicalantipsychotic.

It is understood that the foregoing detailed description andaccompanying examples are merely illustrative and are not to be taken aslimitations upon the scope of the invention, which is defined solely bythe appended claims and their equivalents.

Various changes and modifications to the disclosed embodiments will beapparent to those skilled in the art. Such changes and modifications,including without limitation those relating to the chemical structures,substituents, derivatives, intermediates, syntheses, formulations, ormethods of use of the invention, may be made without departing from thespirit and scope thereof.

1. The compound of formula (I),

or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof,wherein n is 1, 2 or 3; A is N or N⁺-0⁻; R is hydrogen, alkyl,cycloalkylalkyl and arylalkyl; L is selected from the group consistingof O, S, and —N(R_(a))—; Ar¹ is a 6-membered aryl or 6-memberedheteroaryl ring; and Ar² is a bicyclic heteroaryl; and R_(a) is selectedfrom the group consisting of hydrogen, alkyl and alkylcarbonyl; providedthat if Ar¹ is

then L is O or S.
 2. The compound of claim 1, wherein Ar¹ is selectedfrom the group consisting of:

wherein R₁, R₂, R₃, R₄ and R₅ are independently selected from the groupconsisting of acyl, acyloxy, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl,alkoxycarbonyl, alkoxyimino, alkoxysulfonyl, alkyl, alkylsulfonyl,alkynyl, amino, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halo,hydroxy, hydroxyalkyl, mercapto, nitro, thioalkoxy, —NR₈R_(j),(NR₈R_(j))alkyl, (NR₈R_(j))alkoxy, (NR₈R_(j))carbonyl, and(NR₈R_(j))sulfonyl; R₈ and R_(j) are each independently selected fromthe group consisting of hydrogen and alkyl.
 3. The compound of claim 1,wherein Ar₂ is selected from the group consisting of

wherein Z₁, Z₂, Z₃ and Z₄ are each independently nitrogen or are carbon,wherein the carbon atom is optionally substituted with a substituentselected from the group consisting of hydrogen, halogen, alkyl, —OR_(c),-alkyl-OR_(c), —NR_(d)R_(e), and -alkyl-NR_(d)R_(e); R_(b) is selectedfrom the group consisting of hydrogen, alkyl and alkylcarbonyl; R_(c) isalkyl; R_(d) and R_(e) are each independently selected from the groupconsisting of hydrogen and alkyl, R₆ and R₇ are each independentlyselected from the group consisting of hydrogen, alkenyl, alkoxy,alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxyimino, alkoxysulfonyl,alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfonyl, alkynyl, carboxy,cyano, formyl, haloalkoxy, haloalkyl, halo, hydrogen, hydroxy,hydroxyalkyl, mercapto, nitro, thio alkoxy, —NR₈R_(j), (NR₈R_(j))alkyl,(NR₈R_(j))alkoxy, (NR₈R_(j))carbonyl, and (NR₈R_(j))sulfonyl; R₈ andR_(j) are each independently selected from the group consisting ofhydrogen and alkyl.
 4. The compound of claim 2, wherein A is N; R ismethyl or hydrogen; L is O; n is 2; and Ar₂ is selected from the groupof consisting of:


5. The compound of claim 2, wherein A is N; R is methyl or hydrogen; Lis O; n is 2; Ar₁ is


6. The compound of claim 2, wherein A is N; R is methyl or hydrogen; Lis O; n is 2; Ar₁ is

and Ar² is


7. The compound of claim 1, selected from the group consisting of:5-{6-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-1H-indole;(endo)-3-(6-benzo[b]thiophen-5-yl-pyridazin-3-yloxy)-8-methyl-8-aza-bicyclo[3.2.1]octane;(endo)-3-[6-(benzofuran-5-yl)-pyridazin-3-yloxy]-8-methyl-8-aza-bicyclo[3.2.1]octane;6-{6-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-1H-indole;5-{6-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-1H-indazole;1-methyl-5-{6-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-1H-indole;5-{6-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-2-trifluoromethyl-1H-indole;5-{6-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-1H-indole;5-{5-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indole;(endo)-3-(6-benzo[b]thiophen-5-yl-pyridin-3-yloxy)-8-methyl-8-aza-bicyclo[3.2.1]octane;5-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indole;(exo)-3-[6-(benzofuran-5-yl)-pyridin-3-yloxy]-8-methyl-8-aza-bicyclo[3.2.1]loctane;5-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indazole;5-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-2-trifluoromethyl-1H-indole;4-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indole;5-{6-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-3-yl}-1H-indole;(endo)-3-(5-benzo[b]thiophen-5-yl-pyridin-2-yloxy)-8-methyl-8-aza-bicyclo[3.2.1]octane;5-{6-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-3-yl}-1H-indole;[6-(1H-indol-5-yl)-pyridin-3-yl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;[6-(benzofuran-5-yl)-pyridin-3-yl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-[6-(2-trifluoromethyl-1H-indol-5-yl)-pyridin-3-yl]-amine;[6-(1H-indazol-5-yl)-pyridin-3-yl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;[6-(1H-indol-4-yl)-pyridin-3-yl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;[(endo)-8-aza-bicyclo[3.2.1]oct-3-yl]-[6-(1H-indol-5-yl)-pyridin-3-yl]amine;[4-(1H-indol-5-yl)-phenyl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;[4-(1H-indazol-5-yl)-phenyl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-[4-(1-methyl-1H-indol-5-yl)-phenyl]-amine;(4-benzo[b]thiophen-5-yl-phenyl)-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;[4-(benzofuran-5-yl)-phenyl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;[4-(1H-indol-4-yl)-phenyl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;[3-(1H-indol-5-yl)-phenyl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;[3-(1H-indol-4-yl)-phenyl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;5-{6-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-2-trifluoromethyl-1H-indole;4-{6-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-1H-indole;5-{6-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-3-yl}-1H-indole;5-{6-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-3-yl}-2-trifluoromethyl-1H-indole;4-{6-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridazin-3-yl}-1H-indole;6-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-indole;5-{5-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indole;4-{5-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H}-indole;6-{5-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indole;[6-(1H-indol-6-yl)-pyridin-3-yl]-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl]-amine;5-{6-[(endo)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yloxy]pyridazin-3-yl}-1H-indole;(endo)-3-[6-(benzo[b]thiophen-5-yl)pyridazin-3-yloxy]-9-methyl-9-azabicyclo[3.3.1]nonane;5-{5-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-pyrrolo[2,3-b]pyridine;5-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-2-yl}-1H-pyrrolo[2,3-b]pyridine;5-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyridin-3-yl}-1H-indole;5-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indole;4-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indole;6-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]-pyrazin-2-yl}-1H-indole.(endo)-N-(5-(1H-Indol-5-yl)pyridin-3-yl)-8-methyl-8-azabicyclo[3.2.1]octan-3-amine(endo)-N-(5-(1H-Indol-4-yl)pyridin-3-yl)-8-methyl-8-azabicyclo[3.2.1]octan-3-amine(endo)-N-(5-(1H-Indol-6-yl)pyridin-3-yl)-8-methyl-8-azabicyclo[3.2.1]octan-3-amine(endo)-N-{5-[2-(trifluoromethyl)-1H-indol-5-yl]pyridin-3-yl}-8-Methyl-8-azabicyclo[3.2.1]octan-3-amine;5-{5-[(endo)-8-Methyl-8-azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-pyrrolo[2,3-b]pyridine;5-{5-[(endo)-8-Methyl-8-azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}indolin-2-one;5-{5-[(endo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-indole;(1R,3r,5S,8s)-3-(6-(1H-Indol-5-yl)pyridin-3-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane8-oxide;(1R,3r,5S,8r)-3-(6-(1H-Indol-5-yl)pyridin-3-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane8-oxide;4-{5-[(endo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-indole;5-{5-[(exo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-indole;5-{5-[(endo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}indolin-2-one;5-{5-[(endo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-pyrrolo[2,3-b]pyridine;5-{5-[(exo)-8-Azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-pyrrolo[2,3-b]pyridine.8. A pharmaceutical composition comprising a therapeutically effectiveamount of a compound of claim 1 in combination with a pharmaceuticallyacceptable carrier.
 9. A method of selectively modulating the effects ofα7 nicotinic acetylcholine receptors, α4β2 nicotinic acetylcholinereceptors, or both α7 and α4β2 nicotinic acetylcholine receptors in amammal comprising administering an effective amount of a compound ofclaim
 1. 10. A method of treating or preventing a condition or disorderselected from the group consisting of attention deficit disorder,attention deficit hyperactivity disorder (ADHD), Alzheimer's disease(AD), mild cognitive impairment, senile dementia, AIDS dementia, Pick'sDisease, dementia associated with Lewy bodies, dementia associated withDown's syndrome, amyotrophic lateral sclerosis, Huntington's disease,diminished CNS function associated with traumatic brain injury, acutepain, post-surgical pain, chronic pain, inflammation, inflammatory pain,neuropathic pain, infertility, need for new blood vessel growthassociated with wound healing, need for new blood vessel growthassociated with vascularization of skin grafts, and lack of circulation,rheumatoid arthritis, Crohn's disease, ulcerative colitis, inflammatorybowel disease, organ transplant rejection, acute immune diseaseassociated with organ transplantation, chronic immune disease associatedwith organ transplantation, septic shock, toxic shock syndrome, sepsissyndrome, depression, and rheumatoid spondylitis, comprising the step ofadministering a compound of claim
 1. 11. The method according to claim10, wherein the condition or disorder is selected from the groupconsisting of a cognitive disorder, neurodegeneration, andschizophrenia.
 12. The method according to claim 10, further comprisingadministering a compound of claim 1 in combination with an atypicalantipsychotic.
 13. The method according to claim 10, further comprisingadministering a compound of claim 1 in combination with a medicationused in the treatment of attention deficit hyperactivity disorders andother cognitive disorders such as Alzheimer's disease.